0001136261-16-000683.txt : 20161121 0001136261-16-000683.hdr.sgml : 20161121 20161121163550 ACCESSION NUMBER: 0001136261-16-000683 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161121 DATE AS OF CHANGE: 20161121 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MMRGlobal, Inc. CENTRAL INDEX KEY: 0001285701 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 330892797 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-51134 FILM NUMBER: 162010679 BUSINESS ADDRESS: STREET 1: 4401 WILSHIRE BLVD. STREET 2: SUITE 200 CITY: LOS ANGELES STATE: CA ZIP: 90010 BUSINESS PHONE: 310 476 7002 MAIL ADDRESS: STREET 1: 4401 WILSHIRE BLVD. STREET 2: SUITE 200 CITY: LOS ANGELES STATE: CA ZIP: 90010 FORMER COMPANY: FORMER CONFORMED NAME: MMR Information Systems, Inc. DATE OF NAME CHANGE: 20090401 FORMER COMPANY: FORMER CONFORMED NAME: FAVRILLE INC DATE OF NAME CHANGE: 20040401 10-Q 1 form10q.htm 10-Q Q3 2016 DOC

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

ý

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
   

SECURITIES EXCHANGE ACT OF 1934
     
   

For the quarterly period ended September 30, 2016
     
   

OR
     

o

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
   

SECURITIES EXCHANGE ACT OF 1934
     
   

For the transition period from ______________ to ________________

Commission file number: 000-51134

MMRGLOBAL, INC.
(Exact name of Registrant as Specified in Its Charter)

DELAWARE

  

33-0892797

(State or Other Jurisdiction of
Incorporation or Organization)

  

(I.R.S. Employer
Identification No.)
     

4401 WILSHIRE BLVD., SUITE 200
LOS ANGELES, CA

 

90010

(Address of Principal Executive Offices)

  

(Zip Code)

(310) 476-7002
 (Registrant's Telephone Number, Including Area Code)

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

                  Yes x       No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

                  Yes x       No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.    

Large accelerated filer o             Accelerated filer o    
Non-accelerated filer o (Do not check if a smaller reporting company)             Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).                   Yes o       No x

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: As of November 21, 2016, the issuer had 252,370,616 shares of common stock outstanding.

TABLE OF CONTENTS
                          Page
Part I.   FINANCIAL INFORMATION                     1
                           
Item 1.   Condensed Consolidated Financial Statements - Unaudited                     1
                           
    Condensed Consolidated Balance Sheets at September 30, 2016 (unaudited) and December 31, 2015 (audited)                     1
                           
    Condensed Consolidated Statements of Operations - Three and Nine Months Ended September 30, 2016 and September 30, 2015 - (unaudited)                     2
                           
    Condensed Consolidated Statements of Cash Flows - Nine Months Ended September 30, 2016 and September 30, 2015 - (unaudited)                     3
                           
    Notes to Condensed Consolidated Financial Statements - Unaudited                     4
                           
Item 2.   Management's Discussion and Analysis of Financial Condition and Results of Operations                     16
                           
Item 3.   Quantitative and Qualitative Disclosures About Market Risk                     20
                           
Item 4.   Controls and Procedures                     20
                           
Part II.   OTHER INFORMATION                     21
                           
Item 1.     Legal Proceedings                     21
                           
Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds                     21
                           
Item 3.   Defaults Upon Senior Securities                     21
                           
Item 4.   Mine Safety Disclosures                     21
                           
Item 5.   Other Information                     21
                           
Item 6.   Exhibits                     22
                           
Signatures                         23

i

PART I - FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements - Unaudited

MMRGLOBAL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
      September 30,     December 31,
      2016     2015
      (unaudited)     (audited)
ASSETS
             
Current assets:            
     Cash and cash equivalents   $ -    $ - 
     Accounts receivable, less allowances of $215,483 and $215,483 in 2016 and 2015, respectively     11,744      27,934 
     Prepaid expenses and other current assets     78,014      - 
          Total current assets     89,758      27,934 
             
Property and equipment, net      8,346      19,071 
Intangible assets, net      569,311      669,603 
          Total assets   $ 667,415    $ 716,608 
             
LIABILITIES AND STOCKHOLDERS' DEFICIT
             
Current liabilities:            
     Line of credit, related party   $ 1,715,646    $ 1,002,428 
     Related party payables     1,920,332      1,385,901 
     Compensation payable     748,160      727,509 
     Severance liability     620,613      620,613 
     Accounts payable and accrued expenses     3,152,583      4,420,585 
     Convertible notes payable     323,749      323,749 
     Notes payable, current portion     382,238      369,413 
     Notes payable, related party     6,743      56,743 
     Capital leases payable, current portion     13,222      13,221 
          Total current liabilities     8,883,286      8,920,162 
Notes payable, noncurrent     328,133      - 
          Total liabilities     9,211,419      8,920,162 
             
Commitments and contingencies (See Note 9)            
             
Stockholders' deficit:            
     Preferred stock - $0.001 par value, 5,000,000 shares authorized, 0 issued and outstanding.             
     Common stock, $0.001 par value, 1,250,000,000 shares authorized, 250,060,616 and 211,851,177 shares
          issued and outstanding as of September 30, 2016 and December 31, 2015, respectively 		    1,099,569      1,059,050 
     Additional paid-in capital     58,938,322      57,687,270 
     Accumulated deficit     (68,581,895)     (66,949,874)
          Total stockholders' deficit     (8,544,004)     (8,203,554)
          Total liabilities and stockholders' deficit   $ 667,415    $ 716,608 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

1

MMRGLOBAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

      Three Months Ended     Nine Months Ended
      September 30,     September 30,
      2016     2015     2016     2015
                         
Revenues   $ 26,340    $ 77,664    $ 53,595    $ 138,716 
Cost of revenues     49,733      45,298      167,941      179,554 
     Gross profit (loss)     (23,393)     32,366      (114,346)     (40,838)
General and administrative expenses     297,500      383,147      1,288,472      1,331,644 
Sales and marketing expenses     87,575      102,504      228,136      420,199 
     Loss from operations     (408,468)     (453,285)     (1,630,954)     (1,792,681)
Other income     27,799      8,914      191,900      60,750 
Interest and other finance charges, net     (70,857)     (44,629)     (192,967)     (191,355)
Net loss   $ (451,526)   $ (489,000)   $ (1,632,021)   $ (1,923,286)
                         
                         
Net loss available to common shareholders per share:                        
Basic and diluted   $ (0.00)   $ (0.00)   $ (0.01)   $ (0.01)
                         
Weighted average common shares outstanding:                        
Basic     250,587,899      178,674,759      232,635,531      166,083,438 
Diluted     250,587,899      178,674,759      232,635,531      166,083,438 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

2

MMRGLOBAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

      Nine Months Ended September 30,
      2016     2015
             
Operating activities:            
Net loss   $ (1,632,021)   $ (1,923,286)
Adjustments to reconcile net loss to net cash             
     used in operating activities:            
          Depreciation and amortization     111,017      217,208 
          Gain on write-off of liabilities     (187,871)     - 
          Warrants issued for services     137,528      11,170 
          Stock-based compensation     16,188      16,759 
          Common stock issued for services     -       38,199 
          Amortization of loan discount     -       55,780 
               Subtotal - Non-cash adjustments     76,862      339,116 
     Effect of changes in:            
          Accounts receivable     16,190      (49,110)
          Prepaid expenses and other current assets     88,782      114,744 
          Accounts payable and accrued expenses     422,057      258,667 
          Related party payables     534,432      519,315 
          Compensation payable      20,651      102,925 
          Deferred revenue     -       (11,050)
               Subtotal - net change in operating assets & liabilities     1,082,112      935,491 
               Net cash used in operating activities     (473,047)     (648,679)
             
Investing activities:            
     Purchase of property and equipment     -      (1,252)
     Payments for note receivable     (5,452)     - 
               Net cash used in investing activities     (5,452)     (1,252)
             
Financing activities:            
     Book overdraft     (34,483)     56,163 
     Proceeds from shares issued for financing activities     -       29,774 
     Proceeds from note payable     -       30,000 
     Payments of note payable     -       (30,000)
     Proceeds on line of credit     512,982      254,601 
               Net cash provided by financing activities     478,499      340,538 
Net increase (decrease) in cash     -      (309,393)
Cash, beginning of period     -      309,393 
Cash, end of period   $ -    $ - 
             
Supplemental disclosures of cash flow information:            
     Interest paid in cash   $ -    $ 93,268 
     Income taxes paid in cash   $ -    $ 1,675 
             
Supplemental disclosure of non-cash investing and financing activities:            
     Conversion of convertible notes into common stock   S -    S 100,800 
     Shares issued for reduction of payables   S 387,855    S 299,420 
     Warrants exercised through reduction of payables   $ 750,000    $ - 
     Conversion of accounts payable to note payable   $ 328,133    $ - 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

3

MMRGLOBAL, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
September 30, 2016

NOTE 1 - NATURE OF OPERATIONS AND BASIS OF PRESENTATION

MMRGlobal Inc. (referred to herein, unless otherwise indicated, as "MMR," the "Company," the "issuer," "we," "us," and "our") was originally incorporated as Favrille, Inc. ("Favrille") in Delaware in 2000, and since its inception and before the Merger (as defined below), operated as a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. In May 2008, Favrille's ongoing Phase 3 registration trial for the FavId vaccine failed to show a statistically significant improvement in the treatment of patients with follicular B-cell Non-Hodgkin's lymphoma. On January 27, 2009, the Company, through MyMedicalRecords, Inc. ("MMR Inc."), what is now our wholly-owned operating subsidiary, conducted a reverse merger with Favrille.

Through our wholly-owned operating subsidiary MMR Inc., the Company's primary business is to license and provide secure and easy-to-use online Personal Health Records ("PHR") and MyEsafeDepositBox storage solutions, including a professional offering to physicians' offices and similar organizations known as MMRPro. Starting in 2005, we began filing for patent protection for our PHR products and services, and we now have patents issued, pending, and applied for in numerous countries around the world. As a result, we have evolved from an operating business selling products to also licensing health information technology patents and other intellectual property. In January 2009, as a result of the Merger, we acquired biotech assets and other intellectual property including anti-CD20 antibodies as well as data and samples from the FavId/Specifid vaccine clinical trials for the treatment of B-cell Non-Hodgkin's lymphoma which the Company continues to work towards maximizing the value of those biotech assets including related biotech patents, anti-CD 20 antibodies, and FavId vaccine technologies acquired by MyMedicalRecords, Inc. through the merger with Favrille. We (formerly Favrille) were incorporated in Delaware in 2000, MMR Inc. was incorporated in Delaware in 2005, and both are headquartered in Los Angeles, CA.

Principles of Consolidation

The consolidated financial statements include the accounts of MMRGlobal, and its wholly-owned subsidiaries MMR and MMR Life Sciences Group, Inc. All intercompany transactions and balances are eliminated upon consolidation.

Basis of Presentation

We have prepared the accompanying consolidated unaudited financial statements in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial statements and with instructions to Form 10-Q pursuant to the rules and regulations of Securities and Exchange Act of 1934, as amended, or the Exchange Act and Article 8-03 of Regulation S-X promulgated under the Exchange Act. Accordingly, these financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of our management, we have included all adjustments considered necessary (consisting of normal recurring adjustments) for a fair presentation. Operating results for the three and nine months ended September 30, 2016 are not indicative of the results that may be expected for the fiscal year ending December 31, 2016. You should read these unaudited condensed consolidated financial statements in conjunction with the audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2015.

Going Concern and Management's Plan

As of September 30, 2016, our current liabilities exceeded our current assets by $8.8 million. Furthermore, during the nine months ended September 30, 2016, we incurred losses of $1,632,021, as further explained in Management's Discussion and Analysis of Financial Condition and Results of Operations appearing in Item 2 of Part I of this Quarterly Report on Form 10-Q.

At September 30, 2016 and December 31, 2015, we had $0 and $0, respectively, in cash and cash equivalents. Historically, we issued capital stock, sold debt and equity securities and received funds from The RHL Group, Inc. (a significant stockholder that is wholly-owned by our Chairman and Chief Executive Officer, Robert H. Lorsch) to operate our business. Although we received additional funding from The RHL Group pursuant to the Eleventh Amended and Restated Note effective June 6, 2016 (the "Line of Credit"), we will still be required to obtain additional financing in order to meet installment payment obligations and the previously existing obligations under the Line of Credit, which had a balance of $2,953,548 at September 30, 2016 and a total Unpaid Balance (as defined in the Line of Credit) of $3,203,548, which includes amounts borrowed under the Line of Credit, unpaid interest fees, any amounts guaranteed by The RHL Group, and other obligations due The RHL Group pursuant to the terms of the Eleventh Amended and Restated Note and the Security Agreement. As a result of the above, we express uncertainty about our ability to continue as a going concern. The components of the RHL Group Note payable and the related balance sheet presentation as of September 30, 2016 are as follows: $1,715,646, which is included in the Line of Credit, related party; and $1,237,902 related to other obligations due to The RHL Group which are included in related party payables.

4

Management's plan regarding this matter is to, amongst other things, continue to utilize our available Line of Credit with The RHL Group (see Note 3). As of September 30, 2016, under the original terms, we had approximately $1,296,452 remaining as available under The RHL Group Line of Credit, but we are now in default under the line of credit. Additionally, we plan to continue selling additional debt and equity securities, continue to settle our existing liabilities through issuance of equity securities, explore other debt financing arrangements, continue to increase our existing subscriber and affiliate customer base, sell MMRPro products, and continue efforts to license our intellectual property to obtain additional cash flow over the next twelve months. We cannot assure that funds from these sources will be available when needed or, if available, will be on terms favorable to us or to our stockholders. If we raise additional funds or settle liabilities by issuing equity securities, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution or such equity securities may provide for rights, preferences or privileges senior to those of the holders of our common stock. If we are unable to utilize our available Line of Credit with The RHL Group or obtain suitable alternative debt or equity financing, our ability to execute our business plan and continue as a going concern may be adversely affected.

These matters raise substantial doubt about our ability to continue as a going concern. These financial statements were prepared under the assumption that we will continue as a going concern and do not include any adjustments that might result from the outcome of that uncertainty.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a) MANAGEMENT'S USE OF ESTIMATES

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net revenue and expenses during each reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowances for doubtful accounts, the valuation of deferred income taxes, tax contingencies, long-lived and intangible assets, valuation of derivative liabilities and stock-based compensation. These estimates are based on historical experience and on various other factors that management believes to be reasonable under the circumstances, although actual results could differ from those estimates.

(b) CASH AND CASH EQUIVALENTS

We consider cash equivalents to be only those investments that are highly liquid, readily convertible to cash and with maturities of 90 days or less at the purchase date. We maintain our cash in bank deposit accounts that, at times, may exceed federally insured limits. We have not experienced any losses in such accounts and believe that we are not exposed to any significant credit or deposit risk on our cash. We had cash and cash equivalents of $0 and $0 as of September 30, 2016 and December 31, 2015, respectively.

(c) TRADE AND OTHER RECEIVABLES

Receivables represent claims against third parties that will be settled in cash. The carrying value of receivables, net of an allowance for doubtful accounts, if any, represents their estimated net realizable value. We estimate the allowance for doubtful accounts, if any, based on historical collection trends, type of customer, the age of outstanding receivables and existing economic conditions. If events or changes in circumstances indicate that specific receivable balances may be impaired, we give further consideration to the collectability of those balances and the allowance is adjusted accordingly. We write off past due receivable balances when collection efforts have been unsuccessful in collecting the amount due.

(d) FAIR VALUE OF FINANCIAL INSTRUMENTS

ASC 820-10, Fair Value Measurements and Disclosures, requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of September 30, 2016 and December 31, 2015, the carrying value of accounts receivable, deposits, related party payables, compensation payable, severance liabilities, and accounts payable and accrued expenses approximates fair value due to the short-term nature of such instruments. The carrying value of short-term debt approximates fair value as the related interest rates approximate rates currently available to us.

We utilize ASC 820-10 for valuing financial assets and liabilities measured on a recurring basis. ASC 820-10 defines fair value, establishes a framework for measuring fair value and generally accepted accounting principles, and expands disclosures about fair value measurements. This standard applies in situations where other accounting pronouncements either permit or require fair value measurements. ASC 820-10 does not require any new fair value measurements.

Accounting guidance also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

5

The standard describes three levels of inputs that may be used to measure fair value:

 

Level 1:

Quoted prices in active markets for identical or similar assets and liabilities.

 

Level 2:

Quoted prices for identical or similar assets and liabilities in markets that are not active or observable inputs other than quoted prices in active markets for identical or similar assets and liabilities.

 

Level 3:

Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

(e) IMPAIRMENT OF LONG-LIVED ASSETS AND INTANGIBLES

We account for long-lived assets, which include property and equipment and identifiable intangible assets with finite useful lives (subject to amortization), in accordance with ASC 350-30. ASC 350-30 requires that we review long-lived assets for impairment whenever events or changes in circumstances indicate that we may not recover the carrying amount of an asset. We measure recoverability by comparing the carrying amount of an asset to the expected future undiscounted net cash flows generated by the asset. If we determine that the asset may not be recoverable, or if the carrying amount of an asset exceeds its estimated future undiscounted cash flows, we recognize an impairment charge to the extent of the difference between the fair value and the asset's carrying amount. Our assessment of the undiscounted future cash flows indicated that the carrying amount of the long-lived and intangible assets are recoverable, therefore, we had no impairment charges during the nine months ended September 30, 2016 and 2015.

(f) REVENUE RECOGNITION

We generate our revenues from services, which are comprised of providing electronic access to consumer medical records and other vital documents, and from the licensing of our intellectual property and services. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and we are reasonably assured of collectability of the resulting receivable.

Our subscriber revenues consist of annual and monthly recurring retail subscriptions and usage-based fees, which are primarily paid in advance by credit card, and corporate accounts that are based on either an access-fee or actual number of users, and in each case billed in advance at the beginning of each month of service. We defer the portions of annual recurring subscription fees collected in advance and recognize them on a straight line basis over the subscription period. As part of our ongoing sales and marketing activities, we also offer sell a Personal Health Record Kit through retailers to the extent reasonably possible.

We license the rights to use portions of our intellectual property portfolio, which includes certain patent rights essential to the sale of certain PHR products. Licensees typically pay a license fee in one or more installments and ongoing royalties based on their sales of products incorporating or using the Company's licensed intellectual property. License fees are recognized over the estimated period of benefit to the licensee, typically five to fifteen years. The Company earns royalties on such licensed products sold by its licensees at the time that the licensees' sales occur. The Company recognizes royalty revenues based on royalties reported by licensees during the quarter and when other revenue recognition criteria are met.

We grant exclusive and non-exclusive licenses for the sale and marketing of our services in international territories in consideration of license fees and ongoing royalties. The royalty fee is usually a percentage of revenue earned by the licensee and there are usually certain minimum guarantees. We defer the recognition of license fee revenues received in advance from international licensees for the grant of the license and recognize them over the period covered by the agreement. We defer the recognition of minimum guaranteed royalty payments received in advance and recognize them over the period to which the royalty relates. We include all such revenues under "License Fees." In those cases where a license agreement contains multiple deliverables, we account for the agreement in accordance with ASC 605-25 - Revenue Recognition - Multiple-Element Arrangements.

We recognize revenue on sales of our MMRPro system in accordance with ASC 605-25, Revenue Recognition, Multiple-Element Arrangements.

6

Our multiple-deliverable arrangements consist solely of our MMRPro product. Deliverables within these arrangements include scanning equipment, various licenses to use third party software, a license to use our proprietary MMRPro application software, installation and training, dedicated telephone lines, secure online storage and warranties.

We determined all elements to be separate units of accounting as they have standalone value to the customers and/or they are sold by other vendors on a standalone basis. Delivery of the hardware and certain software elements of these arrangements occur at the inception of the agreement. We deliver installation and training at the inception of the agreement. We also provide software licenses, telephone lines and online secure storage over the three-year term of an MMRPro agreement. We include warranties in the arrangements, however the third party product manufacturer, and not us, is obligated to fulfill such warranties. The third-party warranty contracts are paid in advance and are not refundable.

We allocate the revenue derived from these arrangements among all the deliverables. We base such allocation on the relative selling price of each deliverable. With the exception of our proprietary MMRPro application software, we use third party evidence to set the selling prices used for this allocation. In all such cases, third parties sell the same or very similar products. For the MMRPro application software, we estimate the selling price based on recent discussions regarding licensure of that particular application on a standalone basis. To date, we have not licensed this software on a standalone basis.

We recognize the allocated revenue for each deliverable in accordance with SEC Staff Accounting Bulletin ("SAB") No. 104, Topic 13: Revenue Recognition. Under this guidance, we recognize revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed and determinable and collectability is reasonably assured. This results in us recognizing revenue for the hardware, certain software and the warranties upon delivery to the customer, for the installation and training upon completion of these services, and ratably over the contract period for the software licenses, telephone lines and online secure storage.

Revenue from the licensing of our biotech assets may include non-refundable license and up-front fees, non- refundable milestone payments that are triggered upon achievement of a specific event, and future royalties or lump-sum payments on sales of related products. For agreements that provide for milestone payments, we adopted ASC 605-28-25, Revenue Recognition Milestone Method.

(g) SHARE-BASED COMPENSATION

We account for share-based compensation in accordance with ASC 718-20, Awards Classified as Equity. We apply ASC 718- 20 in accounting for stock-based awards issued to employees under the recognition of compensation expense related to the fair value of employee share-based awards, including stock options and restricted stock. Determining the fair value of options at the grant date requires judgment, including estimating the expected term that stock options will be outstanding prior to exercise, the associated volatility and the expected dividends. Judgment is required in estimating the amount of share-based awards expected to be forfeited prior to vesting. If actual forfeitures differ significantly from these estimates, share- based compensation expense could be materially impacted.

We account for options and warrants issued to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. We treat options and warrants issued to non-employees the same as those issued to employees with the exception of determination of the measurement date. The measurement date is the earlier of (1) the date at which a commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty's performance is complete. Options and warrants granted to consultants are valued at their respective measurement dates, and recognized as an expense based on the portion of the total consulting services provided during the applicable period. As further consulting services are provided in future periods, we will revalue the associated options and warrants and recognize additional expense based on their then current values.

We estimate the fair value of each stock option on the date of grant using the Black-Scholes option pricing model. We determine assumptions relative to volatility and anticipated forfeitures at the time of grant. No stock options were granted during the nine months ended September 30, 2016. We valued grants of stock options and warrants during the nine months ended September 30, 2016 using the following assumptions.

Expected life in years   2 - 5 Years
Stock price volatility   79%
Risk free interest rate   0.04 - 1.38%
Expected dividends   None
Forfeiture rate   0%

7

We base the assumptions used in the Black-Scholes models upon the following data: (1) our use of the contractual life of the underlying non-employee warrants as the expected life; the expected life of the employee options used in this calculation is the period of time the options are expected to be outstanding and has been determined based on historical exercise experience; (2) in the absence of an extensive public market for our shares, the expected stock price volatility of the underlying shares over the expected term of the option or warrant was taken at approximately the mid-point of the range for similar companies at the various grant dates; (3) we base the risk free interest rate on published U.S. Treasury Department interest rates for the expected terms of the underlying options or warrants; (4) we base expected dividends on historical dividend data and expected future dividend activity; and (5) we base the expected forfeiture rate on historical forfeiture activity and assumptions regarding future forfeitures based on the composition of current grantees.

(h) NET INCOME/LOSS PER SHARE

We apply the guidance of ASC 260-10, Earnings Per Share for calculating the basic and diluted loss per share. We calculate basic loss per share by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding. We compute diluted loss per share similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential shares had been issued and if the additional shares were dilutive. We exclude common equivalent shares from the computation of net loss per share if their effect is anti-dilutive.

We excluded all potential anti-dilutive common shares from the computation of diluted net loss per common share for the nine months ended September 30, 2016 and 2015 because they were anti-dilutive due to our net loss position. Stock options, warrants and convertible notes excluded from the computation totaled 43,208,730 shares for the nine months ended September 30, 2016 and 33,251,116 shares for the nine months ended September 30, 2015, respectively.

(i) RECENT ACCOUNTING PRONOUNCEMENTS

In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. This new guidance is effective for annual and interim periods beginning after December 15, 2017, with no early adoption permitted. The standard permits the use of either the retrospective or cumulative effect transition method. At this time we have not selected a transition method. We are currently evaluating the effect that ASU 2014-09 will have on our consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

In August 2014, the FABS issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern ("ASU 2014-15"). ASU 2014-15 will explicitly require management to assess an entity's ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. These changes became effective for the Company for the 2016 annual period. The adoption of these changes did not have an impact on the consolidated financial statements.

In February 2015, the FASB issued ASU 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis. This standard modifies existing consolidation guidance for reporting organizations that are required to evaluate whether they should consolidate certain legal entities. ASU 2015-02 is effective for fiscal years and interim periods within those years beginning after December 15, 2015, and requires either a retrospective or a modified retrospective approach to adoption. Early adoption is permitted. The adoption of this standard did not have an impact on the Company's Consolidated Financial Statements.

In April 2015, the FASB issued ASU No 2015-3, Simplifying the Presentation of Debt Issuance Costs. This update changes the presentation of debt issuance costs in the balance sheet. ASU 2015-03 requires debt issuance costs related to a recognized debt obligation to be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability rather than being presented as an asset. Amortization of debt issuance costs will continue to be reported as interest expense. In August 2015, the FASB issued ASU 2015-15, "Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements". This ASU clarified guidance in ASC 2015-03 stating that the SEC staff would not object to a company presenting debt issuance costs related to a line-of-credit arrangement on the balance sheet as a deferred asset, regardless of whether there were any outstanding borrowings at period-end. This update is effective for annual and interim periods beginning after December 15, 2015, which required us to adopt these provisions starting the first quarter of 2016. This guidance did not have a material impact to our financial position or results of operations.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes existing guidance on accounting for leases in "Leases (Topic 840)" and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

8

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting. This ASU affects entities that issue share-based payment awards to their employees. The ASU is designed to simplify several aspects of accounting for share-based payment award transactions which include - the income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows and forfeiture rate calculations. ASU 2016-09 will become effective for the Company in the first quarter of fiscal 2018. Early adoption is permitted in any interim or annual period. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.

In April 2016, the FASB issued AS 2016-10, Revenue from Contracts with Customers (Topic 606), which amends certain aspects of the Board's new revenue standard, ASU 2014-09, Revenue from Contracts with Customers. The standard should be adopted concurrently with adoption of ASU 2014-09 which is effective for annual and interim periods beginning after December 15, 2017. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

(j) RECLASSIFICATIONS

Certain numbers in the prior year have been reclassified to conform to the current year's presentation.

NOTE 3 - RELATED PARTY PAYABLES, LINE OF CREDIT AND NOTE PAYABLE

On June 6, 2016, we and The RHL Group entered into an Eleventh Amended and Restated Promissory Note (the "Amended Note"), effective as of June 6, 2016. The Eleventh Note amends and restates that certain Tenth Amended Note entered into between the foregoing parties, effective May 20, 2015 (the " Existing Note") and together with its predecessor notes and the Amended Note, the ("Credit Facility"), by: (i) extending the maturity date to June 6, 2017. In connection with the Eleventh Amended Note, we issued The RHL Group warrants to purchase 2,777,714 shares of our common stock at $0.011 per share on June 6, 2016. Other than for the amounts as disclosed herein, The Eleventh Amended Note does not materially alter the terms of the previous Tenth Amended Note.

Historically, the predecessor notes have increased over time the maximum amount of credit available under the Credit Facility from $100,000 to $1,000,000 to $3,000,000 to $4,500,000. The maximum amount of the Amended Note is $4,500,000. The Amended Note continues to bear interest at the lesser of 10% or the highest rate then permitted by law, and is secured (similar to the Existing Note) by a Security Agreement, which has been in effect since July 31, 2007, as renewed and amended to date (the "Security Agreement").

The Eleventh Amended Note had a current balance of $2,953,548 at September 30, 2016. The components of the Eleventh Amended Note and the related balance sheet presentation as of September 30, 2016 are as follows: $1,715,646, which is included in the Line of Credit, related party; and $1,237,902 for other obligations due to The RHL Group, which is included in related party payables.

Total interest expense on the Line of Credit for the three months ended September 30, 2016 and 2015 amounted to $70,925 and $36,699, respectively. Total interest expense on the Line of Credit for the nine months ended September 30, 2016 and 2015 amounted to $200,237 and $102,433, respectively. The unpaid interest balances as of September 30, 2016 and December 31, 2015 were $321,737 and $60,257, respectively.

In conjunction with the Eleventh Amended Note, we were required to maintain certain financial covenants, including the requirement that we have at least $200,000 of cash in our bank accounts or such other amount as necessary to maintain operations through the subsequent thirty (30) days and timely pay any obligations due respecting payroll and all associated payroll taxes at any time during the term of the Note. As of November 21st, the Company was not in compliance with certain of the financial covenants and The RHL Group has not waived any of the covenants.

NOTE 4 - INCOME TAXES

Under ASC 740-270, Income Taxes - Interim Reporting, we are required to adjust our effective tax rate each quarter to be consistent with the estimated annual effective tax rate. We are also required to record the tax impact of certain discrete items, unusual or infrequently occurring, including changes in judgment about valuation allowances and effects of changes in tax laws or rates, in the interim period in which they occur. In addition, we exclude jurisdictions with a projected loss for the year or a year-to-date loss where we cannot recognize a tax benefit from our estimated annual effective tax rate. The impact of such an exclusion could result in a higher or lower effective tax rate during a particular quarter, based upon the mix and timing of actual earnings versus annual projections.

Pursuant to ASC 740, Income Taxes, we performed an analysis of previous tax filings and determined that there were no positions taken that it considered uncertain. Therefore, there were no unrecognized tax benefits as of September 30, 2016.

9

MMR Inc., in its capacity as the operating company taking over our income tax positions in addition to its own positions after January 27, 2009 (see Note 1), has estimated its annual effective tax rate to be zero. MMRGlobal has based this on an expectation that the combined entity will generate net operating losses in 2016, and it is not likely that those losses will be recovered using future taxable income. Therefore, no provision for income tax has been recorded as of and for the nine months ended September 30, 2016.

We account for income taxes in accordance with ASC 740-10, Income Taxes. We recognize deferred tax assets and liabilities to reflect the estimated future tax effects, calculated at the tax rate expected to be in effect at the time of realization. We record a valuation allowance related to a deferred tax asset when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.

NOTE 5 - COMMITMENTS AND CONTINGENCIES

Leases

Effective September 1, 2013, we renewed our lease for office space in Los Angeles, California with a term through August 31, 2018. The lease currently requires a monthly payment of $8,250. Total rent expense for the nine months ended September 30, 2016 and 2015 were $79,335 and $86,854 respectively. Future minimum lease payments as of September 30, 2016, under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:

Year Ending     Operating     Capital
December 31,     Leases     Leases
             
     2016 (Remainder of)    $ 24,750    $ 13,222 
     2017      99,000      -  
     2018      66,000      -  
Total minimum lease payments    $ 189,750    $ 13,222 

Litigation Matters

From time to time, we are involved in various legal proceedings generally incidental to our business. While the result of any litigation contains an element of uncertainty, our management presently believes that the outcome of any known, pending or threatened legal proceeding or claim, individually or combined, will not have a material adverse effect on our financial statements.

On December 9, 2011, MyMedicalRecords, Inc. entered into a Non-Exclusive Settlement and Patent License Agreement with Surgery Center Management LLC ("SCM"). In consideration for the rights granted under that Agreement and in consideration of a settlement and release agreement, SCM contracted to pay MyMedicalRecords, Inc. an initial payment of $5 million payable on December 23, 2011, and additional payments of $5 million per year for five consecutive years. After unsuccessful attempts to collect the past due amount of $5 million, on January 19, 2012, MyMedicalRecords, Inc. filed a lawsuit in the Superior Court of the State of California for the County of Los Angeles for breach of contract. On February 13, 2014, SCM filed a cross-complaint alleging claims for breach of that contract, among other things, which SCM has amended twice. On September 29, 2016, the court granted a motion for summary judgment filed by Robert Lorsch, a cross-defendant. The case between MyMedicalRecords, Inc. and SCM began trial on November 1, 2016.  MyMedicalRecords, Inc. will continue to pursue its claim and defenses, but the Company cannot predict the chances of either a favorable or unfavorable outcome, nor does the Company have sufficient information regarding its ability to collect any judgment MyMedicalRecords, Inc. may obtain against SCM.

On April 2, 2015, the Company and Stradling Yocca Carlson & Rauth, P.C. ("SYCR"), were notified of the determination of an arbitrator in regards to disputes over amounts of monies due SYCR regarding prior services rendered. SYCR and the Company had previously agreed to a non-binding arbitration of the matter. The Company received an award in favor of SYCR in the amount of $285,000 which the Company disputed, notwithstanding, that it represented a reduction of SYCR's original $571,000 claim or $286,000 in favor of the Company. On September 1, 2016, the Company settled with SYCR through the signing of an eighteen-month unsecured Promissory Note in the amount of $328,133.

10

Two separate MyMedicalRecords health IT patents were accepted by the Australia Patent Office in 2015 and subject to Opposition. On January 8, 2015, Australia Patent Application No. 2011307287, "Universal Patient Record Conversion Tool," was accepted by the Australia Patent Office. An opposition was filed on April 21, 2015 by The Crown in the Right of the Commonwealth of Australia (Department of Health). A second opposition was filed on April 22, 2015 by the Medical Software Industry Association, Inc. which aligned itself with the Crown.  In the interim, a divisional application, Australia Patent Application No.2015201900, was filed on October 15, 2015.  Rather than continue to bear the legal costs of defending these patents before the Governmental Department of Health, MMR determined it was in the Company's best interest to withdraw the patent and the divisional application and this action was officially acknowledged by the Australian Government on August 4, 2016, thereby ending any further opposition.  Separately, Australia Patent Application No. 2013212253, "Mobile Platform for Personal Health Records," was also accepted by the Australia Patent Office after which oppositions were filed.  Subsequently, the Company filed a request this quarter for withdrawal of the disputed application and also surrender of a related innovation patent No. 2015101556.  The Australian Government acknowledged these actions on September 13, 2016 and we do not expect any further potential litigation in this matter. MMR continues to maintain two previously issued Australia health IT patents under the title "Method and System for Providing Online Medical Records": Patent No. 2006202057 issued on May 29, 2008 and Patent No. 2008202401 issued on December 24, 2009.

NOTE 6 - STOCKHOLDERS' DEFICIT

Preferred Stock

We have 5,000,000 shares of preferred stock authorized. As of September 30, 2016 and December 31, 2015, there were no shares of preferred stock issued and outstanding.

Common Stock

As of September 30, 2016, we are authorized to issue 1,250,000,000 shares of common stock.

On February 2, 2016, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the "Certificate of Amendment") with the Secretary of State of the State of Delaware effecting a five for one reverse stock split of the Company's common stock (the "Reverse Stock Split") which became effective in the marketplace on February 8, 2016. The number of shares and per share amounts have been retroactively restated to reflect this reverse stock split.

As of September 30, 2016, the total shares of our common stock issued and outstanding amounted to 252,370,616.

NOTE 7 - EQUITY ISSUANCES

Stock Option Activity

Our 2001 Equity Incentive Plan (the "2001 Plan") expired on June 5, 2011 and no options were issued under the 2001 Plan since that date. As of September 30, 2016, 2,626,911 shares remain issued under the 2001 Plan.

On September 1, 2011, our Board of Directors approved the adoption of a new plan to replace the 2001 Plan under the same general terms as the 2001 Plan. On June 20, 2012, our stockholders voted and approved the 2011 Equity Incentive Plan (the " 2011 Plan") at our 2012 Annual Stockholder Meeting. As of September 30, 2016, 2.65 million shares remain issued under the 2011 Plan, and 7.29 million shares of our common stock are reserved for future issuance under our 2011 Plan, which includes an automatic 1 million share annual increase pursuant to the terms of the 2011 Plan and a 5 million share increase authorized during our 2013 Annual Stockholder's Meeting.

11

A summary of option activity for the nine months ended September 30, 2016 is presented below. Options granted by MMR Inc. prior to the date of the Merger have been retroactively restated to reflect the conversion ratio of MMR Inc. to MMR shares

              Weighted-Average      
          Weighted-   Remaining      
          Average   Contractual     Aggregate
          Exercise   Life     Intrinsic
    Options     Price   (Years)     Value
Outstanding at December 31, 2015   7,488,345    $ 0.50    3.62    $ -  
Granted   -       -            
Exercised   -       -            
Cancelled   (2,208,052)     0.65           
Outstanding at September 30, 2016 (Unaudited)   5,280,293    $ 0.45    4.15    $ -  
                     
Vested and expected to vest                    
     at September 30, 2016 (Unaudited)   5,280,293    $ 0.45    4.15    $ -  
                     
Exercisable at September 30, 2016 (Unaudited)   5,280,293    $ 0.45    4.15    $ -  

The aggregate intrinsic value in the table above is before applicable income taxes and is calculated based on the difference between the exercise price of the options and the quoted price of the common stock as of the reporting date.

There were no options issued during the nine months ended September 30, 2016.

Total stock option expenses recorded during the nine months ended September 30, 2016 and 2015 were $16,188 and $16,759, respectively, and is reflected in operating expenses in the accompanying consolidated statements of operations.

The following table summarizes information about stock options outstanding and exercisable at September 30, 2016.

      Options Outstanding   Options Exercisable
            Weighted     Weighted       Weighted     Weighted
            Average     Average       Average     Average
  Exercise   Number     Remaining     Exercise   Number   Remaining     Exercise
  Price   of Shares     Life (Years)     Price   of Shares   Life (Years)     Price
                                 
$ 0.25 - 0.45   2,560,000      5.11   $ 0.35    2,560,000    5.11   $ 0.35 
$ 0.50 - 0.75   2,520,293      3.21   $ 0.55    2,520,293    3.21   $ 0.55 
$ > 0.75   200,000      3.71   $ 0.90    200,000    3.71   $ 0.90 
      5,280,293                5,280,293           

12

Warrants

During the nine months ended September 30, 2016, there were 40,227,714 warrants issued. During the nine months ended September 30, 2016, 11,750,000 warrants were exercised, which was paid by the reduction of our accounts payable balance owed to the vendor/warrant holder in the aggregate amount of $750,000.

A summary of the activity of our warrants for the nine months ended September 30, 2016 is presented below:

        Weighted Avg
  Shares     Exercise Price
Outstanding at December 31, 2015 11,428,610    $ 0.30 
Granted 40,227,714      0.02 
Exercised (11,750,000)     0.06 
Cancelled (3,333,818)     0.49 
Outstanding at September 30, 2016 (Unaudited) 36,572,506    $ 0.06 
         
Exercisable at September 30, 2016 (Unaudited) 34,539,173    $ 0.06 

Total warrant expenses recorded during the nine months ended September 30, 2016 and 2015 were $137,528 and $11,170, respectively.

The following summarizes the total warrants outstanding and exercisable as of September 30, 2016:

    Warrants Outstanding   Warrants Exercisable
    Warrants   Weighted Avg     Weighted Avg   Warrants   Weighted Avg     Weighted Avg
Ranges   Outstanding   Remaining Life     Exercise Price   Exercisable   Remaining Life     Exercise Price
                           
$0.02 - $0.30   35,794,569   2.61   $ 0.05   33,761,236   2.59   $ 0.05
$0.30 - $0.50   255,000   0.53     0.50   255,000   0.53     0.50
Greater $0.50   522,937   0.58     1.05   522,937   0.58     1.05
                             
    36,572,506             34,539,173          

The inputs used for the Black-Scholes option and warrant valuation model were as follows:

Expected life in years   2 - 5 Years
Stock price volatility   79%
Risk free interest rate   0.04 - 1.38%
Expected dividends   None
Forfeiture rate   0%

Shares Issued for Services or Reduction to Liabilities

During the nine months ended September 30, 2016, we issued 28,769,439 shares of common stock with a value of $387,855 to various third parties and charged the proceeds to the appropriate accounts for the following reasons:

    Nine Months Ended September 30, 2016
           
Purpose   Shares     Value
           
Services provided   -     $ -  
Reduction of payables   28,769,439      387,855 
Totals    28,769,439    $ 387,855 

13

The 28,769,439 issued shares were not contractually restricted. However, as these shares have not been registered under the Securities Act of 1933, as amended (the "Act"), they are restricted from sale until they are registered under the Act, or qualify for resale under the rules promulgated under the Act. All such shares were calculated at the trading closing price on the date of issuance.

Stock Bonus Agreements

From time to time, we issue shares of our common stock as a bonus for services rendered. Stock bonuses may be awarded upon satisfaction of specified performance goals pursuant to the Performance Stock Bonus Agreement.

On each grant date, we valued the stock bonus based on the share price and the expenses were amortized using the straight line method. Total stock bonus expenses recorded during the nine months ended September 30, 2016 and 2015 were $0 and $0, respectively and are reflected in operating expenses in the accompanying consolidated statements of operations.

NOTE 8 - NOTES PAYABLE

Notes payable consisted of the following:

      September 30,     December 31,
      2016     2015
             
Promissory notes payable due to the former officers of MMRGlobal as part of severance
packages, due in full on August 31, 2009 with no stated interest		   $ 76,783    $ 76,783 
             
Promissory notes payable due to the former officers of MMRGlobal pursuant to the
Resignation and Post-Merger Employment Arrangement, due in full on August 31, 2009
with no stated interest		     25,444      25,444 
             
Promissory notes payable due to vendors relating to settlement of certain outstanding
accounts payable, payable in 18 equal monthly installments commencing on July 27, 2009
and ending on January 27, 2011, with no stated interest		     223,116      223,116 
             
Short-term loan due to a third-party with 6% interest     56,896      44,070 
             
Long term note payable relating to legal accounts payable, payable in full on March 30, 2018 with 10% interest per annum     328,133      - 
             
      710,372      369,413 
Less: current portion     (382,239)     (369,413)
Notes payable, less current portion   $ 328,133    $ - 
             
Short term loan due to a related-party, payable in full on January 2, 2014 with 12% interest    $ 6,743    $ 6,743 
             
Short term loan due to a related-party, payable in full on May 31, 2014 with 12% interest      -      50,000 
             
Notes payable related party, current portion     6,743      56,743 
             
Less: current portion     (6,743)     (56,743)
Notes payable related party, less current portion   $ -    $ - 

NOTE 9 - CONVERTIBLE PROMISSORY NOTES

From time to time, we issue Convertible Promissory Notes. As of September 30, 2016, a total of $323,749 in convertible notes remained outstanding and have matured. However, the Company and the Holders have agreed to keep the balance as a Note Payable and the note holders have elected not to convert their note balances into shares of our common stock as of September 30, 2016.

14

Each Note contains the following general terms and provisions:

  • The principal amount owed under each note becomes due and payable one year or less from the investment date provided that, upon ten (10) days' prior written notice to the holder, we may, in our sole discretion, extend the maturity date for an additional six month term. The Notes can be further extended upon mutual agreement.
  • These notes bear interest at a rate of 0%-6% per annum payable in cash or shares of common stock or a combination of cash and shares of common stock at our option.

During the third quarter of 2016, we did not enter into any Convertible Promissory Notes.

Shares issuable upon conversion for convertible notes payable was 1,355,932 as of September 30, 2016.

The total interest expense attributed to the Beneficial Conversion Feature of the Notes and related warrants for the nine months ended September 30, 2016 and 2015 was $0 and $55,780, respectively.

NOTE 10 - RESTRUCTURING ACTIVITIES

In connection with the merger with Favrille, Inc. in 2009, we signed promissory notes with certain former executives totaling $76,783.

As of September 30, 2016, the total remaining severance liabilities amounted to $620,613, which is reflected as severance liability on the accompanying consolidated balance sheets. This consists of $571,362 payable to former non-executive employees.

NOTE 11 - RELATED PARTY TRANSACTIONS

Our Chairman and Chief Executive Officer, Robert H. Lorsch, is also the Chief Executive Officer of The RHL Group, Inc. and has full voting power over all of the capital stock of The RHL Group, Inc. Mr. Lorsch directly and indirectly through The RHL Group, Inc., beneficially owns approximately 32.1% our total outstanding voting stock. The RHL Group, Inc. has loaned us money pursuant to the Eleventh Amended Note and all predecessor notes. See Note 3 - Related Party Note Payable above.

The RHL Group is an investment holding company which provides consulting, operational and technical services to us, which we refer to as the RHL Services. As part of the RHL Services, The RHL Group provides us with unrestricted access to its internal business and relationship contact database of more than 10,000 persons and entities, which includes clients of The RHL Group and other individuals which may hold value to us. The RHL Group also provides infrastructure support to us, including allowing us unlimited access to its facilities, equipment, and data, information management and server systems. In addition to allowing us the use of its office support personnel, The RHL Group has also consented to allow us to utilize the full-time services of Mr. Lorsch as our President, Chairman and Chief Executive Officer, which requires substantial time and energy away from his required duties as The RHL Group's Chairman and Chief Executive Officer. In addition, The RHL Group has made Kira Reed, available as our spokesperson. Ms. Reed, who is Mr. Lorsch's spouse, also manages our social networking activities.

In consideration for the above, The RHL Group, Inc. has a consulting arrangement with MMR. A copy of the consulting agreement is filed as an exhibit in our Form 8-K, as filed with the SEC on May 4, 2009 and is hereby incorporated by reference.

We incurred $37,500 during the nine months ended September 30, 2016 and 2015, toward marketing consulting services from Bernard Stolar, a director. We included $260,523 and $206,272 in related party payables as of September 30, 2016 and December 31, 2015, respectively, in connection with these services and board fees.

We contract with a significant vendor for the development and maintenance of the software applications necessary to run our MyMedicalRecords PHR, MyEsafeDepositBox and MyMedicalRecords Pro products. Our outside developer supports our software development needs through a team of software engineers, programmers, quality control personnel and testers, who work with our internal product development team on all aspects of application development, design, integration and support of our products. This vendor is also a stockholder. For the nine months ended September 30, 2016 and 2015, the total expenses relating to this stockholder amounted to $90,000 and $90,000, respectively. In addition, we capitalized $0 of software development costs for the quarter ended September 30, 2016. As of September 30, 2016 and December 31, 2015, the total amounts due to the stockholder and included in related party payables amounted to $195,000 and $105,000 respectively.

15

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion of our financial condition and results of operations in conjunction with our financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and the description of our business appearing in our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on April 14, 2016, as amended by Form 10-K/A for the year ended December 31, 2015, as filed with the SEC on April 21, 2016 (together, the "Form 10-K"). This discussion contains forward-looking statements, which inherently involve risks and uncertainties. Please see "Cautionary Note Regarding Forward-Looking Statements" below. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the risks faced by us described in "Risk Factors" in Item 1A of the Form 10-K.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains certain forward-looking statements. The words "anticipate," "expect," "believe," "plan," "intend," "will" and similar expressions are intended to identify such statements. Although the forward-looking statements in this Quarterly Report on Form 10-Q reflects the good faith judgment of our management, such statements are subject to various risks and uncertainties, including but not limited to the risks identified in our Form 10-K and in our press releases and other filings with the SEC.

Assumptions related to forward-looking statements involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control. Any of such assumptions could be inaccurate. You should not place undue reliance on these forward-looking statements, which are based on our current views and assumptions. In evaluating these statements, you should specifically consider various factors, including the foregoing risks and those outlined under "Risk Factors" in Item 1A of the Form 10-K. Our forward-looking statements represent estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q. Except as required by law, we undertake no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date of this Quarterly Report on Form 10-Q.

Overview

Background

As described above, on January 27, 2009, we consummated a transaction with MMR, Inc. through a merger of our wholly-owned subsidiary with and into MMR pursuant to the terms of the Merger Agreement. In connection with the Merger, MMR Inc. became our wholly-owned subsidiary, with the former stockholders of MMR Inc. collectively owning (or having the right to acquire) shares of our common stock representing approximately 60.3% of the voting power of our capital stock on a fully diluted basis.

For accounting purposes, the Merger was treated as a reverse acquisition with MMR Inc. being the accounting acquirer. Accordingly, the historical financial results prior to the Merger are those of MMR Inc. and replace our historical financial results as we existed prior to the Merger.

We were incorporated in Delaware in 2000 and are headquartered in Los Angeles, CA. Effective February 9, 2009, after the Merger, we changed our corporate name to MMR Information Systems, Inc., or MMRIS. Subsequently, on June 16, 2010, we changed our name to MMRGlobal, Inc., which we believe more accurately reflects the nature of our operations as a provider of secure and easy-to-use online Personal Health Records, electronic safe deposit box storage solutions, and document management and imaging systems for healthcare professionals.

Starting in 2005, we began filing for patent protection for our PHR products and services. Over the last eight years, these patents have been in the process of issuance and we now have patents issued, pending, and applied for in numerous countries around the world. MMR's most recent health IT patent was issued in Singapore on July 26, 2016 as Patent No. 189139, titled "Universal Patient Record Conversion Tool." We are also continuing to file new patent applications and continuation applications. As a result, we have evolved from an operating business selling products and services to consumers and healthcare professionals to a company whose value proposition is based on a combination of factors including:

  • A Personal Health Records company specializing in storing and sharing medical records and other important documents for consumers and healthcare professionals
  • A document imaging and management company for healthcare professionals
  • A licensor of Health Information Technology patents and other Intellectual Property in numerous countries around the world
  • A licensor of Bio-technology patents and other Bio-technology Intellectual Property and patient samples.in numerous countries around the world

16

Tbe Company acquired a portfolio of biotech assets developed at a cost of more than $100 million from the Favrille, Inc. Merger completed in January 2009. These assets include, but are not limited to, the exploitation and licensing of patents globally, data and samples from our pre-Merger clinical vaccine trials, the FavId/Specifid idiotype vaccine, and anti-CD20 antibodies. To date, patents for our biotechnology IP have been issued in Australia, China, Japan, Mexico, Singapore, South Korea and European territories in addition to the United States. Two China patents for our monoclonal anti-CD20 antibodies intellectual property titled "Antibodies and Methods for Making and Using Them," were issued most recently as Patent Nos. 201310355119.6 and 200780051557.6 on February 24, 2016.

On February 2, 2016, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the "Certificate of Amendment") with the Secretary of State of the State of Delaware effecting a five for one reverse stock split of the Company's common stock (the "Reverse Stock Split"). The Reverse Stock Split became effective in the marketplace on February 8, 2016 at which time every five (5) shares of the Company's issued and outstanding common stock were automatically converted into one (1) issued and outstanding share of the Company's common stock, without any change in the par value per share. The Certificate of Amendment provides that no fractional shares will be issued. Instead, the Company will issue to the Stockholders one additional share of Common Stock for each fractional share. The new CUSIP number for the Company's common stock following the Reverse Stock Split is 55314U207. All previously reported common stock share amounts in the Form 10-K, including the accompanying financial statements and related notes have been retroactively adjusted to reflect the reverse stock split and unless otherwise indicated in this report, all share and per share figures in this report have been adjusted to reflect the reverse stock split.

Source of Revenues

MMR remains focused on its primary Health IT business of selling the MyMedicalRecords PHR and MMRPro document and imaging systems for healthcare professionals. We derive revenues from the provision of services, which are comprised of facilitating electronic access to consumer medical records and other vital documents through subscribers on a direct subscription basis or an "access" basis through various types of organizations including direct sales, affinity and membership groups, healthcare organizations and retailers, and in both cases, we record these revenues under "Subscriber" in our income statement. We also sell direct to consumers through paid advertising or other per enquiry marketing relationships. When sold to corporations, affinity and membership organizations, hospitals and other business to business customers, we charge a minimum monthly fee plus user fees to the organization based on the number of users who will have access to our services through such organization, whether or not such users actually activate their authorized account. During the nine months ended September 30, 2016, we received $54,971 from subscriber revenues.

In addition, MMR has numerous patents issued, pending or applied for pertaining to provisioning of online medical and Personal Health Records in 12 countries of commercial interest including the U.S., and defends its global intellectual property rights through the filing of patent infringement complaints.

We also focus on generating revenues from the licensing of our Health IT and biotech assets, which may include non-refundable license and up-front fees, non-refundable milestone payments that are triggered upon achievement of a specific event and future royalties or lump-sum payments on sales of related products. We record these licensing revenues under "License Fees" in our income statement. We have been paid upfront license fees and milestone payments and we recognize those fees as revenue as payments are received. We record those fees as revenue when payments are received. During the nine months ended September 30, 2016, we received $0 from license fees revenues.

We also have generated revenues from licensing the sale and marketing of our services internationally and, to a lesser extent, from ancillary fee payments including web and marketing development services, amongst others. We record these licensing revenues under "License Fees" and other ancillary revenues under "Other Revenues" in our income statement. When we enter into a licensing arrangement, we are sometimes paid an upfront license fee and typically receive ongoing royalty payments that are often based on a percentage of revenue earned by our licensee. We recognize these fees over the license period. When we receive ancillary one-time payments, we record them when services or products are delivered.

MMR also plans on entering the medical Cannabis industry by entering into strategic relationships with a group of existing operating companies located domestically and internationally through leveraging MMR's access to the public markets and utilizing our health information technology products, services, and experience to support development stage Cannabis-related businesses. The Company is already talking with groups in Oregon, California, Washington, Canada, and Australia. The Company also perceives opportunities in using its significant tax loss carryforwards while providing access to its proprietary health information technology products, services, and experience to support development stage Cannabis-related businesses.

The Company plans on helping early stage companies entering the Cannabis marketplace attract funding and management expertise while giving them the ability to tap into the public markets for financing of facilities, product distribution, market research, and consulting services. Through MMR's strategic relationships, the Company plans on offering branded products and a suite of vertically integrated services supported by experienced consultants, developers, and manufacturers to assist in the growth and expansion of Cannabis-related businesses. Using the Company's patient Personal Health Records products and services, MMR represents the opportunity to also provide branded patient tracking and operating solution supporting the clinical application of Cannabinoid (CBD) products to improve the health of people suffering from chronic illness and diseases.

17

Cost of Revenue

Our cost of revenue includes the cost of manufacturing our retail product and related packaging, maintaining our voice and fax mailboxes, long-distance call transport costs, fax and voice call processing costs, credit card transaction processing costs, web hosting and management fees, website maintenance and support costs, costs associated with creating and mailing enrollment packages to our subscribers and the cost of scanners. Cost of revenue also includes customer service costs. We also charge to cost of revenue our direct selling costs, which include commissions paid to sales representatives who sell our wholesale and access based accounts.

Operating Expenses

The largest component of our operating expenses is our general and administrative expenses, which include personnel salaries and benefits, office rent and supplies, insurance costs, fees for legal and professional services, as well as our expenses for corporate telecommunications and Internet access not associated with our products. Our operating expenses also include sales and marketing expenses (which over time have included expenses associated with attending trade shows and travel costs, as well as a portion of salaries allocated to sales and marketing activities), as well as technology development expenses (which has included expenses related to research and development as well as a portion of personnel salaries allocated to development activities).

Recent Accounting Pronouncements

For a description of recent accounting pronouncements and how we apply such pronouncements to our financial statements, see the accompanying notes to our consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.

Competition

The following competitive factors may affect our future performance.

MyMedicalRecords PHR

Although we believe that no other product in the marketplace compares to what we provide in our comprehensive PHR and other offerings, there are other PHR providers in the consumer health information management marketplace today that compete for our services. These include NoMoreClipboard.com, Dossia, WebMD Health Manager, ZweenaHealth, MiVia, and numerous others including patient portals offered by EMR Vendors, health exchanges, and insurance companies, physicians and physician groups hospitals and HMOs for their policyholders and patients. Each of our competitors offers varying PHR products and services for online storage and access to medical records at varying price points depending on any particular service offering.

MyEsafeDepositBox

Our MyEsafeDepositBox product competes with a number of online backup and electronic data storage services. The increasing use of external hard drives and flash drives to backup data also has the potential to compete with online data storage services such as our MyEsafeDepositBox product.

MMRPro

MMRPro competes with scanning services that market their services to doctors seeking to convert their historical paper records into electronic files, as well as EMR systems.

MMRPro also competes with services that may be included in EMR systems that offer doctors the opportunity to make their entire office paperless.

Results of Operations for the three and nine months ended September 30, 2016 as compared to the three and nine months ended September 30, 2015

Revenues

Revenues for the nine months ended September 30, 2016 and 2015 were $53,595 and $138,716, respectively, a decrease of $85,121, or 61%, and for the three months ended September 30, 2016 and 2015, were $26,340 and $77,664, respectively, a decrease of $51,324, or 66%. The decrease for the nine month period and quarter was primarily due to a decline in licensing fees and the expiration of certain recurring revenue contracts. Despite the changing environment in the U.S. regarding patent laws, the Company believes that recent changes in government will help give the Company more opportunities to monetize its domestic health information technology patent portfolio domestically and globally in both health information technology and biotechnology.

Cost of revenue

Cost of revenue for the nine months ended September 30, 2016 and 2015 was $167,941 and $179,554, respectively, a decrease of $11,613, or 6%. Cost of revenues for the three months ended September 30, 2016 and 2015 was $49,733 and $45,298, respectively, for an increase of $4,435, or 10%. The decrease was due to the Company's ability to renegotiate with our telecommunications providers resulting in lower costs of goods.

18

As a result, gross loss for the nine months ended September 30, 2016 was $114,346 compared to a gross loss of $40,838 for the nine months ended September 30, 2015, for an increase of $73,508 or 180%. Gross loss for the three months ended September 30, 2016 was $23,393 compared to a gross profit of $32,366 for the period ended September 30, 2015, for a decrease of $55,759, or 172%.

Operating expenses

Total operating expenses for the nine months ended September 30, 2016 and 2015 were $1,516,608 and $1,751,843, respectively, a decrease of $235,235, or 13%. Total operating expenses for the three months ended September 30, 2016 and 2015 were $385,075 and $485,651, respectively, for a decrease of $100,576, or 21%. The decrease for the quarter period was primarily due to decrease in investor relations expenses, and marketing, legal and other expenses.

General and administrative expenses for the nine months ended September 30, 2016 and 2015 were $1,288,472 and $1,331,644, respectively, a decrease of $43,172 or 3% General and administrative expenses for the three months ended September 30, 2016 and 2015 were $297,500 and $383,147, respectively, for a decrease of $85,647 or 22%. The decrease for the nine month period was primarily due to decrease in investor relations expenses, salaries, non-cash compensation expenses, and consulting expenses.

Sales and marketing expenses for the nine months ended September 30, 2016 and 2015 were $228,136 and $420,199, respectively, a decrease of $192,063, or 46%. Sales and marketing expenses for the three months ended September 30, 2016 and 2015 were $87,575 and $102,504, respectively, for a decrease of $14,929 or 15%. The decrease for the quarter and nine month period was primarily due to lower business development fees and marketing consulting fees.

Interest and Other Finance Charges, Net

Interest and other finance charges for the nine months ended September 30, 2016 and 2015 were $192,967 and $191,355, respectively, an increase of $1,612 or 1%. Interest and other finance charges for the three months ended September 30, 2016 and 2015 were $70,857 and $44,629, respectively, for an increase of $26,228, or 59%. The increase for the nine month period was primarily due to interest expense related to convertible promissory notes.

Net loss

As a result of the foregoing, net loss for the nine months ended September 30, 2016 and 2015 was $1,632,021 and $1,923,286, respectively, a decrease of $291,265 or 15%. Net loss for the three month period ended September 30, 2016 and 2015 was $451,526 and $489,000, respectively, for a decrease of $37,474, or 8%.

Going Concern

As more fully described in Note 1 to the consolidated financial statements appearing above in this Quarterly Report on Form 10-Q, our independent registered public accounting firm included an explanatory paragraph in their report on our 2015 financial statements for the year ended December 31, 2015 related to the uncertainty of our ability to continue as a going concern. As of September 30, 2016, our current liabilities of $8.8 million exceeded our current assets of $0.1 million by $8.7 million.

For a description of our management's plan regarding our ability to continue as a going concern, please see Note 1 to the financial statements included above.

Liquidity and Capital Resources

As of September 30, 2016, our current liabilities exceeded our current assets by $8.8 million. Furthermore, during the quarter ended September 30, 2016, we incurred losses of $1,632,021. At the current level of borrowing, we require cash of $275,000 per year to service our debt and, in order to continue operating its business, we use an average of $172,000 cash per month, or $2.06 million per year.

In addition to the above cash burn from operations, we will be required to obtain additional financing in order to meet the obligations for installment payments of $621,000 under the Creditor Plan and our obligations under the secured indebtedness to The RHL Group under the Eleventh Amended Note, which had a balance of $2.94 million at September 30, 2016, amongst other debt obligations. Such obligations are currently due and payable pursuant to the terms of the notes.

To finance our activities, we have relied on the issuance of stock and debt to The RHL Group. At September 30, 2016, we had a Line of Credit with the RHL Group in the amount of $4.5 million. Availability under this Line of Credit, at the lender's discretion, was $1.30 million as of September 30, 2016.

19

In addition, we may continue to offer restricted stock to accredited investors and issue limited amounts of convertible debt. During 2015, we raised $62,000 in sales of restricted common stock to accredited investors. We expect to continue offering limited amounts of convertible debt in 2016. The Company believes it can continue to generate revenue from its biotech and health information technology assets. We also expect to continue receiving (i) royalties from license fees related to our health information technology patents and other intellectual property; and (ii) revenue from sales of PHRs, MMRPro services, and other products and services including our new mHealth applications that will help reduce annual cash burn from operations. The Company is also planning on selling data and samples from its FavId vaccine trials to pharmaceutical manufacturers, universities and others for use in helping to speed the process of clinical trials for new drugs and disease management programs.

Cash Flows for the nine months ended September 30, 2016 compared to nine months ended September 30, 2015

Net cash used in operating activities for the nine months ended September 30, 2016 and 2015 was $473,047 and $648,679, respectively. In 2016, we had a net loss of $1,632,021, plus non-cash adjustments (depreciation, amortization, common stock and warrants issued for services and interest, amortization of loan discount, conversion of accounts payable to note payable, and stock compensation expense) of $404,995, plus changes in operating assets and liabilities of $753,979. In 2015, net cash used in operating activities of $648,679 was comprised of a net loss of $1,923,286, plus similar non-cash adjustments of $339,116 plus changes in operating assets and liabilities of $648,679. Compared to 2015, the operating cash flow activities in 2016 were lower primarily due to timing of payments of current liabilities.

Net cash used in investing activities in the nine months ended September 30, 2016 and 2015 totaled $5,452 and $1,252, respectively. Compared to 2015, investing activities in 2016 were higher mainly due to an increase in note receivables payments.

Net cash provided by financing activities in the nine months ended September 30, 2016 and 2015 totaled $478,499 and $340,538, respectively. Financing activities primarily included proceeds from Line of Credit. Compared to 2015, financing activities in 2016 were higher primarily due to an increase in proceeds from Line of Credit.

As of September 30, 2016, we had cash and cash equivalents of $0, compared to $0 as of September 30, 2015.

Description of Indebtedness

For a description of our indebtedness to The RHL Group, please See Note 3 - Related Party Note Payable, included above in this Quarterly Report on Form 10-Q.

Convertible Notes

For information relating to our Convertible Notes, please see Note 9 to our financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.

Commitments and Contingencies

For information relating to our commitments and contingent liabilities, please see Note 5 to our financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are a smaller reporting company and therefore, we are not required to provide information required by this item of Form 10-Q.

Item 4. Controls and Procedures

Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Acting Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure.

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

20

As required by Rule 13a-15(b) under the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Acting Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures.

Based on the foregoing, our Chief Executive Officer and Acting Chief Financial Officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective and were operating at a reasonable assurance level.

Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting or in other factors identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during the quarter ended September 30, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

The information in response to this item is incorporated herein by reference to Note 5 - Commitments and Contingencies under the "Litigation Matters" section of the Consolidated Condensed Financial Statements of this Quarterly Report.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following is a summary of transactions by us since our previous disclosure on Form 10-Q filed with the Securities and Exchange Commission on August 19, 2016 involving sales of our securities that were not registered under the Securities Act of 1933, as amended (the "Securities Act"). Each offer and sale was exempt from registration under either Section 4(2) of the Securities Act or Rule 506 under Regulation D of the Securities Act because (i) the securities were offered and sold only to accredited investors; (ii) there was no general solicitation or general advertising related to the offerings; (iii) each investor was given the opportunity to ask questions and receive answers concerning the terms of and conditions of the offering and to obtain additional information; (iv) the investors represented that they were acquiring the securities for their own account and for investment; and (v) the securities were issued with restrictive legends:

On September 9, 2016, we granted 2,310,000 shares of Common Stock at $0.02 per share to a vendor in exchange for a reduction in payables.

All securities granted or sold under these agreements are unregistered and may only be resold or transferred if they later become registered or fall under an exemption to the Securities Act or applicable state laws.  Our typical investor or grantee generally relies upon Rule 144 of the Securities Act, which, in addition to requiring several other conditions before resale may occur, requires that the securities issued be held for a minimum of six months.  We generally used the proceeds of the foregoing sales of securities for repayment of indebtedness, working capital and other general corporate purposes.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

21

Item 6. Exhibits

Exhibit
Number		   Exhibit Description
     
31.1   Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934.
     
31.2   Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934.
     
32.1   Certification of Chief Executive Officer Pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350.
     
32.2   Certification of Chief Financial Officer Pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350.
     
101.INS   XBRL Instance Document
     
101.SCH   XBRL Taxonomy Extension Schema Document
     
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB   XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document

22

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 21, 2016

MMRGlobal, Inc.

By: /s/ Robert H. Lorsch                                  
 Robert H. Lorsch
Chairman, Chief Executive Officer and
President

By: /s/ Bernard Stolar                                    
 Bernard Stolar
Acting Chief Financial Officer

 

 

23

EXHIBIT INDEX

Exhibit
Number		   Exhibit Description
     
31.1   Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934.
     
31.2   Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934.
     
32.1   Certification of Chief Executive Officer Pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350.
     
32.2   Certification of Chief Financial Officer Pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350.
     
101.INS   XBRL Instance Document
     
101.SCH   XBRL Taxonomy Extension Schema Document
     
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB   XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document

 

 

 

24

 

EX-31 2 exh31-1.htm CEO 302 CERTIFICATE Q3 2016 Exhibit 31.1

Exhibit 31.1

Certification

I, Robert H. Lorsch, certify that:

1. I have reviewed this quarterly report on Form 10-Q of MMRGlobal, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 21, 2016

 

/s/ Robert H. Lorsch

Name: Robert H. Lorsch
Title: Chief Executive Officer







EX-31 3 exh31-2.htm CFO 302 CERTIFICATE Q3 2016 Exhibit 31.2

Exhibit 31.2

Certification

I, Bernard Stolar, certify that:

1. I have reviewed this quarterly report on Form 10-Q of MMRGlobal, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 21, 2016

 

/s/ Bernard Stolar

Name: Bernard Stolar
Title: Acting Chief Financial Officer







EX-32 4 exh32-1.htm CEO 906 CERTIFICATE Q3 2016 Exhibit 32.1

Exhibit 32.1

Certification

I, Robert H. Lorsch, certify, pursuant to Rule 13(a)-14(b) or Rule 15(d)-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that (i) the Quarterly Report on Form 10-Q of MMRGlobal, Inc. for the quarterly period ended September 30, 2016 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of1934, and (ii) the information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of MMRGlobal, Inc.

/s/ Robert H. Lorsch

Name:

 

Robert H. Lorsch

Title:

 

Chief Executive Officer

Date:

 

November 21, 2016

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and is not being "filed" as part of the Form 10-Q or as a separate disclosure document for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under that section. This certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act except to the extent that this Exhibit 32.1 is expressly and specifically incorporated by reference in any such filing.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.







 EX-32 5 exh32-2.htm CFO 906 CERTIFICATE Q3 2016 Exhibit 32.2

Exhibit 32.2

Certification

I, Bernard Stolar, certify, pursuant to Rule 13(a)-14(b) or Rule 15(d)-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that (i) the Quarterly Report on Form 10-Q of MMRGlobal, Inc. for the quarterly period ended September 30, 2016 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii) the information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of MMRGlobal, Inc.

/s/ Bernard Stolar

Name:

 

Bernard Stolar

Title:

 

Acting Chief Financial Officer

Date:

 

November 21, 2016

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and is not being "filed" as part of the Form 10-Q or as a separate disclosure document for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under that section. This certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act except to the extent that this Exhibit 32.2 is expressly and specifically incorporated by reference in any such filing.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.







 GRAPHIC 6 image1066.jpg LOGO begin 644 image1066.jpg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mmrf-20160930.xml XBRL INSTANCE DOCUMENT 0001285701 2015-12-31 0001285701 2016-09-30 0001285701 2016-01-01 2016-09-30 0001285701 2015-01-01 2015-09-30 0001285701 2016-11-21 0001285701 MMRF:FormerOfficersOfMMRGlobalSeverancePackageNotesMember 2016-01-01 2016-09-30 0001285701 MMRF:FormerOfficersOfMMRGlobalSeverancePackageNotesMember 2016-09-30 0001285701 MMRF:FormerOfficersOfMMRGlobalSeverancePackageNotesMember 2015-12-31 0001285701 MMRF:ResignationAndPostMergerEmploymentArrangementNotesMember 2016-01-01 2016-09-30 0001285701 MMRF:ResignationAndPostMergerEmploymentArrangementNotesMember 2016-09-30 0001285701 MMRF:ResignationAndPostMergerEmploymentArrangementNotesMember 2015-12-31 0001285701 MMRF:VendorsNotesPayableMember 2016-01-01 2016-09-30 0001285701 MMRF:VendorsNotesPayableMember 2016-09-30 0001285701 MMRF:VendorsNotesPayableMember 2015-12-31 0001285701 MMRF:TenthAmendedAndRestatedSecuredPromissoryNoteMember 2016-09-30 0001285701 MMRF:TenthAmendedAndRestatedSecuredPromissoryNoteMember 2015-12-31 0001285701 MMRF:TenthAmendedAndRestatedSecuredPromissoryNoteMember 2016-01-01 2016-09-30 0001285701 MMRF:TenthAmendedAndRestatedSecuredPromissoryNoteMember 2015-01-01 2015-09-30 0001285701 MMRF:September2013LeaseMember 2016-01-01 2016-09-30 0001285701 MMRF:RHLGroupMember 2016-01-01 2016-09-30 0001285701 MMRF:BernardStolarMember 2016-01-01 2016-09-30 0001285701 MMRF:BernardStolarMember 2015-01-01 2015-09-30 0001285701 MMRF:BernardStolarMember 2016-09-30 0001285701 MMRF:BernardStolarMember 2015-12-31 0001285701 MMRF:SignificantVendorMember 2016-01-01 2016-09-30 0001285701 MMRF:SignificantVendorMember 2015-01-01 2015-09-30 0001285701 MMRF:SignificantVendorMember 2016-09-30 0001285701 MMRF:SignificantVendorMember 2015-12-31 0001285701 us-gaap:FacilityClosingMember 2016-01-01 2016-09-30 0001285701 us-gaap:FacilityClosingMember 2016-09-30 0001285701 MMRF:ShortTermLoanTwoDueToThirdPartyMember 2016-01-01 2016-09-30 0001285701 MMRF:ShortTermLoanTwoDueToThirdPartyMember 2015-12-31 0001285701 MMRF:ShortTermLoanTwoDueToThirdPartyMember 2016-09-30 0001285701 MMRF:ShortTermLoanOneDueToRelatedPartyMember 2016-01-01 2016-09-30 0001285701 MMRF:ShortTermLoanOneDueToRelatedPartyMember 2015-12-31 0001285701 MMRF:ShortTermLoanOneDueToRelatedPartyMember 2016-09-30 0001285701 MMRF:ShortTermLoanTwoDueToRelatedPartyMember 2016-01-01 2016-09-30 0001285701 MMRF:ShortTermLoanTwoDueToRelatedPartyMember 2015-12-31 0001285701 MMRF:ShortTermLoanTwoDueToRelatedPartyMember 2016-09-30 0001285701 2014-12-31 0001285701 2016-07-01 2016-09-30 0001285701 2015-07-01 2015-09-30 0001285701 2015-09-30 0001285701 MMRF:TenthAmendedAndRestatedSecuredPromissoryNoteMember 2016-07-01 2016-09-30 0001285701 MMRF:TenthAmendedAndRestatedSecuredPromissoryNoteMember 2015-07-01 2015-09-30 0001285701 MMRF:ZeroPointZeroTwoToZeroPointThreeZeroMember 2016-01-01 2016-09-30 0001285701 MMRF:ZeroPointZeroTwoToZeroPointThreeZeroMember 2016-09-30 0001285701 MMRF:ZeroPointThreeZeroToZeroPointFiveZeroMember 2016-01-01 2016-09-30 0001285701 MMRF:ZeroPointThreeZeroToZeroPointFiveZeroMember 2016-09-30 0001285701 MMRF:GreaterThanZeroPointFiveZeroMember 2016-01-01 2016-09-30 0001285701 MMRF:GreaterThanZeroPointFiveZeroMember 2016-09-30 0001285701 MMRF:ZeroPointTwoFiveToZeroPointFourFiveMember 2016-01-01 2016-09-30 0001285701 MMRF:ZeroPointTwoFiveToZeroPointFourFiveMember 2016-09-30 0001285701 MMRF:ZeroPointFiveZeroToZeroPointSevenFiveMember 2016-01-01 2016-09-30 0001285701 MMRF:ZeroPointFiveZeroToZeroPointSevenFiveMember 2016-09-30 0001285701 MMRF:GreaterThanZeroPointSevenFiveMember 2016-01-01 2016-09-30 0001285701 MMRF:GreaterThanZeroPointSevenFiveMember 2016-09-30 0001285701 MMRF:LongTermLegalNoteMember 2016-01-01 2016-09-30 0001285701 MMRF:LongTermLegalNoteMember 2015-12-31 0001285701 MMRF:LongTermLegalNoteMember 2016-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:USD MMRF:Unit MMRGlobal, Inc. 0001285701 10-Q 2016-09-30 false --12-31 No No Yes Smaller Reporting Company Q3 2016 <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>NOTE 1 - NATURE OF OPERATIONS AND BASIS OF PRESENTATION</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">MMRGlobal Inc. (referred to herein, unless otherwise indicated, as &#34;MMR,&#34; the &#34;Company,&#34; the &#34;issuer,&#34; &#34;we,&#34; &#34;us,&#34; and &#34;our&#34;) was originally incorporated as Favrille, Inc. (&#34;Favrille&#34;) in Delaware in 2000, and since its inception and before the Merger (as defined below), operated as a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. In May 2008, Favrille's ongoing Phase 3 registration trial for the FavId vaccine failed to show a statistically significant improvement in the treatment of patients with follicular B-cell Non-Hodgkin's lymphoma. On January 27, 2009, the Company, through MyMedicalRecords, Inc. (&#34;MMR Inc.&#34;), what is now our wholly-owned operating subsidiary, conducted a reverse merger with Favrille.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Through our wholly-owned operating subsidiary MMR Inc., the Company's primary business is to license and provide secure and easy-to-use online Personal Health Records (&#34;PHR&#34;) and MyEsafeDepositBox storage solutions, including a professional offering to physicians' offices and similar organizations known as MMRPro. Starting in 2005, we began filing for patent protection for our PHR products and services, and we now have patents issued, pending, and applied for in numerous countries around the world. As a result, we have evolved from an operating business selling products to also licensing health information technology patents and other intellectual property. In January 2009, as a result of the Merger, we acquired biotech assets and other intellectual property including anti-CD20 antibodies as well as data and samples from the FavId/Specifid vaccine clinical trials for the treatment of B-cell Non-Hodgkin's lymphoma which the Company continues to work towards maximizing the value of those biotech assets including related biotech patents, anti-CD 20 antibodies, and FavId vaccine technologies acquired by MyMedicalRecords, Inc. through the merger with Favrille. We (formerly Favrille) were incorporated in Delaware in 2000, MMR Inc. was incorporated in Delaware in 2005, and both are headquartered in Los Angeles, CA.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Principles of Consolidation</b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The consolidated financial statements include the accounts of MMRGlobal, and its wholly-owned subsidiaries MMR and MMR Life Sciences Group, Inc. All intercompany transactions and balances are eliminated upon consolidation.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Basis of Presentation</b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We have prepared the accompanying consolidated unaudited financial statements in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial statements and with instructions to Form 10-Q pursuant to the rules and regulations of Securities and Exchange Act of 1934, as amended, or the Exchange Act and Article 8-03 of Regulation S-X promulgated under the Exchange Act. Accordingly, these financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of our management, we have included all adjustments considered necessary (consisting of normal recurring adjustments) for a fair presentation. Operating results for the three and nine months ended September 30, 2016 are not indicative of the results that may be expected for the fiscal year ending December 31, 2016. You should read these unaudited condensed consolidated financial statements in conjunction with the audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2015.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Going Concern and Management's Plan</b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">As of September 30, 2016, our current liabilities exceeded our current assets by $8.8 million. Furthermore, during the nine months ended September 30, 2016, we incurred losses of $1,632,021, as further explained in Management's Discussion and Analysis of Financial Condition and Results of Operations appearing in Item 2 of Part I of this Quarterly Report on Form 10-Q.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">At September 30, 2016 and December 31, 2015, we had $0 and $0, respectively, in cash and cash equivalents. Historically, we issued capital stock, sold debt and equity securities and received funds from The RHL Group, Inc. (a significant stockholder that is wholly-owned by our Chairman and Chief Executive Officer, Robert H. Lorsch) to operate our business. Although we received additional funding from The RHL Group pursuant to the Eleventh Amended and Restated Note effective June 6, 2016 (the &#34;Line of Credit&#34;), we will still be required to obtain additional financing in order to meet installment payment obligations and the previously existing obligations under the Line of Credit, which had a balance of $2,953,548 at September 30, 2016 and a total Unpaid Balance (as defined in the Line of Credit) of $3,203,548, which includes amounts borrowed under the Line of Credit, unpaid interest fees, any amounts guaranteed by The RHL Group, and other obligations due The RHL Group pursuant to the terms of the Eleventh Amended and Restated Note and the Security Agreement. As a result of the above, we express uncertainty about our ability to continue as a going concern. The components of the RHL Group Note payable and the related balance sheet presentation as of September 30, 2016 are as follows: $1,715,646, which is included in the Line of Credit, related party; and $1,237,902 related to other obligations due to The RHL Group which are included in related party payables.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Management's plan regarding this matter is to, amongst other things, continue to utilize our available Line of Credit with The RHL Group (see Note 3). As of September 30, 2016, under the original terms, we had approximately $1,296,452 remaining as available under The RHL Group Line of Credit, but we are now in default under the line of credit. Additionally, we plan to continue selling additional debt and equity securities, continue to settle our existing liabilities through issuance of equity securities, explore other debt financing arrangements, continue to increase our existing subscriber and affiliate customer base, sell MMRPro products, and continue efforts to license our intellectual property to obtain additional cash flow over the next twelve months. We cannot assure that funds from these sources will be available when needed or, if available, will be on terms favorable to us or to our stockholders. If we raise additional funds or settle liabilities by issuing equity securities, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution or such equity securities may provide for rights, preferences or privileges senior to those of the holders of our common stock. If we are unable to utilize our available Line of Credit with The RHL Group or obtain suitable alternative debt or equity financing, our ability to execute our business plan and continue as a going concern may be adversely affected.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">These matters raise substantial doubt about our ability to continue as a going concern. These financial statements were prepared under the assumption that we will continue as a going concern and do not include any adjustments that might result from the outcome of that uncertainty.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>(a) MANAGEMENT'S USE OF ESTIMATES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net revenue and expenses during each reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowances for doubtful accounts, the valuation of deferred income taxes, tax contingencies, long-lived and intangible assets, valuation of derivative liabilities and stock-based compensation. These estimates are based on historical experience and on various other factors that management believes to be reasonable under the circumstances, although actual results could differ from those estimates.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>(b) CASH AND CASH EQUIVALENTS</b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We consider cash equivalents to be only those investments that are highly liquid, readily convertible to cash and with maturities of 90 days or less at the purchase date. We maintain our cash in bank deposit accounts that, at times, may exceed federally insured limits. We have not experienced any losses in such accounts and believe that we are not exposed to any significant credit or deposit risk on our cash. We had cash and cash equivalents of $0 and $0 as of September 30, 2016 and December 31, 2015, respectively.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>(c) TRADE AND OTHER RECEIVABLES</b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Receivables represent claims against third parties that will be settled in cash. The carrying value of receivables, net of an allowance for doubtful accounts, if any, represents their estimated net realizable value. We estimate the allowance for doubtful accounts, if any, based on historical collection trends, type of customer, the age of outstanding receivables and existing economic conditions. If events or changes in circumstances indicate that specific receivable balances may be impaired, we give further consideration to the collectability of those balances and the allowance is adjusted accordingly. We write off past due receivable balances when collection efforts have been unsuccessful in collecting the amount due.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>(d) FAIR VALUE OF FINANCIAL INSTRUMENTS</b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">ASC 820-10, <i>Fair Value Measurements and Disclosures,</i> requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of September 30, 2016 and December 31, 2015, the carrying value of accounts receivable, deposits, related party payables, compensation payable, severance liabilities, and accounts payable and accrued expenses approximates fair value due to the short-term nature of such instruments. The carrying value of short-term debt approximates fair value as the related interest rates approximate rates currently available to us.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We utilize ASC 820-10 for valuing financial assets and liabilities measured on a recurring basis. ASC 820-10 defines fair value, establishes a framework for measuring fair value and generally accepted accounting principles, and expands disclosures about fair value measurements. This standard applies in situations where other accounting pronouncements either permit or require fair value measurements. ASC 820-10 does not require any new fair value measurements.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Accounting guidance also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The standard describes three levels of inputs that may be used to measure fair value:</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="width: 28%; padding: 0.75pt">&#160;</td> <td style="vertical-align: top; width: 31%; padding: 0.75pt"><font style="font-size: 9pt">Level 1:</font></td> <td style="vertical-align: top; width: 41%; padding: 0.75pt"><font style="font-size: 9pt">Quoted prices in active markets for identical or similar assets and liabilities.</font></td></tr> <tr> <td style="padding: 0.75pt">&#160;</td> <td style="vertical-align: top; padding: 0.75pt"><font style="font-size: 9pt">Level 2:</font></td> <td style="vertical-align: top; padding: 0.75pt"><font style="font-size: 9pt">Quoted prices for identical or similar assets and liabilities in markets that are not active or observable inputs other than quoted prices in active markets for identical or similar assets and liabilities.</font></td></tr> <tr> <td style="padding: 0.75pt">&#160;</td> <td style="vertical-align: top; padding: 0.75pt"><font style="font-size: 9pt">Level 3:</font></td> <td style="vertical-align: top; padding: 0.75pt"><font style="font-size: 9pt">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></td></tr> </table> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>(e) IMPAIRMENT OF LONG-LIVED ASSETS AND INTANGIBLES</b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We account for long-lived assets, which include property and equipment and identifiable intangible assets with finite useful lives (subject to amortization), in accordance with ASC 350-30. ASC 350-30 requires that we review long-lived assets for impairment whenever events or changes in circumstances indicate that we may not recover the carrying amount of an asset. We measure recoverability by comparing the carrying amount of an asset to the expected future undiscounted net cash flows generated by the asset. If we determine that the asset may not be recoverable, or if the carrying amount of an asset exceeds its estimated future undiscounted cash flows, we recognize an impairment charge to the extent of the difference between the fair value and the asset's carrying amount. Our assessment of the undiscounted future cash flows indicated that the carrying amount of the long-lived and intangible assets are recoverable, therefore, we had no impairment charges during the nine months ended September 30, 2016 and 2015.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>(f) REVENUE RECOGNITION</b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We generate our revenues from services, which are comprised of providing electronic access to consumer medical records and other vital documents, and from the licensing of our intellectual property and services. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and we are reasonably assured of collectability of the resulting receivable.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Our subscriber revenues consist of annual and monthly recurring retail subscriptions and usage-based fees, which are primarily paid in advance by credit card, and corporate accounts that are based on either an access-fee or actual number of users, and in each case billed in advance at the beginning of each month of service. We defer the portions of annual recurring subscription fees collected in advance and recognize them on a straight line basis over the subscription period. As part of our ongoing sales and marketing activities, we also offer sell a Personal Health Record Kit through retailers to the extent reasonably possible.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We license the rights to use portions of our intellectual property portfolio, which includes certain patent rights essential to the sale of certain PHR products. Licensees typically pay a license fee in one or more installments and ongoing royalties based on their sales of products incorporating or using the Company's licensed intellectual property. License fees are recognized over the estimated period of benefit to the licensee, typically five to fifteen years. The Company earns royalties on such licensed products sold by its licensees at the time that the licensees' sales occur. The Company recognizes royalty revenues based on royalties reported by licensees during the quarter and when other revenue recognition criteria are met.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We grant exclusive and non-exclusive licenses for the sale and marketing of our services in international territories in consideration of license fees and ongoing royalties. The royalty fee is usually a percentage of revenue earned by the licensee and there are usually certain minimum guarantees. We defer the recognition of license fee revenues received in advance from international licensees for the grant of the license and recognize them over the period covered by the agreement. We defer the recognition of minimum guaranteed royalty payments received in advance and recognize them over the period to which the royalty relates. We include all such revenues under &#34;License Fees.&#34; In those cases where a license agreement contains multiple deliverables, we account for the agreement in accordance with ASC 605-25 <i>- Revenue Recognition - Multiple-Element Arrangements</i>.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We recognize revenue on sales of our MMRPro system in accordance with ASC 605-25, <i>Revenue Recognition, Multiple-Element Arrangements</i>.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Our multiple-deliverable arrangements consist solely of our MMRPro product. Deliverables within these arrangements include scanning equipment, various licenses to use third party software, a license to use our proprietary MMRPro application software, installation and training, dedicated telephone lines, secure online storage and warranties.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We determined all elements to be separate units of accounting as they have standalone value to the customers and/or they are sold by other vendors on a standalone basis. Delivery of the hardware and certain software elements of these arrangements occur at the inception of the agreement. We deliver installation and training at the inception of the agreement. We also provide software licenses, telephone lines and online secure storage over the three-year term of an MMRPro agreement. We include warranties in the arrangements, however the third party product manufacturer, and not us, is obligated to fulfill such warranties. The third-party warranty contracts are paid in advance and are not refundable.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We allocate the revenue derived from these arrangements among all the deliverables. We base such allocation on the relative selling price of each deliverable. With the exception of our proprietary MMRPro application software, we use third party evidence to set the selling prices used for this allocation. In all such cases, third parties sell the same or very similar products. For the MMRPro application software, we estimate the selling price based on recent discussions regarding licensure of that particular application on a standalone basis. To date, we have not licensed this software on a standalone basis.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We recognize the allocated revenue for each deliverable in accordance with SEC Staff Accounting Bulletin (&#34;SAB&#34;) No. 104, <i>Topic 13: Revenue Recognition</i>. Under this guidance, we recognize revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed and determinable and collectability is reasonably assured. This results in us recognizing revenue for the hardware, certain software and the warranties upon delivery to the customer, for the installation and training upon completion of these services, and ratably over the contract period for the software licenses, telephone lines and online secure storage.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Revenue from the licensing of our biotech assets may include non-refundable license and up-front fees, non- refundable milestone payments that are triggered upon achievement of a specific event, and future royalties or lump-sum payments on sales of related products. For agreements that provide for milestone payments, we adopted ASC 605-28-25, <i>Revenue Recognition Milestone Method</i>.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>(g) SHARE-BASED COMPENSATION</b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We account for share-based compensation in accordance with ASC 718-20, <i>Awards Classified as Equity</i>. We apply ASC 718- 20 in accounting for stock-based awards issued to employees under the recognition of compensation expense related to the fair value of employee share-based awards, including stock options and restricted stock. Determining the fair value of options at the grant date requires judgment, including estimating the expected term that stock options will be outstanding prior to exercise, the associated volatility and the expected dividends. Judgment is required in estimating the amount of share-based awards expected to be forfeited prior to vesting. If actual forfeitures differ significantly from these estimates, share- based compensation expense could be materially impacted.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We account for options and warrants issued to non-employees in accordance with ASC 505-50, <i>Equity-Based Payments to Non-Employees</i>. We treat options and warrants issued to non-employees the same as those issued to employees with the exception of determination of the measurement date. The measurement date is the earlier of (1) the date at which a commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty's performance is complete. Options and warrants granted to consultants are valued at their respective measurement dates, and recognized as an expense based on the portion of the total consulting services provided during the applicable period. As further consulting services are provided in future periods, we will revalue the associated options and warrants and recognize additional expense based on their then current values.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We estimate the fair value of each stock option on the date of grant using the Black-Scholes option pricing model. We determine assumptions relative to volatility and anticipated forfeitures at the time of grant. No stock options were granted during the nine months ended September 30, 2016. We valued grants of stock options and warrants during the nine months ended September 30, 2016 using the following assumptions.</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 9pt">Expected life in years</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: center"><font style="font-size: 9pt">2 - 5 Years </font></td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 9pt">Stock price volatility</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: center"><font style="font-size: 9pt">79%</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 9pt">Risk free interest rate</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: center"><font style="font-size: 9pt">0.04 - 1.38%</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 9pt">Expected dividends</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: center"><font style="font-size: 9pt">None</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 9pt">Forfeiture rate</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: center"><font style="font-size: 9pt">0%</font></td></tr> </table> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We base the assumptions used in the Black-Scholes models upon the following data: (1) our use of the contractual life of the underlying non-employee warrants as the expected life; the expected life of the employee options used in this calculation is the period of time the options are expected to be outstanding and has been determined based on historical exercise experience; (2) in the absence of an extensive public market for our shares, the expected stock price volatility of the underlying shares over the expected term of the option or warrant was taken at approximately the mid-point of the range for similar companies at the various grant dates; (3) we base the risk free interest rate on published U.S. Treasury Department interest rates for the expected terms of the underlying options or warrants; (4) we base expected dividends on historical dividend data and expected future dividend activity; and (5) we base the expected forfeiture rate on historical forfeiture activity and assumptions regarding future forfeitures based on the composition of current grantees.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>(h) NET INCOME/LOSS PER SHARE</b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We apply the guidance of ASC 260-10, <i>Earnings Per Share</i> for calculating the basic and diluted loss per share. We calculate basic loss per share by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding. We compute diluted loss per share similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential shares had been issued and if the additional shares were dilutive. We exclude common equivalent shares from the computation of net loss per share if their effect is anti-dilutive.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We excluded all potential anti-dilutive common shares from the computation of diluted net loss per common share for the nine months ended September 30, 2016 and 2015 because they were anti-dilutive due to our net loss position. Stock options, warrants and convertible notes excluded from the computation totaled 43,208,730 shares for the nine months ended September 30, 2016 and 33,251,116 shares for the nine months ended September 30, 2015, respectively.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>(i) RECENT ACCOUNTING PRONOUNCEMENTS</b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) 2014-09, <i>Revenue from Contracts with Customers</i>, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. This new guidance is effective for annual and interim periods beginning after December 15, 2017, with no early adoption permitted. The standard permits the use of either the retrospective or cumulative effect transition method. At this time we have not selected a transition method. We are currently evaluating the effect that ASU 2014-09 will have on our consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In August 2014, the FABS issued ASU No. 2014-15, <i>Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern</i> (&#34;ASU 2014-15&#34;). ASU 2014-15 will explicitly require management to assess an entity's ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. These changes became effective for the Company for the 2016 annual period. The adoption of these changes did not have an impact on the consolidated financial statements.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In February 2015, the FASB issued ASU 2015-02, <i>Consolidation (Topic 810): Amendments to the Consolidation Analysis</i>. This standard modifies existing consolidation guidance for reporting organizations that are required to evaluate whether they should consolidate certain legal entities. ASU 2015-02 is effective for fiscal years and interim periods within those years beginning after December 15, 2015, and requires either a retrospective or a modified retrospective approach to adoption. Early adoption is permitted. The adoption of this standard did not have an impact on the Company's Consolidated Financial Statements.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In April 2015, the FASB issued ASU No 2015-3, <i>Simplifying the Presentation of Debt Issuance Costs.</i> This update changes the presentation of debt issuance costs in the balance sheet. ASU 2015-03 requires debt issuance costs related to a recognized debt obligation to be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability rather than being presented as an asset. Amortization of debt issuance costs will continue to be reported as interest expense. In August 2015, the FASB issued ASU 2015-15, &#34;Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements&#34;. This ASU clarified guidance in ASC 2015-03 stating that the SEC staff would not object to a company presenting debt issuance costs related to a line-of-credit arrangement on the balance sheet as a deferred asset, regardless of whether there were any outstanding borrowings at period-end. This update is effective for annual and interim periods beginning after December 15, 2015, which required us to adopt these provisions starting the first quarter of 2016. This guidance did not have a material impact to our financial position or results of operations.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In February 2016, the FASB issued ASU 2016-02,&#160;<i>Leases (Topic 842)</i>, which supersedes existing guidance on accounting for leases in&#160;&#34;Leases (Topic 840)&#34;&#160;and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In March 2016, the FASB issued ASU 2016-09,&#160;<i>Improvements to Employee Share-Based Payment Accounting</i>. This ASU affects entities that issue share-based payment awards to their employees. The ASU is designed to simplify several aspects of accounting for share-based payment award transactions which include - the income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows and forfeiture rate calculations. ASU 2016-09 will become effective for the Company in the first quarter of fiscal 2018. Early adoption is permitted in any interim or annual period. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In April 2016, the FASB issued AS 2016-10, <i>Revenue from Contracts with Customers (Topic 606)</i>, which amends certain aspects of the Board's new revenue standard, ASU 2014-09, Revenue from Contracts with Customers. The standard should be adopted concurrently with adoption of ASU 2014-09 which is effective for annual and interim periods beginning after December 15, 2017. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>(j) RECLASSIFICATIONS</b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Certain numbers in the prior year have been reclassified to conform to the current year's presentation.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>NOTE 3 - RELATED PARTY PAYABLES, LINE OF CREDIT AND NOTE PAYABLE</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On June 6, 2016, we and The RHL Group entered into an Eleventh Amended and Restated Promissory Note (the &#34;<u>Amended Note</u>&#34;), effective as of June 6, 2016. The Eleventh Note amends and restates that certain Tenth Amended Note entered into between the foregoing parties, effective May 20, 2015 (the &#34; <u>Existing Note</u>&#34;) and together with its predecessor notes and the Amended Note, the (&#34;<u>Credit Facility</u>&#34;), by: (i) extending the maturity date to June 6, 2017. In connection with the Eleventh Amended Note, we issued The RHL Group warrants to purchase 2,777,714 shares of our common stock at $0.011 per share on June 6, 2016. Other than for the amounts as disclosed herein, The Eleventh Amended Note does not materially alter the terms of the previous Tenth Amended Note.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Historically, the predecessor notes have increased over time the maximum amount of credit available under the Credit Facility from $100,000 to $1,000,000 to $3,000,000 to $4,500,000. The maximum amount of the Amended Note is $4,500,000. The Amended Note continues to bear interest at the lesser of 10% or the highest rate then permitted by law, and is secured (similar to the Existing Note) by a Security Agreement, which has been in effect since July 31, 2007, as renewed and amended to date (the &#34;Security Agreement&#34;).</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Eleventh Amended Note had a current balance of $2,953,548 at September 30, 2016. The components of the Eleventh Amended Note and the related balance sheet presentation as of September 30, 2016 are as follows: $1,715,646, which is included in the Line of Credit, related party; and $1,237,902 for other obligations due to The RHL Group, which is included in related party payables.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Total interest expense on the Line of Credit for the three months ended September 30, 2016 and 2015 amounted to $70,925 and $36,699, respectively. Total interest expense on the Line of Credit for the nine months ended September 30, 2016 and 2015 amounted to $200,237 and $102,433, respectively. The unpaid interest balances as of September 30, 2016 and December 31, 2015 were $321,737 and $60,257, respectively.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In conjunction with the Eleventh Amended Note, we were required to maintain certain financial covenants, including the requirement that we have at least $200,000 of cash in our bank accounts or such other amount as necessary to maintain operations through the subsequent thirty (30) days and timely pay any obligations due respecting payroll and all associated payroll taxes at any time during the term of the Note. As of November 21<sup>st</sup>, the Company was not in compliance with certain of the financial covenants and The RHL Group has not waived any of the covenants.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>NOTE 4 - INCOME TAXES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Under ASC 740-270, <i>Income Taxes - Interim Reporting</i>, we are required to adjust our effective tax rate each quarter to be consistent with the estimated annual effective tax rate. We are also required to record the tax impact of certain discrete items, unusual or infrequently occurring, including changes in judgment about valuation allowances and effects of changes in tax laws or rates, in the interim period in which they occur. In addition, we exclude jurisdictions with a projected loss for the year or a year-to-date loss where we cannot recognize a tax benefit from our estimated annual effective tax rate. The impact of such an exclusion could result in a higher or lower effective tax rate during a particular quarter, based upon the mix and timing of actual earnings versus annual projections.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Pursuant to ASC 740, <i>Income Taxes</i>, we performed an analysis of previous tax filings and determined that there were no positions taken that it considered uncertain. Therefore, there were no unrecognized tax benefits as of September 30, 2016.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">MMR Inc., in its capacity as the operating company taking over our income tax positions in addition to its own positions after January 27, 2009 (see Note 1), has estimated its annual effective tax rate to be zero. MMRGlobal has based this on an expectation that the combined entity will generate net operating losses in 2016, and it is not likely that those losses will be recovered using future taxable income. Therefore, no provision for income tax has been recorded as of and for the nine months ended September 30, 2016.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We account for income taxes in accordance with ASC 740-10,<i>&#160;Income Taxes</i>. We recognize deferred tax assets and liabilities to reflect the estimated future tax effects, calculated at the tax rate expected to be in effect at the time of realization. We record a valuation allowance related to a deferred tax asset when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>NOTE 5 - COMMITMENTS AND CONTINGENCIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><i>Leases</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Effective September 1, 2013, we renewed our lease for office space in Los Angeles, California with a term through August 31, 2018. The lease currently requires a monthly payment of $8,250. Total rent expense for the nine months ended September 30, 2016 and 2015 were $79,335 and $86,854 respectively. Future minimum lease payments as of September 30, 2016, under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 9pt"><b>Year Ending </b></font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: center"><font style="font-size: 9pt"><b>Operating</b></font></td> <td style="padding: 0.75pt; text-align: center">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: center"><font style="font-size: 9pt"><b>Capital</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; padding: 0.75pt"><font style="font-size: 9pt"><b>December 31, </b></font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; padding: 0.75pt; text-align: center"><font style="font-size: 9pt"><b>Leases</b></font></td> <td style="padding: 0.75pt; text-align: center">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; padding: 0.75pt; text-align: center"><font style="font-size: 9pt"><b>Leases</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 9pt">&#160;&#160;&#160;&#160; 2016 (Remainder of)&#160;</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right"><font style="font-size: 9pt">$</font></td> <td style="padding: 0.75pt; text-align: right"><font style="font-size: 9pt">24,750&#160;</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right"><font style="font-size: 9pt">$</font></td> <td style="padding: 0.75pt; text-align: right"><font style="font-size: 9pt">13,222&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 9pt">&#160;&#160;&#160;&#160; 2017&#160;</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right"><font style="font-size: 9pt">99,900&#160;</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right"><font style="font-size: 9pt">- &#160;</font></td></tr> <tr style="vertical-align: top"> <td style="padding: 0.75pt"><font style="font-size: 9pt">&#160;&#160;&#160;&#160; 2018&#160;</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; padding: 0.75pt; text-align: right"><font style="font-size: 9pt">66,000&#160;</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; padding: 0.75pt; text-align: right"><font style="font-size: 9pt">- &#160;</font></td></tr> <tr style="vertical-align: top"> <td style="padding: 0.75pt"><font style="font-size: 9pt">Total minimum lease payments&#160;</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right"><font style="font-size: 9pt">$</font></td> <td style="border-bottom: black 2.25pt double; padding: 0.75pt; text-align: right"><font style="font-size: 9pt">189,750&#160;</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right"><font style="font-size: 9pt">$</font></td> <td style="border-bottom: black 2.25pt double; padding: 0.75pt; text-align: right"><font style="font-size: 9pt">13,222&#160;</font></td></tr> </table> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>NOTE 6 - STOCKHOLDERS' DEFICIT</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><i>Preferred Stock</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We have 5,000,000 shares of preferred stock authorized. As of September 30, 2016 and December 31, 2015, there were no shares of preferred stock issued and outstanding.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><i>Common Stock</i></b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">As of September 30, 2016, we are authorized to issue 1,250,000,000 shares of common stock.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On February 2, 2016, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the &#34;Certificate of Amendment&#34;) with the Secretary of State of the State of Delaware effecting a five for one reverse stock split of the Company's common stock (the &#34;Reverse Stock Split&#34;) which became effective in the marketplace on February 8, 2016. The number of shares and per share amounts have been retroactively restated to reflect this reverse stock split.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">As of September 30, 2016, the total shares of our common stock issued and outstanding amounted to 252,370,616.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>NOTE 7 - EQUITY ISSUANCES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><i>Stock Option Activity</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Our 2001 Equity Incentive Plan (the &#34;2001 Plan&#34;) expired on June 5, 2011 and no options were issued under the 2001 Plan since that date. As of September 30, 2016, 2,626,911 shares remain issued under the 2001 Plan.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On September 1, 2011, our Board of Directors approved the adoption of a new plan to replace the 2001 Plan under the same general terms as the 2001 Plan. On June 20, 2012, our stockholders voted and approved the 2011 Equity Incentive Plan (the &#34; 2011 Plan&#34;) at our 2012 Annual Stockholder Meeting. As of September 30, 2016, 2.65 million shares remain issued under the 2011 Plan, and 7.29 million shares of our common stock are reserved for future issuance under our 2011 Plan, which includes an automatic 1 million share annual increase pursuant to the terms of the 2011 Plan and a 5 million share increase authorized during our 2013 Annual Stockholder's Meeting.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">A summary of option activity for the nine months ended September 30, 2016 is presented below. Options granted by MMR Inc. prior to the date of the Merger have been retroactively restated to reflect the conversion ratio of MMR Inc. to MMR shares</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Weighted-Average </b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Weighted-</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Remaining </b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Average</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Contractual</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Aggregate</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Exercise</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Life</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Intrinsic</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Options</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Price</b></font></td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>(Years)</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Value</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">Outstanding at December 31, 2015</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">7,488,345&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">0.50&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">3.62&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">- &#160;</font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">Granted</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">- &#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">- &#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">Exercised</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">- &#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">- &#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 9pt">Cancelled</font></td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 9pt">(2,208,052)</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">0.65&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 9pt">Outstanding at September 30, 2016 (Unaudited)</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 9pt">5,280,293&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">0.45&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">4.15&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">- &#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">Vested and expected to vest</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 9pt">&#160;&#160;&#160;&#160; at September 30, 2016 (Unaudited)</font></td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 9pt">5,280,293&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">0.45&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">4.15&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">- &#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 9pt">Exercisable at September 30, 2016 (Unaudited)</font></td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 9pt">5,280,293&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">0.45&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">4.15&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">- &#160;</font></td></tr> </table> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The aggregate intrinsic value in the table above is before applicable income taxes and is calculated based on the difference between the exercise price of the options and the quoted price of the common stock as of the reporting date.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">There were no options issued during the nine months ended September 30, 2016.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Total stock option expenses recorded during the nine months ended September 30, 2016 and 2015 were $16,188 and $16,759, respectively, and is reflected in operating expenses in the accompanying consolidated statements of operations.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The following table summarizes information about stock options outstanding and exercisable at September 30, 2016.</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Options Outstanding</b></font></td> <td style="text-align: center">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Options Exercisable</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Weighted</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Weighted</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Weighted</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Weighted</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Average</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Average</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Average</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Average</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Exercise </b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Number</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Remaining</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Exercise</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Number</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Remaining</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Exercise</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Price</b></font></td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>of Shares</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Life (Years)</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Price</b></font></td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>of Shares</b></font></td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Life (Years)</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Price</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: center"><font style="font-size: 9pt">0.25 - 0.45</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">2,560,000&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">5.11</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">0.35&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">2,560,000&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">5.11</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">0.35&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: center"><font style="font-size: 9pt">0.50 - 0.75</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">2,520,293&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">3.21</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">0.55&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">2,520,293&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">3.21</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">0.55&#160;</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: center"><font style="font-size: 9pt">&#62; 0.75</font></td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 9pt">200,000&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">3.71</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">0.90&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 9pt">200,000&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">3.71</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">0.90&#160;</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 9pt">5,280,293&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 9pt">5,280,293&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> </table> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Warrants </b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">During the nine months ended September 30, 2016, there were 40,227,714 warrants issued. During the nine months ended September 30, 2016, 11,750,000 warrants were exercised, which was paid by the reduction of our accounts payable balance owed to the vendor/warrant holder in the aggregate amount of $750,000.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">A summary of the activity of our warrants for the nine months ended September 30, 2016 is presented below:</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Weighted Avg</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Shares</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Exercise Price</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">Outstanding at December 31, 2015</font></td> <td style="text-align: right"><font style="font-size: 9pt">11,428,610&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">0.30&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">Granted</font></td> <td style="text-align: right"><font style="font-size: 9pt">40,227,714&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">0.02&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">Exercised</font></td> <td style="text-align: right"><font style="font-size: 9pt">(11,750,000)</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">0.06&#160;</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 9pt">Cancelled</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 9pt">(3,333,818)</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">0.49&#160;</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 9pt">Outstanding at September 30, 2016 (Unaudited)</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 9pt">36,572,506&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">0.06&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 9pt">Exercisable at September 30, 2016 (Unaudited)</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 9pt">34,539,173&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">0.06&#160;</font></td></tr> </table> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Total warrant expenses recorded during the nine months ended September 30, 2016 and 2015 were $137,528 and $11,170, respectively.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The following summarizes the total warrants outstanding and exercisable as of September 30, 2016:</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Warrants Outstanding</b></font></td> <td style="text-align: right">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Warrants Exercisable</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Warrants</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Weighted Avg</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Weighted Avg</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Warrants </b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Weighted Avg</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Weighted Avg</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 9pt"><b>Ranges</b></font></td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Outstanding</b></font></td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Remaining Life</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Exercise Price</b></font></td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Exercisable</b></font></td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Remaining Life</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Exercise Price</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">$0.02 - $0.30</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">35,794,569 </font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">2.61</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: center"><font style="font-size: 9pt">0.05</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">33,761,236 </font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">2.59</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: center"><font style="font-size: 9pt">0.05</font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">$0.30 - $0.50</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">255,000 </font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">0.53</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">0.50</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">255,000 </font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">0.53</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">0.50</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 9pt">Greater $0.50</font></td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 9pt">522,937 </font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">0.58</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">1.05</font></td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 9pt">522,937 </font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">0.58</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">1.05</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 9pt">36,572,506 </font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 9pt">34,539,173 </font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td></tr> </table> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The inputs used for the Black-Scholes option and warrant valuation model were as follows:</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 9pt">Expected life in years</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: center"><font style="font-size: 9pt">2 - 5 Years </font></td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 9pt">Stock price volatility</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: center"><font style="font-size: 9pt">79%</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 9pt">Risk free interest rate</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: center"><font style="font-size: 9pt">0.04 - 1.38%</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 9pt">Expected dividends</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: center"><font style="font-size: 9pt">None</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 9pt">Forfeiture rate</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: center"><font style="font-size: 9pt">0%</font></td></tr> </table> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><i>Shares Issued for Services or Reduction to Liabilities</i></b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">During the nine months ended September 30, 2016, we issued 28,769,439 shares of common stock with a value of $387,855 to various third parties and charged the proceeds to the appropriate accounts for the following reasons:</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Nine Months Ended September 30, 2016 </b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Purpose </b></font></td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Shares </b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Value </b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">Services provided </font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">- &#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">- &#160;</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 9pt">Reduction of payables </font></td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 9pt">28,769,439&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 9pt">387,855&#160;</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 9pt">Totals&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 9pt">28,769,439&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 9pt">387,855&#160;</font></td></tr> </table> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The 28,769,439 issued shares were not contractually restricted. However, as these shares have not been registered under the Securities Act of 1933, as amended (the &#34;Act&#34;), they are restricted from sale until they are registered under the Act, or qualify for resale under the rules promulgated under the Act. All such shares were calculated at the trading closing price on the date of issuance.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><i>Stock Bonus Agreements</i></b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">From time to time, we issue shares of our common stock as a bonus for services rendered. Stock bonuses may be awarded upon satisfaction of specified performance goals pursuant to the Performance Stock Bonus Agreement.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On each grant date, we valued the stock bonus based on the share price and the expenses were amortized using the straight line method. Total stock bonus expenses recorded during the nine months ended September 30, 2016 and 2015 were $0 and $0, respectively and are reflected in operating expenses in the accompanying consolidated statements of operations.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>NOTE 8 - NOTES PAYABLE</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Notes payable consisted of the following:</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: center"><font style="font-size: 7pt"><b>September 30,</b></font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: center"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: center"><font style="font-size: 7pt"><b>December 31, </b></font></td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%"><font style="font-size: 7pt">&#160;</font></td> <td style="width: 1%; text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="width: 1%; text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 7pt"><b>2016</b></font></td> <td style="width: 1%; text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="width: 1%; text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 7pt"><b>2015</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 7pt">Promissory notes payable due to the former officers of MMRGlobal as part of severance <br /> packages, due in full on August 31, 2009 with no stated interest</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">$</font></td> <td style="text-align: right"><font style="font-size: 7pt">76,783&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">$</font></td> <td style="text-align: right"><font style="font-size: 7pt">76,783&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 7pt">Promissory notes payable due to the former officers of MMRGlobal pursuant to the<br /> Resignation and Post-Merger Employment Arrangement, due in full on August 31, 2009<br /> with no stated interest</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">25,444&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">25,444&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 7pt">Promissory notes payable due to vendors relating to settlement of certain outstanding <br /> accounts payable, payable in 18 equal monthly installments commencing on July 27, 2009 <br /> and ending on January 27, 2011, with no stated interest</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">223,116&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">223,116&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 7pt">Short-term loan due to a third-party with 6% interest</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">56,896&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">44,070&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 7pt">Long term note payable relating to legal accounts payable, payable in full on March 30, 2018 with 10% interest per annum</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 7pt">328,133&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 7pt">-&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">710,372&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">369,413&#160;</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 7pt">Less: current portion</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 7pt">(382,239)</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 7pt">(369,413)</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 7pt">Notes payable, less current portion</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 7pt">328,133&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 7pt">-&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 7pt">Short term loan due to a related-party, payable in full on January 2, 2014 with 12% interest&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">$</font></td> <td style="text-align: right"><font style="font-size: 7pt">6,743&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">$</font></td> <td style="text-align: right"><font style="font-size: 7pt">6,743&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 7pt">Short term loan due to a related-party, payable in full on May 31, 2014 with 12% interest&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 7pt">-&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 7pt">50,000&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 7pt">Notes payable related party, current portion</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">6,743&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">56,743&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td></tr> <tr> <td style="vertical-align: top"><font style="font-size: 7pt">Less: current portion</font></td> <td style="vertical-align: top; text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="vertical-align: top; text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 7pt">(6,743)</font></td> <td style="text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="vertical-align: top; text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 7pt">(56,743)</font></td></tr> <tr> <td style="vertical-align: top"><font style="font-size: 7pt">Notes payable related party, less current portion</font></td> <td style="vertical-align: top; text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="vertical-align: top; text-align: right"><font style="font-size: 7pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 7pt">-&#160;</font></td> <td style="vertical-align: top; text-align: right"><font style="font-size: 7pt">&#160;</font></td> <td style="vertical-align: top; text-align: right"><font style="font-size: 7pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 7pt">-&#160;</font></td></tr> </table> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 7pt">&#160;</font></p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>NOTE 9 - CONVERTIBLE PROMISSORY NOTES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">From time to time, we issue Convertible Promissory Notes. As of September 30, 2016, a total of $323,749 in convertible notes remained outstanding and have matured. However, the Company and the Holders have agreed to keep the balance as a Note Payable and the note holders have elected not to convert their note balances into shares of our common stock as of September 30, 2016.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Each Note contains the following general terms and provisions:</p> <ul> <li style="margin: 0pt 0 12pt; font-size: 9pt">The principal amount owed under each note becomes due and payable one year or less from the investment date provided that, upon ten (10) days' prior written notice to the holder, we may, in our sole discretion, extend the maturity date for an additional six month term. The Notes can be further extended upon mutual agreement.</li> <li style="margin: 0pt 0 12pt; font-size: 9pt">These notes bear interest at a rate of 0%-6% per annum payable in cash or shares of common stock or a combination of cash and shares of common stock at our option.</li> </ul> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">During the third quarter of 2016, we did not enter into any Convertible Promissory Notes.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Shares issuable upon conversion for convertible notes payable was 1,355,932 as of September 30, 2016.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The total interest expense attributed to the Beneficial Conversion Feature of the Notes and related warrants for the nine months ended September 30, 2016 and 2015 was $0 and $55,780, respectively.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>NOTE 10 - RESTRUCTURING ACTIVITIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In connection with the merger with Favrille, Inc. in 2009, we signed promissory notes with certain former executives totaling $76,783.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">As of September 30, 2016, the total remaining severance liabilities amounted to $620,613, which is reflected as severance liability on the accompanying consolidated balance sheets. This consists of $571,362 payable to former non-executive employees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>NOTE 11 - RELATED PARTY TRANSACTIONS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Our Chairman and Chief Executive Officer, Robert H. Lorsch, is also the Chief Executive Officer of The RHL Group, Inc. and has full voting power over all of the capital stock of The RHL Group, Inc. Mr. Lorsch directly and indirectly through The RHL Group, Inc., beneficially owns approximately 32.1% our total outstanding voting stock. The RHL Group, Inc. has loaned us money pursuant to the Eleventh Amended Note and all predecessor notes. See Note 3 - Related Party Note Payable above.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The RHL Group is an investment holding company which provides consulting, operational and technical services to us, which we refer to as the RHL Services. As part of the RHL Services, The RHL Group provides us with unrestricted access to its internal business and relationship contact database of more than 10,000 persons and entities, which includes clients of The RHL Group and other individuals which may hold value to us. The RHL Group also provides infrastructure support to us, including allowing us unlimited access to its facilities, equipment, and data, information management and server systems. In addition to allowing us the use of its office support personnel, The RHL Group has also consented to allow us to utilize the full-time services of Mr. Lorsch as our President, Chairman and Chief Executive Officer, which requires substantial time and energy away from his required duties as The RHL Group's Chairman and Chief Executive Officer. In addition, The RHL Group has made Kira Reed, available as our spokesperson. Ms. Reed, who is Mr. Lorsch's spouse, also manages our social networking activities.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In consideration for the above, The RHL Group, Inc. has a consulting arrangement with MMR. A copy of the consulting agreement is filed as an exhibit in our Form 8-K, as filed with the SEC on May 4, 2009 and is hereby incorporated by reference.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We incurred $37,500 during the nine months ended September 30, 2016 and 2015, toward marketing consulting services from Bernard Stolar, a director. We included $260,523 and $206,272 in related party payables as of September 30, 2016 and December 31, 2015, respectively, in connection with these services and board fees.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We contract with a significant vendor for the development and maintenance of the software applications necessary to run our MyMedicalRecords PHR, MyEsafeDepositBox and MyMedicalRecords Pro products. Our outside developer supports our software development needs through a team of software engineers, programmers, quality control personnel and testers, who work with our internal product development team on all aspects of application development, design, integration and support of our products. This vendor is also a stockholder. For the nine months ended September 30, 2016 and 2015, the total expenses relating to this stockholder amounted to $90,000 and $90,000, respectively. In addition, we capitalized $0 of software development costs for the quarter ended September 30, 2016. As of September 30, 2016 and December 31, 2015, the total amounts due to the stockholder and included in related party payables amounted to $195,000 and $105,000 respectively.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> 0 0 309393 0 27934 11744 0 78014 27934 89758 19071 8346 669603 569311 716608 667415 1385901 1920332 260523 206272 195000 105000 620613 620613 620613 1059050 1099569 0.001 0.001 5000000 5000000 0 0 0 0 0.001 0.001 1250000000 1250000000 56743 6743 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Principles of Consolidation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The consolidated financial statements include the accounts of MMRGlobal, and its wholly-owned subsidiaries MMR and MMR Life Sciences Group, Inc. All intercompany transactions and balances are eliminated upon consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>(a) MANAGEMENT'S USE OF ESTIMATES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net revenue and expenses during each reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowances for doubtful accounts, the valuation of deferred income taxes, tax contingencies, long-lived and intangible assets, valuation of derivative liabilities and stock-based compensation. These estimates are based on historical experience and on various other factors that management believes to be reasonable under the circumstances, although actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>(f) REVENUE RECOGNITION</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We generate our revenues from services, which are comprised of providing electronic access to consumer medical records and other vital documents, and from the licensing of our intellectual property and services. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and we are reasonably assured of collectability of the resulting receivable.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Our subscriber revenues consist of annual and monthly recurring retail subscriptions and usage-based fees, which are primarily paid in advance by credit card, and corporate accounts that are based on either an access-fee or actual number of users, and in each case billed in advance at the beginning of each month of service. We defer the portions of annual recurring subscription fees collected in advance and recognize them on a straight line basis over the subscription period. As part of our ongoing sales and marketing activities, we also offer sell a Personal Health Record Kit through retailers to the extent reasonably possible.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We license the rights to use portions of our intellectual property portfolio, which includes certain patent rights essential to the sale of certain PHR products. Licensees typically pay a license fee in one or more installments and ongoing royalties based on their sales of products incorporating or using the Company's licensed intellectual property. License fees are recognized over the estimated period of benefit to the licensee, typically five to fifteen years. The Company earns royalties on such licensed products sold by its licensees at the time that the licensees' sales occur. The Company recognizes royalty revenues based on royalties reported by licensees during the quarter and when other revenue recognition criteria are met.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We grant exclusive and non-exclusive licenses for the sale and marketing of our services in international territories in consideration of license fees and ongoing royalties. The royalty fee is usually a percentage of revenue earned by the licensee and there are usually certain minimum guarantees. We defer the recognition of license fee revenues received in advance from international licensees for the grant of the license and recognize them over the period covered by the agreement. We defer the recognition of minimum guaranteed royalty payments received in advance and recognize them over the period to which the royalty relates. We include all such revenues under &#34;License Fees.&#34; In those cases where a license agreement contains multiple deliverables, we account for the agreement in accordance with ASC 605-25 <i>- Revenue Recognition - Multiple-Element Arrangements</i>.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We recognize revenue on sales of our MMRPro system in accordance with ASC 605-25, <i>Revenue Recognition, Multiple-Element Arrangements</i>.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Our multiple-deliverable arrangements consist solely of our MMRPro product. Deliverables within these arrangements include scanning equipment, various licenses to use third party software, a license to use our proprietary MMRPro application software, installation and training, dedicated telephone lines, secure online storage and warranties.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We determined all elements to be separate units of accounting as they have standalone value to the customers and/or they are sold by other vendors on a standalone basis. Delivery of the hardware and certain software elements of these arrangements occur at the inception of the agreement. We deliver installation and training at the inception of the agreement. We also provide software licenses, telephone lines and online secure storage over the three-year term of an MMRPro agreement. We include warranties in the arrangements, however the third party product manufacturer, and not us, is obligated to fulfill such warranties. The third-party warranty contracts are paid in advance and are not refundable.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We allocate the revenue derived from these arrangements among all the deliverables. We base such allocation on the relative selling price of each deliverable. With the exception of our proprietary MMRPro application software, we use third party evidence to set the selling prices used for this allocation. In all such cases, third parties sell the same or very similar products. For the MMRPro application software, we estimate the selling price based on recent discussions regarding licensure of that particular application on a standalone basis. To date, we have not licensed this software on a standalone basis.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We recognize the allocated revenue for each deliverable in accordance with SEC Staff Accounting Bulletin (&#34;SAB&#34;) No. 104, <i>Topic 13: Revenue Recognition</i>. Under this guidance, we recognize revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed and determinable and collectability is reasonably assured. This results in us recognizing revenue for the hardware, certain software and the warranties upon delivery to the customer, for the installation and training upon completion of these services, and ratably over the contract period for the software licenses, telephone lines and online secure storage.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Revenue from the licensing of our biotech assets may include non-refundable license and up-front fees, non- refundable milestone payments that are triggered upon achievement of a specific event, and future royalties or lump-sum payments on sales of related products. For agreements that provide for milestone payments, we adopted ASC 605-28-25, <i>Revenue Recognition Milestone Method</i>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>(d) FAIR VALUE OF FINANCIAL INSTRUMENTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">ASC 820-10,<i> Fair Value Measurements and Disclosures,</i> requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of June 30, 2016 and December 31, 2015, the carrying value of accounts receivable, deposits, related party payables, compensation payable, severance liabilities, and accounts payable and accrued expenses approximates fair value due to the short-term nature of such instruments. The carrying value of short-term debt approximates fair value as the related interest rates approximate rates currently available to us.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We utilize ASC 820-10 for valuing financial assets and liabilities measured on a recurring basis. ASC 820-10 defines fair value, establishes a framework for measuring fair value and generally accepted accounting principles, and expands disclosures about fair value measurements. This standard applies in situations where other accounting pronouncements either permit or require fair value measurements. ASC 820-10 does not require any new fair value measurements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Accounting guidance also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif">The standard describes three levels of inputs that may be used to measure fair value:</font></p> <table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="width: 7%; padding: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; width: 17%; padding: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Level 1:</font></td> <td style="vertical-align: top; width: 76%; padding: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Quoted prices in active markets for identical or similar assets and liabilities.</font></td></tr> <tr> <td style="padding: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; padding: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Level 2:</font></td> <td style="vertical-align: top; padding: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Quoted prices for identical or similar assets and liabilities in markets that are not active or observable inputs other than quoted prices in active markets for identical or similar assets and liabilities.</font></td></tr> <tr> <td style="padding: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="vertical-align: top; padding: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Level 3:</font></td> <td style="vertical-align: top; padding: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0pt"><b>(g) SHARE-BASED COMPENSATION</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0pt"></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We account for share-based compensation in accordance with ASC 718-20, <i>Awards Classified as Equity</i>. We apply ASC 718- 20 in accounting for stock-based awards issued to employees under the recognition of compensation expense related to the fair value of employee share-based awards, including stock options and restricted stock. Determining the fair value of options at the grant date requires judgment, including estimating the expected term that stock options will be outstanding prior to exercise, the associated volatility and the expected dividends. Judgment is required in estimating the amount of share-based awards expected to be forfeited prior to vesting. If actual forfeitures differ significantly from these estimates, share- based compensation expense could be materially impacted.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We account for options and warrants issued to non-employees in accordance with ASC 505-50, <i>Equity-Based Payments to Non-Employees</i>. We treat options and warrants issued to non-employees the same as those issued to employees with the exception of determination of the measurement date. The measurement date is the earlier of (1) the date at which a commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty's performance is complete. Options and warrants granted to consultants are valued at their respective measurement dates, and recognized as an expense based on the portion of the total consulting services provided during the applicable period. As further consulting services are provided in future periods, we will revalue the associated options and warrants and recognize additional expense based on their then current values.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We estimate the fair value of each stock option on the date of grant using the Black-Scholes option pricing model. We determine assumptions relative to volatility and anticipated forfeitures at the time of grant. No stock options were granted during the nine months ended September 30, 2016. We valued grants of stock options and warrants during the nine months ended September 30, 2016 using the following assumptions.</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 9pt">Expected life in years</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: center"><font style="font-size: 9pt">2 - 5 Years </font></td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 9pt">Stock price volatility</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: center"><font style="font-size: 9pt">79%</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 9pt">Risk free interest rate</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: center"><font style="font-size: 9pt">0.04 - 1.38%</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 9pt">Expected dividends</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: center"><font style="font-size: 9pt">None</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 9pt">Forfeiture rate</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: center"><font style="font-size: 9pt">0%</font></td></tr> </table> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We base the assumptions used in the Black-Scholes models upon the following data: (1) our use of the contractual life of the underlying non-employee warrants as the expected life; the expected life of the employee options used in this calculation is the period of time the options are expected to be outstanding and has been determined based on historical exercise experience; (2) in the absence of an extensive public market for our shares, the expected stock price volatility of the underlying shares over the expected term of the option or warrant was taken at approximately the mid-point of the range for similar companies at the various grant dates; (3) we base the risk free interest rate on published U.S. Treasury Department interest rates for the expected terms of the underlying options or warrants; (4) we base expected dividends on historical dividend data and expected future dividend activity; and (5) we base the expected forfeiture rate on historical forfeiture activity and assumptions regarding future forfeitures based on the composition of current grantees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>(h) NET INCOME/LOSS PER SHARE</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We apply the guidance of ASC 260-10, <i>Earnings Per Share</i> for calculating the basic and diluted loss per share. We calculate basic loss per share by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding. We compute diluted loss per share similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential shares had been issued and if the additional shares were dilutive. We exclude common equivalent shares from the computation of net loss per share if their effect is anti-dilutive.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We excluded all potential anti-dilutive common shares from the computation of diluted net loss per common share for the nine months ended September 30, 2016 and 2015 because they were anti-dilutive due to our net loss position. Stock options, warrants and convertible notes excluded from the computation totaled 43,208,730 shares for the nine months ended September 30, 2016 and 33,251,116 shares for the nine months ended September 30, 2015, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>(i) RECENT ACCOUNTING PRONOUNCEMENTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) 2014-09, <i>Revenue from Contracts with Customers</i>, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. This new guidance is effective for annual and interim periods beginning after December 15, 2017, with no early adoption permitted. The standard permits the use of either the retrospective or cumulative effect transition method. At this time we have not selected a transition method. We are currently evaluating the effect that ASU 2014-09 will have on our consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In August 2014, the FABS issued ASU No. 2014-15, <i>Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern</i> (&#34;ASU 2014-15&#34;). ASU 2014-15 will explicitly require management to assess an entity's ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. These changes became effective for the Company for the 2016 annual period. The adoption of these changes did not have an impact on the consolidated financial statements.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In February 2015, the FASB issued ASU 2015-02, <i>Consolidation (Topic 810): Amendments to the Consolidation Analysis</i>. This standard modifies existing consolidation guidance for reporting organizations that are required to evaluate whether they should consolidate certain legal entities. ASU 2015-02 is effective for fiscal years and interim periods within those years beginning after December 15, 2015, and requires either a retrospective or a modified retrospective approach to adoption. Early adoption is permitted. The adoption of this standard did not have an impact on the Company's Consolidated Financial Statements.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In April 2015, the FASB issued ASU No 2015-3, <i>Simplifying the Presentation of Debt Issuance Costs.</i> This update changes the presentation of debt issuance costs in the balance sheet. ASU 2015-03 requires debt issuance costs related to a recognized debt obligation to be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability rather than being presented as an asset. Amortization of debt issuance costs will continue to be reported as interest expense. In August 2015, the FASB issued ASU 2015-15, &#34;Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements&#34;. This ASU clarified guidance in ASC 2015-03 stating that the SEC staff would not object to a company presenting debt issuance costs related to a line-of-credit arrangement on the balance sheet as a deferred asset, regardless of whether there were any outstanding borrowings at period-end. This update is effective for annual and interim periods beginning after December 15, 2015, which required us to adopt these provisions starting the first quarter of 2016. This guidance did not have a material impact to our financial position or results of operations.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In February 2016, the FASB issued ASU 2016-02,&#160;<i>Leases (Topic 842)</i>, which supersedes existing guidance on accounting for leases in&#160;&#34;Leases (Topic 840)&#34;&#160;and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In March 2016, the FASB issued ASU 2016-09,&#160;<i>Improvements to Employee Share-Based Payment Accounting</i>. This ASU affects entities that issue share-based payment awards to their employees. The ASU is designed to simplify several aspects of accounting for share-based payment award transactions which include - the income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows and forfeiture rate calculations. ASU 2016-09 will become effective for the Company in the first quarter of fiscal 2018. Early adoption is permitted in any interim or annual period. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In April 2016, the FASB issued AS 2016-10, <i>Revenue from Contracts with Customers (Topic 606)</i>, which amends certain aspects of the Board's new revenue standard, ASU 2014-09, Revenue from Contracts with Customers. The standard should be adopted concurrently with adoption of ASU 2014-09 which is effective for annual and interim periods beginning after December 15, 2017. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The inputs used for the Black-Scholes option and warrant valuation model were as follows:</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 10pt">Expected life in years</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: center"><font style="font-size: 10pt">2 - 5 Years </font></td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 10pt">Stock price volatility</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: center"><font style="font-size: 10pt">79%</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 10pt">Risk free interest rate</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: center"><font style="font-size: 10pt">0.04 - 1.38%</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 10pt">Expected dividends</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: center"><font style="font-size: 10pt">None</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 10pt">Forfeiture rate</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: center"><font style="font-size: 10pt">0%</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Future minimum lease payments as of September 30, 2016, under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 10pt"><b>Year Ending </b></font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: center"><font style="font-size: 10pt"><b>Operating</b></font></td> <td style="padding: 0.75pt; text-align: center">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: center"><font style="font-size: 10pt"><b>Capital</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; padding: 0.75pt"><font style="font-size: 10pt"><b>December 31, </b></font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; padding: 0.75pt; text-align: center"><font style="font-size: 10pt"><b>Leases</b></font></td> <td style="padding: 0.75pt; text-align: center">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; padding: 0.75pt; text-align: center"><font style="font-size: 10pt"><b>Leases</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 10pt">&#160;&#160;&#160;&#160; 2016 (Remainder of)&#160;</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right"><font style="font-size: 10pt">$</font></td> <td style="padding: 0.75pt; text-align: right"><font style="font-size: 10pt">24,750&#160;</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right"><font style="font-size: 10pt">$</font></td> <td style="padding: 0.75pt; text-align: right"><font style="font-size: 10pt">13,222&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0.75pt"><font style="font-size: 10pt">&#160;&#160;&#160;&#160; 2017&#160;</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right"><font style="font-size: 10pt">99,000&#160;</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right"><font style="font-size: 10pt">- &#160;</font></td></tr> <tr style="vertical-align: top"> <td style="padding: 0.75pt"><font style="font-size: 10pt">&#160;&#160;&#160;&#160; 2018&#160;</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; padding: 0.75pt; text-align: right"><font style="font-size: 10pt">66,000&#160;</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; padding: 0.75pt; text-align: right"><font style="font-size: 10pt">- &#160;</font></td></tr> <tr style="vertical-align: top"> <td style="padding: 0.75pt"><font style="font-size: 10pt">Total minimum lease payments&#160;</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; padding: 0.75pt; text-align: right"><font style="font-size: 10pt">189,750&#160;</font></td> <td style="padding: 0.75pt; text-align: right">&#160;</td> <td style="padding: 0.75pt; text-align: right"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; padding: 0.75pt; text-align: right"><font style="font-size: 10pt">13,222&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Notes payable consisted of the following:</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>September 30,</b></font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>December 31, </b></font></td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%">&#160;</td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>2016</b></font></td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>2015</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">Promissory notes payable due to the former officers of MMRGlobal as part of severance </font><br /> <font style="font-size: 9pt">packages, due in full on August 31, 2009 with no stated interest</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">76,783&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">76,783&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">Promissory notes payable due to the former officers of MMRGlobal pursuant to the</font><br /> <font style="font-size: 9pt">Resignation and Post-Merger Employment Arrangement, due in full on August 31, 2009</font><br /> <font style="font-size: 9pt">with no stated interest</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">25,444&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">25,444&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">Promissory notes payable due to vendors relating to settlement of certain outstanding </font><br /> <font style="font-size: 9pt">accounts payable, payable in 18 equal monthly installments commencing on July 27, 2009 </font><br /> <font style="font-size: 9pt">and ending on January 27, 2011, with no stated interest</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">223,116&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">223,116&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">Short-term loan due to a third-party with 6% interest</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">56,896&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">44,070&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 9pt">Long term note payable relating to legal accounts payable, payable in full on March 30, 2018 with 10% interest per annum</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; vertical-align: bottom"><font style="font-size: 9pt">328,133&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; vertical-align: bottom"><font style="font-size: 9pt">-&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">710,372&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">369,413&#160;</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 9pt">Less: current portion</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 9pt">(382,239)</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 9pt">(369,413)</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 9pt">Notes payable, less current portion</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 9pt">328,133&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 9pt">-&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">Short term loan due to a related-party, payable in full on January 2, 2014 with 12% interest&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">6,743&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">6,743&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 9pt">Short term loan due to a related-party, payable in full on May 31, 2014 with 12% interest&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 9pt">-&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 9pt">50,000&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">Notes payable related party, current portion</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">6,743&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">56,743&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr> <td style="vertical-align: top"><font style="font-size: 9pt">Less: current portion</font></td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 9pt">(6,743)</font></td> <td style="text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 9pt">(56,743)</font></td></tr> <tr> <td style="vertical-align: top"><font style="font-size: 9pt">Notes payable related party, less current portion</font></td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 9pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 9pt">-&#160;</font></td> <td style="vertical-align: top; text-align: right">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font-size: 9pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 9pt">-&#160;</font></td></tr> </table> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> 0 0.0 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">A summary of option activity for the nine months ended September 30, 2016 is presented below. Options granted by MMR Inc. prior to the date of the Merger have been retroactively restated to reflect the conversion ratio of MMR Inc. to MMR shares</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Weighted-Average </b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Weighted-</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Remaining </b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Average</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Contractual</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Aggregate</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Exercise</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Life</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Intrinsic</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Options</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Price</b></font></td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>(Years)</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Value</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">Outstanding at December 31, 2015</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">7,488,345&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">0.50&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">3.62&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">- &#160;</font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">Granted</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">- &#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">- &#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">Exercised</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">- &#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">- &#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 9pt">Cancelled</font></td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 9pt">(2,208,052)</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">0.65&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 9pt">Outstanding at September 30, 2016 (Unaudited)</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; vertical-align: bottom"><font style="font-size: 9pt">5,280,293&#160;</font></td> <td style="text-align: right; vertical-align: bottom">&#160;</td> <td style="text-align: right; vertical-align: bottom"><font style="font-size: 9pt">$</font></td> <td style="text-align: right; vertical-align: bottom"><font style="font-size: 9pt">0.45&#160;</font></td> <td style="text-align: right; vertical-align: bottom">&#160;</td> <td style="text-align: right; vertical-align: bottom"><font style="font-size: 9pt">4.15&#160;</font></td> <td style="text-align: right; vertical-align: bottom">&#160;</td> <td style="text-align: right; vertical-align: bottom"><font style="font-size: 9pt">$</font></td> <td style="text-align: right; vertical-align: bottom"><font style="font-size: 9pt">- &#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">Vested and expected to vest</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 9pt">&#160;&#160;&#160;&#160; at September 30, 2016 (Unaudited)</font></td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 9pt">5,280,293&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">0.45&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">4.15&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">- &#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 9pt">Exercisable at September 30, 2016 (Unaudited)</font></td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; vertical-align: bottom"><font style="font-size: 9pt">5,280,293&#160;</font></td> <td style="text-align: right; vertical-align: bottom">&#160;</td> <td style="text-align: right; vertical-align: bottom"><font style="font-size: 9pt">$</font></td> <td style="text-align: right; vertical-align: bottom"><font style="font-size: 9pt">0.45&#160;</font></td> <td style="text-align: right; vertical-align: bottom">&#160;</td> <td style="text-align: right; vertical-align: bottom"><font style="font-size: 9pt">4.15&#160;</font></td> <td style="text-align: right; vertical-align: bottom">&#160;</td> <td style="text-align: right; vertical-align: bottom"><font style="font-size: 9pt">$</font></td> <td style="text-align: right; vertical-align: bottom"><font style="font-size: 9pt">- &#160;</font></td></tr> </table> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The following table summarizes information about stock options outstanding and exercisable at September 30, 2016.</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Options Outstanding</b></font></td> <td style="text-align: center">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Options Exercisable</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Weighted</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Weighted</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Weighted</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Weighted</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Average</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Average</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Average</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Average</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Exercise </b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Number</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Remaining</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Exercise</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Number</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Remaining</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Exercise</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Price</b></font></td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>of Shares</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Life (Years)</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Price</b></font></td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>of Shares</b></font></td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Life (Years)</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Price</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: center"><font style="font-size: 9pt">0.25 - 0.45</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">2,560,000&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">5.11</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">0.35&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">2,560,000&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">5.11</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">0.35&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: center"><font style="font-size: 9pt">0.50 - 0.75</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">2,520,293&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">3.21</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">0.55&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">2,520,293&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">3.21</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">0.55&#160;</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: center"><font style="font-size: 9pt">&#62; 0.75</font></td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 9pt">200,000&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">3.71</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">0.90&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 9pt">200,000&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">3.71</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">0.90&#160;</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 9pt">5,280,293&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 9pt">5,280,293&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> </table> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The following summarizes the total warrants outstanding and exercisable as of September 30, 2016:</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Warrants Outstanding</b></font></td> <td style="text-align: right">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Warrants Exercisable</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Warrants</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Weighted Avg</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Weighted Avg</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Warrants </b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Weighted Avg</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Weighted Avg</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 9pt"><b>Ranges</b></font></td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Outstanding</b></font></td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Remaining Life</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Exercise Price</b></font></td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Exercisable</b></font></td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Remaining Life</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Exercise Price</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">$0.02 - $0.30</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">35,794,569 </font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">2.61</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: center"><font style="font-size: 9pt">0.05</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">33,761,236 </font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">2.59</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: center"><font style="font-size: 9pt">0.05</font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">$0.30 - $0.50</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">255,000 </font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">0.53</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">0.50</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">255,000 </font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">0.53</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">0.50</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 9pt">Greater $0.50</font></td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 9pt">522,937 </font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">0.58</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">1.05</font></td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 9pt">522,937 </font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">0.58</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt">1.05</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 9pt">36,572,506 </font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 9pt">34,539,173 </font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td></tr> </table> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">A summary of the activity of our warrants for the nine months ended September 30, 2016 is presented below:</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 9pt"><b>Weighted Avg</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Shares</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Exercise Price</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">Outstanding at December 31, 2015</font></td> <td style="text-align: right"><font style="font-size: 9pt">11,428,610&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">0.30&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">Granted</font></td> <td style="text-align: right"><font style="font-size: 9pt">40,227,714&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">0.02&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">Exercised</font></td> <td style="text-align: right"><font style="font-size: 9pt">(11,750,000)</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">0.06&#160;</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 9pt">Cancelled</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 9pt">(3,333,818)</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">0.49&#160;</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 9pt">Outstanding at September 30, 2016 (Unaudited)</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 9pt">36,572,506&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">0.06&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 9pt">Exercisable at September 30, 2016 (Unaudited)</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 9pt">34,539,173&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">0.06&#160;</font></td></tr> </table> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">During the nine months ended September 30, 2016, we issued 28,769,439 shares of common stock with a value of $387,855 to various third parties and charged the proceeds to the appropriate accounts for the following reasons:</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Nine Months Ended September 30, 2016 </b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Purpose </b></font></td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Shares </b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 9pt"><b>Value </b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 9pt">Services provided </font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">- &#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="text-align: right"><font style="font-size: 9pt">- &#160;</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 9pt">Reduction of payables </font></td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 9pt">28,769,439&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 9pt">387,855&#160;</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 9pt">Totals&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 9pt">28,769,439&#160;</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 9pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 9pt">387,855&#160;</font></td></tr> </table> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> 0.0 0.79 0.79 0.0004 0.0138 24750 99000 189750 13222 13222 7488345 5280293 2560000 2520293 200000 0 0 2208052 0 0 0.45 0.50 0.45 0.35 0.55 0.90 0 0 11428610 36572506 35794569 255000 522937 40227714 11750000 3333818 0.30 0.06 0.02 0.06 0 <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Effective September 1, 2013, we renewed our lease for office space in Los Angeles, California with a term through August 31, 2018. The lease currently requires a monthly payment of $8,250.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> 79335 86854 2777714 0.011 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Our Chairman and Chief Executive Officer, Robert H. Lorsch, is also the Chief Executive Officer of The RHL Group, Inc. and has full voting power over all of the capital stock of The RHL Group, Inc. Mr. Lorsch directly and indirectly through The RHL Group, Inc., beneficially owns approximately 32.1% our total outstanding voting stock. The RHL Group, Inc. has loaned us money pursuant to the Eleventh Amended Note and all predecessor notes. See Note 3 - Related Party Note Payable above.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The RHL Group is an investment holding company which provides consulting, operational and technical services to us, which we refer to as the RHL Services. As part of the RHL Services, The RHL Group provides us with unrestricted access to its internal business and relationship contact database of more than 10,000 persons and entities, which includes clients of The RHL Group and other individuals which may hold value to us. The RHL Group also provides infrastructure support to us, including allowing us unlimited access to its facilities, equipment, and data, information management and server systems. In addition to allowing us the use of its office support personnel, The RHL Group has also consented to allow us to utilize the full-time services of Mr. Lorsch as our President, Chairman and Chief Executive Officer, which requires substantial time and energy away from his required duties as The RHL Group's Chairman and Chief Executive Officer. In addition, The RHL Group has made Kira Reed, available as our spokesperson. Ms. Reed, who is Mr. Lorsch's spouse, also manages our social networking activities.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In consideration for the above, The RHL Group, Inc. has a consulting arrangement with MMR. A copy of the consulting agreement is filed as an exhibit in our Form 8-K, as filed with the SEC on May 4, 2009 and is hereby incorporated by reference.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We incurred $37,500 during the nine months ended September 30, 2016 and 2015, toward marketing consulting services from Bernard Stolar, a director. We included $260,523 and $206,272 in related party payables as of September 30, 2016 and December 31, 2015, respectively, in connection with these services and board fees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We contract with a significant vendor for the development and maintenance of the software applications necessary to run our MyMedicalRecords PHR, MyEsafeDepositBox and MyMedicalRecords Pro products. Our outside developer supports our software development needs through a team of software engineers, programmers, quality control personnel and testers, who work with our internal product development team on all aspects of application development, design, integration and support of our products. This vendor is also a stockholder. For the nine months ended September 30, 2016 and 2015, the total expenses relating to this stockholder amounted to $90,000 and $90,000, respectively. In addition, we capitalized $0 of software development costs for the quarter ended September 30, 2016. As of September 30, 2016 and December 31, 2015, the total amounts due to the stockholder and included in related party payables amounted to $195,000 and $105,000 respectively.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> 37500 37500 90000 90000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In connection with the merger with Favrille, Inc. in 2009, we signed promissory notes with certain former executives totaling $76,783.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">As of September 30, 2016, the total remaining severance liabilities amounted to $620,613, which is reflected as severance liability on the accompanying consolidated balance sheets. This consists of $571,362 payable to former non-executive employees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> 571362 76783 16188 16759 211851177 250060616 211851177 250060616 <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>(b) CASH AND CASH EQUIVALENTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We consider cash equivalents to be only those investments that are highly liquid, readily convertible to cash and with maturities of 90 days or less at the purchase date. We maintain our cash in bank deposit accounts that, at times, may exceed federally insured limits. We have not experienced any losses in such accounts and believe that we are not exposed to any significant credit or deposit risk on our cash. We had cash and cash equivalents of $0 and $0 as of September 30, 2016 and December 31, 2015, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>(c) TRADE AND OTHER RECEIVABLES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Receivables represent claims against third parties that will be settled in cash. The carrying value of receivables, net of an allowance for doubtful accounts, if any, represents their estimated net realizable value. We estimate the allowance for doubtful accounts, if any, based on historical collection trends, type of customer, the age of outstanding receivables and existing economic conditions. If events or changes in circumstances indicate that specific receivable balances may be impaired, we give further consideration to the collectability of those balances and the allowance is adjusted accordingly. We write off past due receivable balances when collection efforts have been unsuccessful in collecting the amount due.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> 0 0 <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Under ASC 740-270, <i>Income Taxes - Interim Reporting</i>, we are required to adjust our effective tax rate each quarter to be consistent with the estimated annual effective tax rate. We are also required to record the tax impact of certain discrete items, unusual or infrequently occurring, including changes in judgment about valuation allowances and effects of changes in tax laws or rates, in the interim period in which they occur. In addition, we exclude jurisdictions with a projected loss for the year or a year-to-date loss where we cannot recognize a tax benefit from our estimated annual effective tax rate. The impact of such an exclusion could result in a higher or lower effective tax rate during a particular quarter, based upon the mix and timing of actual earnings versus annual projections.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Pursuant to ASC 740, <i>Income Taxes</i>, we performed an analysis of previous tax filings and determined that there were no positions taken that it considered uncertain. Therefore, there were no unrecognized tax benefits as of September 30, 2016.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">MMR Inc., in its capacity as the operating company taking over our income tax positions in addition to its own positions after January 27, 2009 (see Note 1), has estimated its annual effective tax rate to be zero. MMRGlobal has based this on an expectation that the combined entity will generate net operating losses in 2016, and it is not likely that those losses will be recovered using future taxable income. Therefore, no provision for income tax has been recorded as of and for the nine months ended September 30, 2016.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We account for income taxes in accordance with ASC 740-10,<i>&#160;Income Taxes</i>. We recognize deferred tax assets and liabilities to reflect the estimated future tax effects, calculated at the tax rate expected to be in effect at the time of realization. We record a valuation allowance related to a deferred tax asset when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="margin: 0"><font style="font-size: 10pt"></font></p> <p style="margin: 0"><font style="font-size: 10pt">Promissory notes payable due to the former officers of MMRGlobal as part of severance packages, due in full on August 31, 2009 with no stated interest</font></p> <p style="margin: 0">&#160;</p> <p style="margin: 0">&#160;</p> <p style="margin: 0">&#160;</p> <p style="margin: 0"></p> <p style="margin: 0"><font style="font-size: 10pt">Promissory notes payable due to the former officers of<br /> MMRGlobal pursuant to the Resignation and Post-Merger Employment<br /> Arrangement, due in full on August 31, 2009 with no stated interest</font></p> <p style="margin: 0"><font style="font-size: 10pt">Promissory notes payable due to vendors relating to settlement of certain<br /> outstanding accounts payable, payable in 18 equal monthly installments commencing<br /> on July 27, 2009 and ending on January 27, 2011, with no stated interest</font></p> <p style="margin: 0"><font style="font-size: 10pt">Short-term loan due to a third-party with 6% interest</font></p> <p style="margin: 0"><font style="font-size: 10pt">&#160;</font></p> <p style="margin: 0"><font style="font-size: 10pt">Short term loan due to a related-party, payable in full on January 2, 2014 with 12% interest&#160;</font></p> <p style="margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif"><font style="font-size: 10pt">Short term loan due to a related-party, payable in full on May 31, 2014 with 12% interest&#160;</font></td></tr> </table> <p style="margin-top: 0; margin-bottom: 0">&#160;</p> <p style="margin-top: 0; margin-bottom: 0">&#160;</p> 369413 382239 76783 76783 25444 25444 223116 223116 44070 56896 6743 6743 50000 0 <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">From time to time, we issue Convertible Promissory Notes. As of September 30, 2016, a total of $323,749 in convertible notes remained outstanding and have matured. However, the Company and the Holders have agreed to keep the balance as a Note Payable and the note holders have elected not to convert their note balances into shares of our common stock as of September 30, 2016.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Each Note contains the following general terms and provisions:</p> <ul> <li style="margin: 0pt 0 12pt; font-size: 9pt">The principal amount owed under each note becomes due and payable one year or less from the investment date provided that, upon ten (10) days' prior written notice to the holder, we may, in our sole discretion, extend the maturity date for an additional six month term. The Notes can be further extended upon mutual agreement.</li> <li style="margin: 0pt 0 12pt; font-size: 9pt">These notes bear interest at a rate of 0%-6% per annum payable in cash or shares of common stock or a combination of cash and shares of common stock at our option.</li> </ul> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> 0 55780 <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On June 6, 2016, we and The RHL Group entered into an Eleventh Amended and Restated Promissory Note (the &#34;<u>Amended Note</u>&#34;), effective as of June 6, 2016. The Eleventh Note amends and restates that certain Tenth Amended Note entered into between the foregoing parties, effective May 20, 2015 (the &#34; <u>Existing Note</u>&#34;) and together with its predecessor notes and the Amended Note, the (&#34;<u>Credit Facility</u>&#34;), by: (i) extending the maturity date to June 6, 2017. In connection with the Eleventh Amended Note, we issued The RHL Group warrants to purchase 2,777,714 shares of our common stock at $0.011 per share on June 6, 2016. Other than for the amounts as disclosed herein, The Eleventh Amended Note does not materially alter the terms of the previous Tenth Amended Note.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Historically, the predecessor notes have increased over time the maximum amount of credit available under the Credit Facility from $100,000 to $1,000,000 to $3,000,000 to $4,500,000. The maximum amount of the Amended Note is $4,500,000. The Amended Note continues to bear interest at the lesser of 10% or the highest rate then permitted by law, and is secured (similar to the Existing Note) by a Security Agreement, which has been in effect since July 31, 2007, as renewed and amended to date (the &#34;Security Agreement&#34;).</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Eleventh Amended Note had a current balance of $2,953,548 at September 30, 2016. The components of the Eleventh Amended Note and the related balance sheet presentation as of September 30, 2016 are as follows: $1,715,646, which is included in the Line of Credit, related party; and $1,237,902 for other obligations due to The RHL Group, which is included in related party payables.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Total interest expense on the Line of Credit for the three months ended September 30, 2016 and 2015 amounted to $70,925 and $36,699, respectively. Total interest expense on the Line of Credit for the nine months ended September 30, 2016 and 2015 amounted to $200,237 and $102,433, respectively. The unpaid interest balances as of September 30, 2016 and December 31, 2015 were $321,737 and $60,257, respectively.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In conjunction with the Eleventh Amended Note, we were required to maintain certain financial covenants, including the requirement that we have at least $200,000 of cash in our bank accounts or such other amount as necessary to maintain operations through the subsequent thirty (30) days and timely pay any obligations due respecting payroll and all associated payroll taxes at any time during the term of the Note. As of November 21<sup>st</sup>, the Company was not in compliance with certain of the financial covenants and The RHL Group has not waived any of the covenants.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> 2017-06-06 1715646 1237902 2953548 P5Y0M0D 0.49 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>(e) IMPAIRMENT OF LONG-LIVED ASSETS AND INTANGIBLES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We account for long-lived assets, which include property and equipment and identifiable intangible assets with finite useful lives (subject to amortization), in accordance with ASC 350-30. ASC 350-30 requires that we review long-lived assets for impairment whenever events or changes in circumstances indicate that we may not recover the carrying amount of an asset. We measure recoverability by comparing the carrying amount of an asset to the expected future undiscounted net cash flows generated by the asset. If we determine that the asset may not be recoverable, or if the carrying amount of an asset exceeds its estimated future undiscounted cash flows, we recognize an impairment charge to the extent of the difference between the fair value and the asset's carrying amount. Our assessment of the undiscounted future cash flows indicated that the carrying amount of the long-lived and intangible assets are recoverable, therefore, we had no impairment charges during the nine months ended September 30, 2016 and 2015.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Basis of Presentation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We have prepared the accompanying consolidated unaudited financial statements in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial statements and with instructions to Form 10-Q pursuant to the rules and regulations of Securities and Exchange Act of 1934, as amended, or the Exchange Act and Article 8-03 of Regulation S-X promulgated under the Exchange Act. Accordingly, these financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of our management, we have included all adjustments considered necessary (consisting of normal recurring adjustments) for a fair presentation. Operating results for the three and nine months ended September 30, 2016 are not indicative of the results that may be expected for the fiscal year ending December 31, 2016. You should read these unaudited condensed consolidated financial statements in conjunction with the audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2015.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><i>Litigation Matters</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">From time to time, we are involved in various legal proceedings generally incidental to our business. While the result of any litigation contains an element of uncertainty, our management presently believes that the outcome of any known, pending or threatened legal proceeding or claim, individually or combined, will not have a material adverse effect on our financial statements.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On December 9, 2011, MyMedicalRecords, Inc. entered into a Non-Exclusive Settlement and Patent License Agreement with Surgery Center Management LLC (&#34;SCM&#34;). In consideration for the rights granted under that Agreement and in consideration of a settlement and release agreement, SCM contracted to pay MyMedicalRecords, Inc. an initial payment of $5 million payable on December 23, 2011, and additional payments of $5 million per year for five consecutive years. After unsuccessful attempts to collect the past due amount of $5 million, on January 19, 2012, MyMedicalRecords, Inc. filed a lawsuit in the Superior Court of the State of California for the County of Los Angeles for breach of contract. On February 13, 2014, SCM filed a cross-complaint alleging claims for breach of that contract, among other things, which SCM has amended twice. On September 29, 2016, the court granted a motion for summary judgment filed by Robert Lorsch, a cross-defendant. The case between MyMedicalRecords, Inc. and SCM began trial on November 1, 2016.&#160; MyMedicalRecords, Inc. will continue to pursue its claim and defenses, but the Company cannot predict the chances of either a favorable or unfavorable outcome, nor does the Company have sufficient information regarding its ability to collect any judgment MyMedicalRecords, Inc. may obtain against SCM.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On April 2, 2015, the Company and Stradling Yocca Carlson &#38; Rauth, P.C. (&#34;SYCR&#34;), were notified of the determination of an arbitrator in regards to disputes&#160;over amounts of monies due SYCR regarding prior services rendered. SYCR and the Company had previously agreed to a non-binding arbitration of the matter. The Company received an award in favor of SYCR in the amount of&#160;$285,000 which the Company disputed, notwithstanding, that it represented a reduction of SYCR's original $571,000 claim or $286,000 in favor of the Company. On September 1, 2016, the Company settled with SYCR through the signing of an eighteen-month unsecured Promissory Note in the amount of $328,133.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Two separate MyMedicalRecords health IT patents were accepted by the Australia Patent Office in 2015 and subject to Opposition. On January 8, 2015, Australia Patent Application No. 2011307287, &#34;Universal Patient Record Conversion Tool,&#34; was accepted by the Australia Patent Office.&#160;An opposition was filed on April 21, 2015 by The Crown in the Right of the Commonwealth of Australia (Department of Health). A second opposition was filed on April 22, 2015 by the Medical Software Industry Association, Inc. which aligned itself with the Crown.&#160; In the interim, a divisional application, Australia Patent Application No.2015201900, was filed on October 15, 2015.&#160; Rather than continue to bear the legal costs of defending these patents before the Governmental Department of Health, MMR determined it was in the Company's best interest to withdraw the patent and the divisional application and this action was officially acknowledged by the Australian Government on August 4, 2016, thereby ending any further opposition.&#160; Separately, Australia Patent Application No. 2013212253, &#34;Mobile Platform for Personal Health Records,&#34; was also accepted by the Australia Patent Office after which oppositions were filed.&#160; Subsequently, the Company filed a request this quarter for withdrawal of the disputed application and also surrender of a related innovation patent No. 2015101556.&#160; The Australian Government acknowledged these actions on September 13, 2016 and we do not expect any further potential litigation in this matter. MMR continues to maintain two previously issued Australia health IT patents under the title &#34;Method and System for Providing Online Medical Records&#34;: Patent No. 2006202057 issued on May 29, 2008 and Patent No. 2008202401 issued on December 24, 2009.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> 0.06 0 0 137528 11170 200237 102433 70925 36699 321727 60257 28769439 387855 0 34539173 P4Y54D P3Y223D 1355932 252370616 2014-04-29 0 -309393 387855 299420 0 0.65 8920162 8883286 13221 13222 369413 382238 323749 323749 4420585 3152583 727509 748160 1002428 1715646 716608 667415 -8203554 -8544004 -66949874 -68581895 57687270 58938322 215483 215483 -5452 -1252 0 1252 0 93268 0 1675 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Going Concern and Management's Plan</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">As of September 30, 2016, our current liabilities exceeded our current assets by $8.8 million. Furthermore, during the nine months ended September 30, 2016, we incurred losses of $1,632,021, as further explained in Management's Discussion and Analysis of Financial Condition and Results of Operations appearing in Item 2 of Part I of this Quarterly Report on Form 10-Q.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">At September 30, 2016 and December 31, 2015, we had $0 and $0, respectively, in cash and cash equivalents. Historically, we issued capital stock, sold debt and equity securities and received funds from The RHL Group, Inc. (a significant stockholder that is wholly-owned by our Chairman and Chief Executive Officer, Robert H. Lorsch) to operate our business. Although we received additional funding from The RHL Group pursuant to the Eleventh Amended and Restated Note effective June 6, 2016 (the &#34;Line of Credit&#34;), we will still be required to obtain additional financing in order to meet installment payment obligations and the previously existing obligations under the Line of Credit, which had a balance of $2,953,548 at September 30, 2016 and a total Unpaid Balance (as defined in the Line of Credit) of $3,203,548, which includes amounts borrowed under the Line of Credit, unpaid interest fees, any amounts guaranteed by The RHL Group, and other obligations due The RHL Group pursuant to the terms of the Eleventh Amended and Restated Note and the Security Agreement. As a result of the above, we express uncertainty about our ability to continue as a going concern. The components of the RHL Group Note payable and the related balance sheet presentation as of September 30, 2016 are as follows: $1,715,646, which is included in the Line of Credit, related party; and $1,237,902 related to other obligations due to The RHL Group which are included in related party payables.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Management's plan regarding this matter is to, amongst other things, continue to utilize our available Line of Credit with The RHL Group (see Note 3). As of September 30, 2016, under the original terms, we had approximately $1,296,452 remaining as available under The RHL Group Line of Credit, but we are now in default under the line of credit. Additionally, we plan to continue selling additional debt and equity securities, continue to settle our existing liabilities through issuance of equity securities, explore other debt financing arrangements, continue to increase our existing subscriber and affiliate customer base, sell MMRPro products, and continue efforts to license our intellectual property to obtain additional cash flow over the next twelve months. We cannot assure that funds from these sources will be available when needed or, if available, will be on terms favorable to us or to our stockholders. If we raise additional funds or settle liabilities by issuing equity securities, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution or such equity securities may provide for rights, preferences or privileges senior to those of the holders of our common stock. If we are unable to utilize our available Line of Credit with The RHL Group or obtain suitable alternative debt or equity financing, our ability to execute our business plan and continue as a going concern may be adversely affected.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">These matters raise substantial doubt about our ability to continue as a going concern. These financial statements were prepared under the assumption that we will continue as a going concern and do not include any adjustments that might result from the outcome of that uncertainty.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> 28769439 387855 43208730 33251116 0.02 0.30 0.50 0.30 0.50 P2Y220D P191D P209D 0.05 0.50 1.05 34539173 33761236 255000 522937 2.59 0.53 0.31 0.05 0.50 1.05 0.25 0.50 0.75 0.45 0.75 P5Y39D P3Y75D P3Y256D 5280293 2560000 2520293 200000 P5Y539D P3Y75D P3Y256D 0.45 0.35 0.55 0.90 5280293 P4Y54D P4Y54D 66000 750000 0 <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>(j) RECLASSIFICATIONS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Certain numbers in the prior year have been reclassified to conform to the current year's presentation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> 8920162 9211419 0 328133 232635531 166083438 250587899 178674759 232635531 166083438 250587899 178674759 -0.01 -0.01 -0.00 0.00 228136 420199 87575 102504 1288472 1331644 297500 383147 -114346 -40838 -23393 32366 167941 179554 49733 45298 53595 138716 26340 77664 -1632021 -1923286 -451526 -489000 192967 191355 70857 44629 191900 60750 27799 8914 -1630954 -1792681 -408468 -453285 111017 217208 0 38199 16188 16759 137528 11170 187871 0 0 55780 76862 339116 -473047 -648679 -1082112 -935491 0 -11050 20651 102925 534432 519315 422057 258667 -88782 -114744 -16190 49110 5452 0 -34483 56163 0 29774 0 30000 512982 254601 478499 340538 0 30000 0 100800 328133 0 <p style="margin: 0"><font style="font-size: 10pt">Long term note payable relating to legal accounts payable, payable in full on March 30, 2018 with 10% interest per annum</font></p> <p style="margin: 0">&#160;</p> <p style="margin: 0">&#160;</p> 0 328133 0 328133 EX-101.SCH 8 mmrf-20160930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION - Note 1 link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Note 2 link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - RELATED PARTY PAYABLES, LINE OF CREDIT AND NOTE PAYABLE - Note 3 link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - INCOME TAXES - Note 4 link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - COMMITMENTS AND CONTINGENCIES - Note 5 link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - STOCKHOLDERS' DEFICIT - Note 6 link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - EQUITY ISSUANCES - Note 7 link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - NOTES PAYABLE - Note 8 link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - CONVERTIBLE PROMISSORY NOTES - Note 9 link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - RESTRUCTURING ACTIVITIES - Note 10 link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - RELATED PARTY TRANSACTIONS - Note 11 link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SHARE-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - EQUITY ISSUANCES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Accounting Policies (Cash and Cash Equivalents) (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Accounting Policies (Intangible Assets and Impairments) (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Accounting Policies (Share-Based Compensation Schedule Of Assumptions Used In Black-Scholes Model) (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Accounting Policies (Net Income/Loss Per Share) (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Related Party Note Payable (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Income Taxes (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Commitments and Contingencies (Operating Leases) (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Commitments and Contingencies (Capital Leases) (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Commitments and Contingencies (Leases Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Equity Issuances (Stock Option Activity Summary Of Option Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Equity Issuances (Stock Option Activity Summary Of Stock Options Outstanding and Exercisable) (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Equity Issuances (Stock Option and Warrant Expense Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Equity Issuances (Summary Of Warrant Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Equity Issuances (Summary Of Warrants Outstanding and Exercisable) (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Equity Issuances (Inputs Used In Black-Scholesl) (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Equity Issuances (Shares Issued for Services or Reduction to Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Equity Issuances (Warrants) (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Equity Issuances (Stock Bonus Agreements) (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Convertible Promissory Notes (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Restructuring Activities (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Related Party Transactions (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 mmrf-20160930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 mmrf-20160930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 mmrf-20160930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Severance Package Notes Debt Instrument [Axis] Resignation and Post-Merger Employment Arrangement Notes Notes Payable - Vendors Tenth Amended and Restated Secured Promissory Note Related Party Transactions, by Related Party [Axis] September 2013 Lease Operating Lease [Axis] The RHL Group, Inc. Bernard Stolar Significant Vendor Favrille Restructuring Cost and Reserve [Axis] Short Term Loan Two Related Party One Related Party Two $0.02 - $0.30 Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type and Plan Name [Axis] $0.30 - $0.50 > $0.50 $0.25 - $0.45 Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Axis] $0.50 - $0.75 > $0.75 Legal Accounts Payable Note Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current assets: Cash and cash equivalents Accounts receivable, less allowances of $215,483 and $215,483 in 2016 and 2015, respectively Inventory Prepaid expenses and other current assets Total current assets Property and equipment, net Intangible assets, net Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities: Line of credit, related party Related party payables Compensation payable Severance liability Accounts payable and accrued expenses Convertible notes payable Notes payable, current portion Notes payable, related party Capital leases payable, current portion Total current liabilities Notes payable, noncurrent Total liabilities Commitments and contingencies (See Note 9) Stockholders' deficit: Preferred stock - $0.001 per value, 5,000,000 shares authorized, 0 issued and outstanding. Common stock, $0.001 par value, 1,250,000,000 shares authorized, 250,060,616 and 211,851,177 shares issued and outstanding as of September 30, 2016 and December 31, 2015, respectively Additional paid-in capital Accumulated deficit Total stockholders' deficit Total liabilities and stockholders' deficit Allowances Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues Cost of revenues Gross profit (loss) General and administrative expenses Sales and marketing expenses Technology development Loss from operations Other income Interest and other finance charges, net Net loss Net loss per share: Basic and diluted Weighted average common shares outstanding: Basic Diluted Statement of Cash Flows [Abstract] Operating activities: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Deferred rent Gain on write-off of liabilities Warrants issued for services Stock-based compensation Common stock issued for services Amortization of loan discount Subtotal - non-cash adjustments Effect of changes in: Accounts receivable Prepaid expenses and other current assets Accounts payable and accrued expenses Related party payables Compensation payable Deferred revenue Subtotal - net change in operating assets and liabilities Net cash used in operating activities Investing activities: Purchase of property and equipment Filing of patents Payments for note receivable Cost of continuing MMRPro and website development Net cash used in investing activities Financing activities: Book overdraft Proceeds from shares issued for financing activities Payments of line of credit Net proceeds from convertible notes Net proceeds from warrant exercises Proceeds from note payable Payments of note payable Proceeds on line of credit Net cash provided by financing activities Net increase (decrease) in cash Cash, beginning of period Cash, end of period Supplemental disclosures of cash flow information: Cash paid for interest Cash paid for income taxes Supplemental disclosure of non-cash investing and financing activities: Conversion of convertible notes into common stock Shares issued for reduction of payables Warrants exercised through reduction of payables Conversion of accounts payable to note payable Notes to Financial Statements NATURE OF OPERATIONS AND BASIS OF PRESENTATION - Note 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Note 2 RELATED PARTY PAYABLES, LINE OF CREDIT AND NOTE PAYABLE - Note 3 INCOME TAXES - Note 4 COMMITMENTS AND CONTINGENCIES - Note 5 Legal Matters and Contingencies - Note 5 STOCKHOLDERS' DEFICIT - Note 6 EQUITY ISSUANCES - Note 7 NOTES PAYABLE - Note 8 CONVERTIBLE PROMISSORY NOTES - Note 9 RESTRUCTURING ACTIVITIES - Note 10 RELATED PARTY TRANSACTIONS - Note 11 Principles of Consolidation Basis of Presentation Going Concern and Management's Plan Management's Use of Estimates Cash and Cash Equivalents Trade and Other Receivables Fair Value of Financial Instruments Impairment of Long-Lived Assets and Intangibles Revenue Recognition Shared-Based Compensation Net Income/Loss Per Share Recent Accounting Pronouncements Reclassifications Income Taxes Share-based Compensation Tables Schedule of Valuation Assumptions to Determine the Fair Value of Stock Options Commitments And Contingencies Tables Schedule of Future Minimum Rental Payments for Operating and Capital Leases Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Summary of Outstanding Option Awards Summary of Stock Options Outstanding and Exercisable Summary of Outstanding Warrant Awards Black-Scholes option and valuation model assumptions Shares Issued for Services or Reduction to Liabilities Notes Payable Tables Notes Payable Accounting Policies Cash And Cash Equivalents Narrative Details Accounting Policies Intangible Assets And Impairments Narrative Details Impairment charges Accounting Policies Share-based Compensation Schedule Of Assumptions Used In Black-scholes Model Details Expected life, in years, maximum Stock price volatility, minimum Stock price volatility, maximum Risk-free interest rate, mimimum Risk-free interest rate, maximum Expected dividends Forfeiture rate Accounting Policies Net Incomeloss Per Share Narrative Details Stock options, warrants and convertible notes excluded from the computation of net loss per share Statement [Table] Statement [Line Items] Related Party [Axis] Date of note Maximum line of credit under note Interest rate Maturity date Warrants granted for shares Warrant price per share Expiration date of warrants Debt component classification: Line of credit, related party Related party payables Total note payable balance Interest expense on line of credit Related party accrued interest Income Taxes Narrative Details Unrecognized tax benefits Income tax rate Commitments And Contingencies Operating Leases Details Year ending December 31: 2016 (Remainder of) 2017 2018 2019 Total minimum lease payments Commitments And Contingencies Capital Leases Details Year ending December31: 2016 (Remainder of) Total minimum lease payments OperatingLeaseAxis [Axis] Operating lease description Rent expense Equity Issuances Stock Option Activity Summary Of Option Activity Details Outstanding at December 31, 2015 Granted Exercised Cancelled Outstanding at September 30, 2016 (Unaudited) Vested and expected to vest at September 30, 2016 (Unaudited) Exercisable at September 30, 2016 (Unaudited) Weighted-Average Exercise Prices, Outstanding at December 31, 2015 Weighted-Average Exercise Prices, Granted Weighted-Average Exercise Prices, Exercised Weighted-Average Exercise Prices, Forfeited, cancelled or expired Weighted-Average Exercise Prices, Outstanding at September 30, 2016 Weighted-Average Exercise Prices, Vested and expected to vest Weighted-Average Exercise Prices, Exercisable Weighted-Average Remaining Contractual Life (in years), Outstanding at December 31, 2015 Weighted-Average Remaining Contractual Life (in years), Outstanding at September 30, 2016 Weighted-Average Remaining Contractual Life (in years), Vested and expected to vest Weighted-Average Remaining Contractual Life (in years), Exercisable Aggregate Intrinsic Value, Outstanding at December 31, 2015 Aggregate Intrinsic Value, Outstanding at September 30, 2016 Aggregate Intrinsic Value, Vested and expected to vest Aggregate Intrinsic Value, Exercisable Exercise Price Range [Axis] Range of Exercise Price, Minimum Range of Exercise Price, Maximum Options Outstanding, Number of Shares Options Outstanding, Weighted-Average Remaining Life (in years) Options Outstanding, Weighted-Average Exercise Price Per Share Options Exercisable, Number of Shares Options Exercisable, Weighted-Average Remaining Life (in years) Options Exercisable, Weighted-Average Exercise Price Per Share Equity Issuances Stock Option And Warrant Expense Narrative Details Stock option expense Warrant expense Equity Issuances Summary Of Warrant Activity Details Warrants outstanding at December 31, 2015 Granted Exercised Cancelled Warrants outstanding at September 30, 2016 Warrants exercisable at September 30, 2016 Weighted-average exercise price, beginning balance Weighted-average exercise price, granted Weighted-average exercise price, exercised during period Weighted-average exercise price, cancelled during period Weighted-average exercise price, ending balance Warrants exercisable, weighted average exercise price Award Type [Axis] Range of Exercise Price, Minimum Range of Exercise Price, Maximum Warrants outstanding, Weighted-average remaining life, in years Warrants outstanding, Weighted-average exercise price Warrants exercisable Warrants exercisable, Weighted-average remaining life, in years Warrants exercisable, Weighted-average exercise price Equity Issuances Inputs Used In Black-scholesl Details Risk-free interest rate, minimum Equity Issuances Shares Issued For Services Or Reduction To Liabilities Details Common stock issued Reduction of payables, shares Reduction of payables, amount Services provided, shares Services provided, amount Total payment of services provided through issuance of common stock, shares Total payment of accounts payable through issuance of common stock, amount Class of Warrant or Right [Axis] January 10 2013 January 21 2013 First January 21 2013 Second January 21 2013 Third February 20 2013 March 13 2013 March 18 2013 A March 18 2013 B April 1 2013 A April 1 2013 B May 13 2013 A May 13 2013 B May 13 2013 C May 13 2013 D May 20 2013 June 12 2013 A March 4 2014 March 4 2014 B March 4 2014 C March 27 2014 April 8 2014 April 30 2014 May 29 2014 A May 29 2014 B July 10 2014 Number of warrants granted Exercise price, per share Title of Warrants Outstanding Defined Benefit Plans and Other Postretirement Benefit Plans [Axis] May 10 2013 May 28 2013 Shares issued for services under Stock Bonus Agreement, shares Shares issued for services, price per share Stock Bonus Agreement expense Unrecognized compensation cost Notes payable consisted of the following: Short-term Debt, Terms Long-term Debt, Description Short-term debt Long-term Debt, Excluding Current Maturities Related party short-term debt Convertible Promissory Notes Narrative Details Debt instrument, description Debt Instrument, Convertible, Number of Equity Instruments Creation of note discount Note discount Amortization of loan discount Convertible notes converted Converted notes, shares issued Interest expense Restructuring Type [Axis] Creditor Plan Restructuring and Related Activities, Description Number of employees terminated Severance liability relating to former Favrille employees at merger date Warrants issued as settlement of severance liability Promissory notes with certain former executives Severance liabilty payable to former non-executive employees in 18 monthly installments starting on July 27, 2009 Total remaining severance liability Amount settled under creditor plan Accounts payable settled Promissory notes settled The Rebensdorf Group, Inc. George Rebensdorf E-Mail Frequency, LLC David Loftus Nature of Common Ownership or Management Control Relationships Related Party Transaction, Amounts of Transaction Related Party Transaction, Expenses from Transactions with Related Party Related Party Transaction, Revenues from Transactions with Related Party Shares issued for services, related party, shares Shares issued for services, related party, amount Amortization of licensee fee Interest expense with related party Software development costs Common Stock Issued Abstract Services paid to third party vendors by the issuance of common stock Highest exercise price range of stock options Line of credit borrowing due to related party. Related party accrued interest The number of shares into which warrants exercisable as of the balance sheet date can be currently converted in the customized range of exercise prices. The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on warrants currently exercisable in the customized range of exercise prices. The weighted average remaining life of the exercisable warrants as of the balance sheet date for all in the customized range of exercise prices. The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock warrants awards other required information pertaining to awards in the customized range. The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock warrants awards other required information pertaining to awards in the customized range. The future forfeture rate assumption based on the composition of current grantees that is used in valuing an option on its own shares. Tabular disclosure of common stock shares issued in payment of services or as a reduction in accounts payable or accrued liabilities. Short-term loan member Total payment of accounts payable and services provided through issuance of common stock, shares Warrant issued for a specific purpose during a specific period of time. Warrant issued for a specific purpose during a specific period of time. Warrant issued for a specific purpose during a specific period of time. Warrant issued for a specific purpose during a specific period of time. Warrant issued for a specific purpose during a specific period of time. Warrant issued for a specific purpose during a specific period of time. Warrant issued for a specific purpose during a specific period of time. Warrant issued for a specific purpose during a specific period of time. Warrant issued for a specific purpose during a specific period of time. Warrant issued for a specific purpose during a specific period of time. Warrant issued for a specific purpose during a specific period of time. Warrant issued for a specific purpose during a specific period of time. Warrant issued for a specific purpose during a specific period of time. Warrant issued for a specific purpose during a specific period of time. Warrant issued for a specific purpose during a specific period of time. Warrant issued for a specific purpose during a specific period of time. Warrant issued for a specific purpose during a specific period of time. Warrant issued for a specific purpose during a specific period of time. Warrant issued for a specific purpose during a specific period of time. Warrant issued for a specific purpose during a specific period of time. Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Income (Loss) Interest and Debt Expense Increase (Decrease) in Deferred Charges Gain (Loss) on Extinguishment of Debt Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities Increase (Decrease) in Accounts Receivable Increase (Decrease) in Prepaid Expense Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Accounts Payable, Related Parties Increase (Decrease) in Accrued Salaries SubtotalNetChangeInOperatingAssetsAndLibilities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Payments to Acquire Machinery and Equipment Payments to Acquire Intangible Assets Payments to Acquire Notes Receivable Payments to Develop Software Net Cash Provided by (Used in) Investing Activities, Continuing Operations Repayments of Lines of Credit Repayments of Notes Payable Net Cash Provided by (Used in) Financing Activities, Continuing Operations Cash and Cash Equivalents, Period Increase (Decrease) Line of Credit, Current Accounts Payable, Related Parties, Current Operating Leases, Future Minimum Payments Due Capital Leases, Future Minimum Payments Due, Next Twelve Months Capital Leases, Future Minimum Payments Due Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePriceRangeLowerRangeLimit SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePriceRangeUpperRangeLimit Amortization of Debt Issuance Costs and Discounts GreaterThanZeroPointOneFiveMember EX-101.PRE 12 mmrf-20160930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 13 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2016
Nov. 21, 2016
Document And Entity Information    
Entity Registrant Name MMRGlobal, Inc.  
Entity Central Index Key 0001285701  
Document Type 10-Q  
Document Period End Date Sep. 30, 2016  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Is Entity a Well-known Seasoned Issuer? No  
Is Entity a Voluntary Filer? No  
Is Entity's Reporting Status Current? Yes  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   252,370,616
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2016  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
Consolidated Balance Sheets - USD ($)
Sep. 30, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 0 $ 0
Accounts receivable, less allowances of $215,483 and $215,483 in 2016 and 2015, respectively 11,744 27,934
Prepaid expenses and other current assets 78,014 0
Total current assets 89,758 27,934
Property and equipment, net 8,346 19,071
Intangible assets, net 569,311 669,603
Total assets 667,415 716,608
Current liabilities:    
Line of credit, related party 1,715,646 1,002,428
Related party payables 1,920,332 1,385,901
Compensation payable 748,160 727,509
Severance liability 620,613 620,613
Accounts payable and accrued expenses 3,152,583 4,420,585
Convertible notes payable 323,749 323,749
Notes payable, current portion 382,238 369,413
Notes payable, related party 6,743 56,743
Capital leases payable, current portion 13,222 13,221
Total current liabilities 8,883,286 8,920,162
Notes payable, noncurrent 328,133 0
Total liabilities 9,211,419 8,920,162
Commitments and contingencies (See Note 9)  
Stockholders' deficit:    
Preferred stock - $0.001 per value, 5,000,000 shares authorized, 0 issued and outstanding.
Common stock, $0.001 par value, 1,250,000,000 shares authorized, 250,060,616 and 211,851,177 shares issued and outstanding as of September 30, 2016 and December 31, 2015, respectively 1,099,569 1,059,050
Additional paid-in capital 58,938,322 57,687,270
Accumulated deficit (68,581,895) (66,949,874)
Total stockholders' deficit (8,544,004) (8,203,554)
Total liabilities and stockholders' deficit $ 667,415 $ 716,608
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2
Consolidated Balance Sheets (Parenthetical) - USD ($)
Sep. 30, 2016
Dec. 31, 2015
Current assets:    
Allowances $ 215,483 $ 215,483
Stockholders' deficit:    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 1,250,000,000 1,250,000,000
Common stock, shares issued 250,060,616 211,851,177
Common stock, shares outstanding 250,060,616 211,851,177
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
Consolidated Statements of Operations - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Income Statement [Abstract]        
Revenues $ 26,340 $ 77,664 $ 53,595 $ 138,716
Cost of revenues 49,733 45,298 167,941 179,554
Gross profit (loss) (23,393) 32,366 (114,346) (40,838)
General and administrative expenses 297,500 383,147 1,288,472 1,331,644
Sales and marketing expenses 87,575 102,504 228,136 420,199
Loss from operations (408,468) (453,285) (1,630,954) (1,792,681)
Other income 27,799 8,914 191,900 60,750
Interest and other finance charges, net (70,857) (44,629) (192,967) (191,355)
Net loss $ (451,526) $ (489,000) $ (1,632,021) $ (1,923,286)
Net loss per share:        
Basic and diluted $ (0.00) $ 0.00 $ (0.01) $ (0.01)
Weighted average common shares outstanding:        
Basic 250,587,899 178,674,759 232,635,531 166,083,438
Diluted 250,587,899 178,674,759 232,635,531 166,083,438
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Operating activities:    
Net loss $ (1,632,021) $ (1,923,286)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 111,017 217,208
Gain on write-off of liabilities (187,871) 0
Warrants issued for services 137,528 11,170
Stock-based compensation 16,188 16,759
Common stock issued for services 0 38,199
Amortization of loan discount 0 55,780
Subtotal - non-cash adjustments 76,862 339,116
Effect of changes in:    
Accounts receivable 16,190 (49,110)
Prepaid expenses and other current assets 88,782 114,744
Accounts payable and accrued expenses 422,057 258,667
Related party payables 534,432 519,315
Compensation payable 20,651 102,925
Deferred revenue 0 (11,050)
Subtotal - net change in operating assets and liabilities 1,082,112 935,491
Net cash used in operating activities (473,047) (648,679)
Investing activities:    
Purchase of property and equipment 0 (1,252)
Payments for note receivable (5,452) 0
Net cash used in investing activities (5,452) (1,252)
Financing activities:    
Book overdraft (34,483) 56,163
Proceeds from shares issued for financing activities 0 29,774
Proceeds from note payable 0 30,000
Payments of note payable 0 (30,000)
Proceeds on line of credit 512,982 254,601
Net cash provided by financing activities 478,499 340,538
Net increase (decrease) in cash 0 (309,393)
Cash, beginning of period 0 309,393
Cash, end of period 0 0
Supplemental disclosures of cash flow information:    
Cash paid for interest 0 93,268
Cash paid for income taxes 0 1,675
Supplemental disclosure of non-cash investing and financing activities:    
Conversion of convertible notes into common stock 0 100,800
Shares issued for reduction of payables 387,855 299,420
Warrants exercised through reduction of payables 750,000 0
Conversion of accounts payable to note payable $ 328,133 $ 0
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
NATURE OF OPERATIONS AND BASIS OF PRESENTATION - Note 1
 9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
NATURE OF OPERATIONS AND BASIS OF PRESENTATION - Note 1

NOTE 1 - NATURE OF OPERATIONS AND BASIS OF PRESENTATION

MMRGlobal Inc. (referred to herein, unless otherwise indicated, as "MMR," the "Company," the "issuer," "we," "us," and "our") was originally incorporated as Favrille, Inc. ("Favrille") in Delaware in 2000, and since its inception and before the Merger (as defined below), operated as a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. In May 2008, Favrille's ongoing Phase 3 registration trial for the FavId vaccine failed to show a statistically significant improvement in the treatment of patients with follicular B-cell Non-Hodgkin's lymphoma. On January 27, 2009, the Company, through MyMedicalRecords, Inc. ("MMR Inc."), what is now our wholly-owned operating subsidiary, conducted a reverse merger with Favrille.

Through our wholly-owned operating subsidiary MMR Inc., the Company's primary business is to license and provide secure and easy-to-use online Personal Health Records ("PHR") and MyEsafeDepositBox storage solutions, including a professional offering to physicians' offices and similar organizations known as MMRPro. Starting in 2005, we began filing for patent protection for our PHR products and services, and we now have patents issued, pending, and applied for in numerous countries around the world. As a result, we have evolved from an operating business selling products to also licensing health information technology patents and other intellectual property. In January 2009, as a result of the Merger, we acquired biotech assets and other intellectual property including anti-CD20 antibodies as well as data and samples from the FavId/Specifid vaccine clinical trials for the treatment of B-cell Non-Hodgkin's lymphoma which the Company continues to work towards maximizing the value of those biotech assets including related biotech patents, anti-CD 20 antibodies, and FavId vaccine technologies acquired by MyMedicalRecords, Inc. through the merger with Favrille. We (formerly Favrille) were incorporated in Delaware in 2000, MMR Inc. was incorporated in Delaware in 2005, and both are headquartered in Los Angeles, CA.

Principles of Consolidation

The consolidated financial statements include the accounts of MMRGlobal, and its wholly-owned subsidiaries MMR and MMR Life Sciences Group, Inc. All intercompany transactions and balances are eliminated upon consolidation.

Basis of Presentation

We have prepared the accompanying consolidated unaudited financial statements in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial statements and with instructions to Form 10-Q pursuant to the rules and regulations of Securities and Exchange Act of 1934, as amended, or the Exchange Act and Article 8-03 of Regulation S-X promulgated under the Exchange Act. Accordingly, these financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of our management, we have included all adjustments considered necessary (consisting of normal recurring adjustments) for a fair presentation. Operating results for the three and nine months ended September 30, 2016 are not indicative of the results that may be expected for the fiscal year ending December 31, 2016. You should read these unaudited condensed consolidated financial statements in conjunction with the audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2015.

Going Concern and Management's Plan

As of September 30, 2016, our current liabilities exceeded our current assets by $8.8 million. Furthermore, during the nine months ended September 30, 2016, we incurred losses of $1,632,021, as further explained in Management's Discussion and Analysis of Financial Condition and Results of Operations appearing in Item 2 of Part I of this Quarterly Report on Form 10-Q.

At September 30, 2016 and December 31, 2015, we had $0 and $0, respectively, in cash and cash equivalents. Historically, we issued capital stock, sold debt and equity securities and received funds from The RHL Group, Inc. (a significant stockholder that is wholly-owned by our Chairman and Chief Executive Officer, Robert H. Lorsch) to operate our business. Although we received additional funding from The RHL Group pursuant to the Eleventh Amended and Restated Note effective June 6, 2016 (the "Line of Credit"), we will still be required to obtain additional financing in order to meet installment payment obligations and the previously existing obligations under the Line of Credit, which had a balance of $2,953,548 at September 30, 2016 and a total Unpaid Balance (as defined in the Line of Credit) of $3,203,548, which includes amounts borrowed under the Line of Credit, unpaid interest fees, any amounts guaranteed by The RHL Group, and other obligations due The RHL Group pursuant to the terms of the Eleventh Amended and Restated Note and the Security Agreement. As a result of the above, we express uncertainty about our ability to continue as a going concern. The components of the RHL Group Note payable and the related balance sheet presentation as of September 30, 2016 are as follows: $1,715,646, which is included in the Line of Credit, related party; and $1,237,902 related to other obligations due to The RHL Group which are included in related party payables.

Management's plan regarding this matter is to, amongst other things, continue to utilize our available Line of Credit with The RHL Group (see Note 3). As of September 30, 2016, under the original terms, we had approximately $1,296,452 remaining as available under The RHL Group Line of Credit, but we are now in default under the line of credit. Additionally, we plan to continue selling additional debt and equity securities, continue to settle our existing liabilities through issuance of equity securities, explore other debt financing arrangements, continue to increase our existing subscriber and affiliate customer base, sell MMRPro products, and continue efforts to license our intellectual property to obtain additional cash flow over the next twelve months. We cannot assure that funds from these sources will be available when needed or, if available, will be on terms favorable to us or to our stockholders. If we raise additional funds or settle liabilities by issuing equity securities, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution or such equity securities may provide for rights, preferences or privileges senior to those of the holders of our common stock. If we are unable to utilize our available Line of Credit with The RHL Group or obtain suitable alternative debt or equity financing, our ability to execute our business plan and continue as a going concern may be adversely affected.

These matters raise substantial doubt about our ability to continue as a going concern. These financial statements were prepared under the assumption that we will continue as a going concern and do not include any adjustments that might result from the outcome of that uncertainty.

 

 
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Note 2
 9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Note 2

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a) MANAGEMENT'S USE OF ESTIMATES

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net revenue and expenses during each reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowances for doubtful accounts, the valuation of deferred income taxes, tax contingencies, long-lived and intangible assets, valuation of derivative liabilities and stock-based compensation. These estimates are based on historical experience and on various other factors that management believes to be reasonable under the circumstances, although actual results could differ from those estimates.

(b) CASH AND CASH EQUIVALENTS

We consider cash equivalents to be only those investments that are highly liquid, readily convertible to cash and with maturities of 90 days or less at the purchase date. We maintain our cash in bank deposit accounts that, at times, may exceed federally insured limits. We have not experienced any losses in such accounts and believe that we are not exposed to any significant credit or deposit risk on our cash. We had cash and cash equivalents of $0 and $0 as of September 30, 2016 and December 31, 2015, respectively.

(c) TRADE AND OTHER RECEIVABLES

Receivables represent claims against third parties that will be settled in cash. The carrying value of receivables, net of an allowance for doubtful accounts, if any, represents their estimated net realizable value. We estimate the allowance for doubtful accounts, if any, based on historical collection trends, type of customer, the age of outstanding receivables and existing economic conditions. If events or changes in circumstances indicate that specific receivable balances may be impaired, we give further consideration to the collectability of those balances and the allowance is adjusted accordingly. We write off past due receivable balances when collection efforts have been unsuccessful in collecting the amount due.

(d) FAIR VALUE OF FINANCIAL INSTRUMENTS

ASC 820-10, Fair Value Measurements and Disclosures, requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of September 30, 2016 and December 31, 2015, the carrying value of accounts receivable, deposits, related party payables, compensation payable, severance liabilities, and accounts payable and accrued expenses approximates fair value due to the short-term nature of such instruments. The carrying value of short-term debt approximates fair value as the related interest rates approximate rates currently available to us.

We utilize ASC 820-10 for valuing financial assets and liabilities measured on a recurring basis. ASC 820-10 defines fair value, establishes a framework for measuring fair value and generally accepted accounting principles, and expands disclosures about fair value measurements. This standard applies in situations where other accounting pronouncements either permit or require fair value measurements. ASC 820-10 does not require any new fair value measurements.

Accounting guidance also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

The standard describes three levels of inputs that may be used to measure fair value:

  Level 1: Quoted prices in active markets for identical or similar assets and liabilities.
  Level 2: Quoted prices for identical or similar assets and liabilities in markets that are not active or observable inputs other than quoted prices in active markets for identical or similar assets and liabilities.
  Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

(e) IMPAIRMENT OF LONG-LIVED ASSETS AND INTANGIBLES

We account for long-lived assets, which include property and equipment and identifiable intangible assets with finite useful lives (subject to amortization), in accordance with ASC 350-30. ASC 350-30 requires that we review long-lived assets for impairment whenever events or changes in circumstances indicate that we may not recover the carrying amount of an asset. We measure recoverability by comparing the carrying amount of an asset to the expected future undiscounted net cash flows generated by the asset. If we determine that the asset may not be recoverable, or if the carrying amount of an asset exceeds its estimated future undiscounted cash flows, we recognize an impairment charge to the extent of the difference between the fair value and the asset's carrying amount. Our assessment of the undiscounted future cash flows indicated that the carrying amount of the long-lived and intangible assets are recoverable, therefore, we had no impairment charges during the nine months ended September 30, 2016 and 2015.

(f) REVENUE RECOGNITION

We generate our revenues from services, which are comprised of providing electronic access to consumer medical records and other vital documents, and from the licensing of our intellectual property and services. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and we are reasonably assured of collectability of the resulting receivable.

Our subscriber revenues consist of annual and monthly recurring retail subscriptions and usage-based fees, which are primarily paid in advance by credit card, and corporate accounts that are based on either an access-fee or actual number of users, and in each case billed in advance at the beginning of each month of service. We defer the portions of annual recurring subscription fees collected in advance and recognize them on a straight line basis over the subscription period. As part of our ongoing sales and marketing activities, we also offer sell a Personal Health Record Kit through retailers to the extent reasonably possible.

We license the rights to use portions of our intellectual property portfolio, which includes certain patent rights essential to the sale of certain PHR products. Licensees typically pay a license fee in one or more installments and ongoing royalties based on their sales of products incorporating or using the Company's licensed intellectual property. License fees are recognized over the estimated period of benefit to the licensee, typically five to fifteen years. The Company earns royalties on such licensed products sold by its licensees at the time that the licensees' sales occur. The Company recognizes royalty revenues based on royalties reported by licensees during the quarter and when other revenue recognition criteria are met.

We grant exclusive and non-exclusive licenses for the sale and marketing of our services in international territories in consideration of license fees and ongoing royalties. The royalty fee is usually a percentage of revenue earned by the licensee and there are usually certain minimum guarantees. We defer the recognition of license fee revenues received in advance from international licensees for the grant of the license and recognize them over the period covered by the agreement. We defer the recognition of minimum guaranteed royalty payments received in advance and recognize them over the period to which the royalty relates. We include all such revenues under "License Fees." In those cases where a license agreement contains multiple deliverables, we account for the agreement in accordance with ASC 605-25 - Revenue Recognition - Multiple-Element Arrangements.

We recognize revenue on sales of our MMRPro system in accordance with ASC 605-25, Revenue Recognition, Multiple-Element Arrangements.

Our multiple-deliverable arrangements consist solely of our MMRPro product. Deliverables within these arrangements include scanning equipment, various licenses to use third party software, a license to use our proprietary MMRPro application software, installation and training, dedicated telephone lines, secure online storage and warranties.

We determined all elements to be separate units of accounting as they have standalone value to the customers and/or they are sold by other vendors on a standalone basis. Delivery of the hardware and certain software elements of these arrangements occur at the inception of the agreement. We deliver installation and training at the inception of the agreement. We also provide software licenses, telephone lines and online secure storage over the three-year term of an MMRPro agreement. We include warranties in the arrangements, however the third party product manufacturer, and not us, is obligated to fulfill such warranties. The third-party warranty contracts are paid in advance and are not refundable.

We allocate the revenue derived from these arrangements among all the deliverables. We base such allocation on the relative selling price of each deliverable. With the exception of our proprietary MMRPro application software, we use third party evidence to set the selling prices used for this allocation. In all such cases, third parties sell the same or very similar products. For the MMRPro application software, we estimate the selling price based on recent discussions regarding licensure of that particular application on a standalone basis. To date, we have not licensed this software on a standalone basis.

We recognize the allocated revenue for each deliverable in accordance with SEC Staff Accounting Bulletin ("SAB") No. 104, Topic 13: Revenue Recognition. Under this guidance, we recognize revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed and determinable and collectability is reasonably assured. This results in us recognizing revenue for the hardware, certain software and the warranties upon delivery to the customer, for the installation and training upon completion of these services, and ratably over the contract period for the software licenses, telephone lines and online secure storage.

Revenue from the licensing of our biotech assets may include non-refundable license and up-front fees, non- refundable milestone payments that are triggered upon achievement of a specific event, and future royalties or lump-sum payments on sales of related products. For agreements that provide for milestone payments, we adopted ASC 605-28-25, Revenue Recognition Milestone Method.

(g) SHARE-BASED COMPENSATION

We account for share-based compensation in accordance with ASC 718-20, Awards Classified as Equity. We apply ASC 718- 20 in accounting for stock-based awards issued to employees under the recognition of compensation expense related to the fair value of employee share-based awards, including stock options and restricted stock. Determining the fair value of options at the grant date requires judgment, including estimating the expected term that stock options will be outstanding prior to exercise, the associated volatility and the expected dividends. Judgment is required in estimating the amount of share-based awards expected to be forfeited prior to vesting. If actual forfeitures differ significantly from these estimates, share- based compensation expense could be materially impacted.

We account for options and warrants issued to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. We treat options and warrants issued to non-employees the same as those issued to employees with the exception of determination of the measurement date. The measurement date is the earlier of (1) the date at which a commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty's performance is complete. Options and warrants granted to consultants are valued at their respective measurement dates, and recognized as an expense based on the portion of the total consulting services provided during the applicable period. As further consulting services are provided in future periods, we will revalue the associated options and warrants and recognize additional expense based on their then current values.

We estimate the fair value of each stock option on the date of grant using the Black-Scholes option pricing model. We determine assumptions relative to volatility and anticipated forfeitures at the time of grant. No stock options were granted during the nine months ended September 30, 2016. We valued grants of stock options and warrants during the nine months ended September 30, 2016 using the following assumptions.

Expected life in years   2 - 5 Years
Stock price volatility   79%
Risk free interest rate   0.04 - 1.38%
Expected dividends   None
Forfeiture rate   0%

 

We base the assumptions used in the Black-Scholes models upon the following data: (1) our use of the contractual life of the underlying non-employee warrants as the expected life; the expected life of the employee options used in this calculation is the period of time the options are expected to be outstanding and has been determined based on historical exercise experience; (2) in the absence of an extensive public market for our shares, the expected stock price volatility of the underlying shares over the expected term of the option or warrant was taken at approximately the mid-point of the range for similar companies at the various grant dates; (3) we base the risk free interest rate on published U.S. Treasury Department interest rates for the expected terms of the underlying options or warrants; (4) we base expected dividends on historical dividend data and expected future dividend activity; and (5) we base the expected forfeiture rate on historical forfeiture activity and assumptions regarding future forfeitures based on the composition of current grantees.

(h) NET INCOME/LOSS PER SHARE

We apply the guidance of ASC 260-10, Earnings Per Share for calculating the basic and diluted loss per share. We calculate basic loss per share by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding. We compute diluted loss per share similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential shares had been issued and if the additional shares were dilutive. We exclude common equivalent shares from the computation of net loss per share if their effect is anti-dilutive.

We excluded all potential anti-dilutive common shares from the computation of diluted net loss per common share for the nine months ended September 30, 2016 and 2015 because they were anti-dilutive due to our net loss position. Stock options, warrants and convertible notes excluded from the computation totaled 43,208,730 shares for the nine months ended September 30, 2016 and 33,251,116 shares for the nine months ended September 30, 2015, respectively.

(i) RECENT ACCOUNTING PRONOUNCEMENTS

In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. This new guidance is effective for annual and interim periods beginning after December 15, 2017, with no early adoption permitted. The standard permits the use of either the retrospective or cumulative effect transition method. At this time we have not selected a transition method. We are currently evaluating the effect that ASU 2014-09 will have on our consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

In August 2014, the FABS issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern ("ASU 2014-15"). ASU 2014-15 will explicitly require management to assess an entity's ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. These changes became effective for the Company for the 2016 annual period. The adoption of these changes did not have an impact on the consolidated financial statements.

In February 2015, the FASB issued ASU 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis. This standard modifies existing consolidation guidance for reporting organizations that are required to evaluate whether they should consolidate certain legal entities. ASU 2015-02 is effective for fiscal years and interim periods within those years beginning after December 15, 2015, and requires either a retrospective or a modified retrospective approach to adoption. Early adoption is permitted. The adoption of this standard did not have an impact on the Company's Consolidated Financial Statements.

In April 2015, the FASB issued ASU No 2015-3, Simplifying the Presentation of Debt Issuance Costs. This update changes the presentation of debt issuance costs in the balance sheet. ASU 2015-03 requires debt issuance costs related to a recognized debt obligation to be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability rather than being presented as an asset. Amortization of debt issuance costs will continue to be reported as interest expense. In August 2015, the FASB issued ASU 2015-15, "Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements". This ASU clarified guidance in ASC 2015-03 stating that the SEC staff would not object to a company presenting debt issuance costs related to a line-of-credit arrangement on the balance sheet as a deferred asset, regardless of whether there were any outstanding borrowings at period-end. This update is effective for annual and interim periods beginning after December 15, 2015, which required us to adopt these provisions starting the first quarter of 2016. This guidance did not have a material impact to our financial position or results of operations.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes existing guidance on accounting for leases in "Leases (Topic 840)" and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting. This ASU affects entities that issue share-based payment awards to their employees. The ASU is designed to simplify several aspects of accounting for share-based payment award transactions which include - the income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows and forfeiture rate calculations. ASU 2016-09 will become effective for the Company in the first quarter of fiscal 2018. Early adoption is permitted in any interim or annual period. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.

In April 2016, the FASB issued AS 2016-10, Revenue from Contracts with Customers (Topic 606), which amends certain aspects of the Board's new revenue standard, ASU 2014-09, Revenue from Contracts with Customers. The standard should be adopted concurrently with adoption of ASU 2014-09 which is effective for annual and interim periods beginning after December 15, 2017. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

(j) RECLASSIFICATIONS

Certain numbers in the prior year have been reclassified to conform to the current year's presentation.

 

 

 
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2
RELATED PARTY PAYABLES, LINE OF CREDIT AND NOTE PAYABLE - Note 3
 9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
RELATED PARTY PAYABLES, LINE OF CREDIT AND NOTE PAYABLE - Note 3

NOTE 3 - RELATED PARTY PAYABLES, LINE OF CREDIT AND NOTE PAYABLE

On June 6, 2016, we and The RHL Group entered into an Eleventh Amended and Restated Promissory Note (the "Amended Note"), effective as of June 6, 2016. The Eleventh Note amends and restates that certain Tenth Amended Note entered into between the foregoing parties, effective May 20, 2015 (the " Existing Note") and together with its predecessor notes and the Amended Note, the ("Credit Facility"), by: (i) extending the maturity date to June 6, 2017. In connection with the Eleventh Amended Note, we issued The RHL Group warrants to purchase 2,777,714 shares of our common stock at $0.011 per share on June 6, 2016. Other than for the amounts as disclosed herein, The Eleventh Amended Note does not materially alter the terms of the previous Tenth Amended Note.

Historically, the predecessor notes have increased over time the maximum amount of credit available under the Credit Facility from $100,000 to $1,000,000 to $3,000,000 to $4,500,000. The maximum amount of the Amended Note is $4,500,000. The Amended Note continues to bear interest at the lesser of 10% or the highest rate then permitted by law, and is secured (similar to the Existing Note) by a Security Agreement, which has been in effect since July 31, 2007, as renewed and amended to date (the "Security Agreement").

The Eleventh Amended Note had a current balance of $2,953,548 at September 30, 2016. The components of the Eleventh Amended Note and the related balance sheet presentation as of September 30, 2016 are as follows: $1,715,646, which is included in the Line of Credit, related party; and $1,237,902 for other obligations due to The RHL Group, which is included in related party payables.

Total interest expense on the Line of Credit for the three months ended September 30, 2016 and 2015 amounted to $70,925 and $36,699, respectively. Total interest expense on the Line of Credit for the nine months ended September 30, 2016 and 2015 amounted to $200,237 and $102,433, respectively. The unpaid interest balances as of September 30, 2016 and December 31, 2015 were $321,737 and $60,257, respectively.

In conjunction with the Eleventh Amended Note, we were required to maintain certain financial covenants, including the requirement that we have at least $200,000 of cash in our bank accounts or such other amount as necessary to maintain operations through the subsequent thirty (30) days and timely pay any obligations due respecting payroll and all associated payroll taxes at any time during the term of the Note. As of November 21st, the Company was not in compliance with certain of the financial covenants and The RHL Group has not waived any of the covenants.

 

 
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2
INCOME TAXES - Note 4
 9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
INCOME TAXES - Note 4

NOTE 4 - INCOME TAXES

Under ASC 740-270, Income Taxes - Interim Reporting, we are required to adjust our effective tax rate each quarter to be consistent with the estimated annual effective tax rate. We are also required to record the tax impact of certain discrete items, unusual or infrequently occurring, including changes in judgment about valuation allowances and effects of changes in tax laws or rates, in the interim period in which they occur. In addition, we exclude jurisdictions with a projected loss for the year or a year-to-date loss where we cannot recognize a tax benefit from our estimated annual effective tax rate. The impact of such an exclusion could result in a higher or lower effective tax rate during a particular quarter, based upon the mix and timing of actual earnings versus annual projections.

Pursuant to ASC 740, Income Taxes, we performed an analysis of previous tax filings and determined that there were no positions taken that it considered uncertain. Therefore, there were no unrecognized tax benefits as of September 30, 2016.

MMR Inc., in its capacity as the operating company taking over our income tax positions in addition to its own positions after January 27, 2009 (see Note 1), has estimated its annual effective tax rate to be zero. MMRGlobal has based this on an expectation that the combined entity will generate net operating losses in 2016, and it is not likely that those losses will be recovered using future taxable income. Therefore, no provision for income tax has been recorded as of and for the nine months ended September 30, 2016.

We account for income taxes in accordance with ASC 740-10, Income Taxes. We recognize deferred tax assets and liabilities to reflect the estimated future tax effects, calculated at the tax rate expected to be in effect at the time of realization. We record a valuation allowance related to a deferred tax asset when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.

 

 

 

 

 
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
COMMITMENTS AND CONTINGENCIES - Note 5
 9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
COMMITMENTS AND CONTINGENCIES - Note 5

NOTE 5 - COMMITMENTS AND CONTINGENCIES

Leases

Effective September 1, 2013, we renewed our lease for office space in Los Angeles, California with a term through August 31, 2018. The lease currently requires a monthly payment of $8,250. Total rent expense for the nine months ended September 30, 2016 and 2015 were $79,335 and $86,854 respectively. Future minimum lease payments as of September 30, 2016, under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:

Year Ending     Operating     Capital
December 31,     Leases     Leases
             
     2016 (Remainder of)    $ 24,750    $ 13,222 
     2017      99,900      -  
     2018      66,000      -  
Total minimum lease payments    $ 189,750    $ 13,222 

 

 

 

 
Legal Matters and Contingencies - Note 5

Litigation Matters

From time to time, we are involved in various legal proceedings generally incidental to our business. While the result of any litigation contains an element of uncertainty, our management presently believes that the outcome of any known, pending or threatened legal proceeding or claim, individually or combined, will not have a material adverse effect on our financial statements.

On December 9, 2011, MyMedicalRecords, Inc. entered into a Non-Exclusive Settlement and Patent License Agreement with Surgery Center Management LLC ("SCM"). In consideration for the rights granted under that Agreement and in consideration of a settlement and release agreement, SCM contracted to pay MyMedicalRecords, Inc. an initial payment of $5 million payable on December 23, 2011, and additional payments of $5 million per year for five consecutive years. After unsuccessful attempts to collect the past due amount of $5 million, on January 19, 2012, MyMedicalRecords, Inc. filed a lawsuit in the Superior Court of the State of California for the County of Los Angeles for breach of contract. On February 13, 2014, SCM filed a cross-complaint alleging claims for breach of that contract, among other things, which SCM has amended twice. On September 29, 2016, the court granted a motion for summary judgment filed by Robert Lorsch, a cross-defendant. The case between MyMedicalRecords, Inc. and SCM began trial on November 1, 2016.  MyMedicalRecords, Inc. will continue to pursue its claim and defenses, but the Company cannot predict the chances of either a favorable or unfavorable outcome, nor does the Company have sufficient information regarding its ability to collect any judgment MyMedicalRecords, Inc. may obtain against SCM.

On April 2, 2015, the Company and Stradling Yocca Carlson & Rauth, P.C. ("SYCR"), were notified of the determination of an arbitrator in regards to disputes over amounts of monies due SYCR regarding prior services rendered. SYCR and the Company had previously agreed to a non-binding arbitration of the matter. The Company received an award in favor of SYCR in the amount of $285,000 which the Company disputed, notwithstanding, that it represented a reduction of SYCR's original $571,000 claim or $286,000 in favor of the Company. On September 1, 2016, the Company settled with SYCR through the signing of an eighteen-month unsecured Promissory Note in the amount of $328,133.

Two separate MyMedicalRecords health IT patents were accepted by the Australia Patent Office in 2015 and subject to Opposition. On January 8, 2015, Australia Patent Application No. 2011307287, "Universal Patient Record Conversion Tool," was accepted by the Australia Patent Office. An opposition was filed on April 21, 2015 by The Crown in the Right of the Commonwealth of Australia (Department of Health). A second opposition was filed on April 22, 2015 by the Medical Software Industry Association, Inc. which aligned itself with the Crown.  In the interim, a divisional application, Australia Patent Application No.2015201900, was filed on October 15, 2015.  Rather than continue to bear the legal costs of defending these patents before the Governmental Department of Health, MMR determined it was in the Company's best interest to withdraw the patent and the divisional application and this action was officially acknowledged by the Australian Government on August 4, 2016, thereby ending any further opposition.  Separately, Australia Patent Application No. 2013212253, "Mobile Platform for Personal Health Records," was also accepted by the Australia Patent Office after which oppositions were filed.  Subsequently, the Company filed a request this quarter for withdrawal of the disputed application and also surrender of a related innovation patent No. 2015101556.  The Australian Government acknowledged these actions on September 13, 2016 and we do not expect any further potential litigation in this matter. MMR continues to maintain two previously issued Australia health IT patents under the title "Method and System for Providing Online Medical Records": Patent No. 2006202057 issued on May 29, 2008 and Patent No. 2008202401 issued on December 24, 2009.

 

 

 

 
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCKHOLDERS' DEFICIT - Note 6
 9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
STOCKHOLDERS' DEFICIT - Note 6

NOTE 6 - STOCKHOLDERS' DEFICIT

Preferred Stock

We have 5,000,000 shares of preferred stock authorized. As of September 30, 2016 and December 31, 2015, there were no shares of preferred stock issued and outstanding.

Common Stock

As of September 30, 2016, we are authorized to issue 1,250,000,000 shares of common stock.

On February 2, 2016, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the "Certificate of Amendment") with the Secretary of State of the State of Delaware effecting a five for one reverse stock split of the Company's common stock (the "Reverse Stock Split") which became effective in the marketplace on February 8, 2016. The number of shares and per share amounts have been retroactively restated to reflect this reverse stock split.

As of September 30, 2016, the total shares of our common stock issued and outstanding amounted to 252,370,616.

 

 

 

 

 
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2
EQUITY ISSUANCES - Note 7
 9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
EQUITY ISSUANCES - Note 7

NOTE 7 - EQUITY ISSUANCES

Stock Option Activity

Our 2001 Equity Incentive Plan (the "2001 Plan") expired on June 5, 2011 and no options were issued under the 2001 Plan since that date. As of September 30, 2016, 2,626,911 shares remain issued under the 2001 Plan.

On September 1, 2011, our Board of Directors approved the adoption of a new plan to replace the 2001 Plan under the same general terms as the 2001 Plan. On June 20, 2012, our stockholders voted and approved the 2011 Equity Incentive Plan (the " 2011 Plan") at our 2012 Annual Stockholder Meeting. As of September 30, 2016, 2.65 million shares remain issued under the 2011 Plan, and 7.29 million shares of our common stock are reserved for future issuance under our 2011 Plan, which includes an automatic 1 million share annual increase pursuant to the terms of the 2011 Plan and a 5 million share increase authorized during our 2013 Annual Stockholder's Meeting.

A summary of option activity for the nine months ended September 30, 2016 is presented below. Options granted by MMR Inc. prior to the date of the Merger have been retroactively restated to reflect the conversion ratio of MMR Inc. to MMR shares

              Weighted-Average      
          Weighted-   Remaining      
          Average   Contractual     Aggregate
          Exercise   Life     Intrinsic
    Options     Price   (Years)     Value
Outstanding at December 31, 2015   7,488,345    $ 0.50    3.62    $ -  
Granted   -       -            
Exercised   -       -            
Cancelled   (2,208,052)     0.65           
Outstanding at September 30, 2016 (Unaudited)   5,280,293    $ 0.45    4.15    $ -  
                     
Vested and expected to vest                    
     at September 30, 2016 (Unaudited)   5,280,293    $ 0.45    4.15    $ -  
                     
Exercisable at September 30, 2016 (Unaudited)   5,280,293    $ 0.45    4.15    $ -  

 

The aggregate intrinsic value in the table above is before applicable income taxes and is calculated based on the difference between the exercise price of the options and the quoted price of the common stock as of the reporting date.

There were no options issued during the nine months ended September 30, 2016.

Total stock option expenses recorded during the nine months ended September 30, 2016 and 2015 were $16,188 and $16,759, respectively, and is reflected in operating expenses in the accompanying consolidated statements of operations.

The following table summarizes information about stock options outstanding and exercisable at September 30, 2016.

      Options Outstanding   Options Exercisable
            Weighted     Weighted       Weighted     Weighted
            Average     Average       Average     Average
  Exercise   Number     Remaining     Exercise   Number   Remaining     Exercise
  Price   of Shares     Life (Years)     Price   of Shares   Life (Years)     Price
                                 
$ 0.25 - 0.45   2,560,000      5.11   $ 0.35    2,560,000    5.11   $ 0.35 
$ 0.50 - 0.75   2,520,293      3.21   $ 0.55    2,520,293    3.21   $ 0.55 
$ > 0.75   200,000      3.71   $ 0.90    200,000    3.71   $ 0.90 
      5,280,293                5,280,293           

 

Warrants

During the nine months ended September 30, 2016, there were 40,227,714 warrants issued. During the nine months ended September 30, 2016, 11,750,000 warrants were exercised, which was paid by the reduction of our accounts payable balance owed to the vendor/warrant holder in the aggregate amount of $750,000.

A summary of the activity of our warrants for the nine months ended September 30, 2016 is presented below:

        Weighted Avg
  Shares     Exercise Price
Outstanding at December 31, 2015 11,428,610    $ 0.30 
Granted 40,227,714      0.02 
Exercised (11,750,000)     0.06 
Cancelled (3,333,818)     0.49 
Outstanding at September 30, 2016 (Unaudited) 36,572,506    $ 0.06 
         
Exercisable at September 30, 2016 (Unaudited) 34,539,173    $ 0.06 

 

Total warrant expenses recorded during the nine months ended September 30, 2016 and 2015 were $137,528 and $11,170, respectively.

The following summarizes the total warrants outstanding and exercisable as of September 30, 2016:

    Warrants Outstanding   Warrants Exercisable
    Warrants   Weighted Avg     Weighted Avg   Warrants   Weighted Avg     Weighted Avg
Ranges   Outstanding   Remaining Life     Exercise Price   Exercisable   Remaining Life     Exercise Price
                             
$0.02 - $0.30   35,794,569   2.61   $ 0.05   33,761,236   2.59   $ 0.05
$0.30 - $0.50   255,000   0.53     0.50   255,000   0.53     0.50
Greater $0.50   522,937   0.58     1.05   522,937   0.58     1.05
                             
    36,572,506             34,539,173          

 

The inputs used for the Black-Scholes option and warrant valuation model were as follows:

Expected life in years   2 - 5 Years
Stock price volatility   79%
Risk free interest rate   0.04 - 1.38%
Expected dividends   None
Forfeiture rate   0%

 

Shares Issued for Services or Reduction to Liabilities

During the nine months ended September 30, 2016, we issued 28,769,439 shares of common stock with a value of $387,855 to various third parties and charged the proceeds to the appropriate accounts for the following reasons:

    Nine Months Ended September 30, 2016
           
Purpose   Shares     Value
           
Services provided   -     $ -  
Reduction of payables   28,769,439      387,855 
Totals    28,769,439    $ 387,855 

 

The 28,769,439 issued shares were not contractually restricted. However, as these shares have not been registered under the Securities Act of 1933, as amended (the "Act"), they are restricted from sale until they are registered under the Act, or qualify for resale under the rules promulgated under the Act. All such shares were calculated at the trading closing price on the date of issuance.

Stock Bonus Agreements

From time to time, we issue shares of our common stock as a bonus for services rendered. Stock bonuses may be awarded upon satisfaction of specified performance goals pursuant to the Performance Stock Bonus Agreement.

On each grant date, we valued the stock bonus based on the share price and the expenses were amortized using the straight line method. Total stock bonus expenses recorded during the nine months ended September 30, 2016 and 2015 were $0 and $0, respectively and are reflected in operating expenses in the accompanying consolidated statements of operations.

 

 

 

 
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTES PAYABLE - Note 8
 9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
NOTES PAYABLE - Note 8

NOTE 8 - NOTES PAYABLE

Notes payable consisted of the following:

      September 30,     December 31,
      2016     2015
             
Promissory notes payable due to the former officers of MMRGlobal as part of severance
packages, due in full on August 31, 2009 with no stated interest		   $ 76,783    $ 76,783 
             
Promissory notes payable due to the former officers of MMRGlobal pursuant to the
Resignation and Post-Merger Employment Arrangement, due in full on August 31, 2009
with no stated interest		     25,444      25,444 
             
Promissory notes payable due to vendors relating to settlement of certain outstanding
accounts payable, payable in 18 equal monthly installments commencing on July 27, 2009
and ending on January 27, 2011, with no stated interest		     223,116      223,116 
             
Short-term loan due to a third-party with 6% interest     56,896      44,070 
             
Long term note payable relating to legal accounts payable, payable in full on March 30, 2018 with 10% interest per annum     328,133      - 
             
      710,372      369,413 
Less: current portion     (382,239)     (369,413)
Notes payable, less current portion   $ 328,133    $ - 
             
Short term loan due to a related-party, payable in full on January 2, 2014 with 12% interest    $ 6,743    $ 6,743 
             
Short term loan due to a related-party, payable in full on May 31, 2014 with 12% interest      -      50,000 
             
Notes payable related party, current portion     6,743      56,743 
             
Less: current portion     (6,743)     (56,743)
Notes payable related party, less current portion   $ -    $ - 

 

 
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONVERTIBLE PROMISSORY NOTES - Note 9
 9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
CONVERTIBLE PROMISSORY NOTES - Note 9

NOTE 9 - CONVERTIBLE PROMISSORY NOTES

From time to time, we issue Convertible Promissory Notes. As of September 30, 2016, a total of $323,749 in convertible notes remained outstanding and have matured. However, the Company and the Holders have agreed to keep the balance as a Note Payable and the note holders have elected not to convert their note balances into shares of our common stock as of September 30, 2016.

Each Note contains the following general terms and provisions:

  • The principal amount owed under each note becomes due and payable one year or less from the investment date provided that, upon ten (10) days' prior written notice to the holder, we may, in our sole discretion, extend the maturity date for an additional six month term. The Notes can be further extended upon mutual agreement.
  • These notes bear interest at a rate of 0%-6% per annum payable in cash or shares of common stock or a combination of cash and shares of common stock at our option.

During the third quarter of 2016, we did not enter into any Convertible Promissory Notes.

Shares issuable upon conversion for convertible notes payable was 1,355,932 as of September 30, 2016.

The total interest expense attributed to the Beneficial Conversion Feature of the Notes and related warrants for the nine months ended September 30, 2016 and 2015 was $0 and $55,780, respectively.

 

 

 
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
RESTRUCTURING ACTIVITIES - Note 10
 9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
RESTRUCTURING ACTIVITIES - Note 10

NOTE 10 - RESTRUCTURING ACTIVITIES

In connection with the merger with Favrille, Inc. in 2009, we signed promissory notes with certain former executives totaling $76,783.

As of September 30, 2016, the total remaining severance liabilities amounted to $620,613, which is reflected as severance liability on the accompanying consolidated balance sheets. This consists of $571,362 payable to former non-executive employees.

 

 

 

 

 

 

 
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
RELATED PARTY TRANSACTIONS - Note 11
 9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
RELATED PARTY TRANSACTIONS - Note 11

NOTE 11 - RELATED PARTY TRANSACTIONS

Our Chairman and Chief Executive Officer, Robert H. Lorsch, is also the Chief Executive Officer of The RHL Group, Inc. and has full voting power over all of the capital stock of The RHL Group, Inc. Mr. Lorsch directly and indirectly through The RHL Group, Inc., beneficially owns approximately 32.1% our total outstanding voting stock. The RHL Group, Inc. has loaned us money pursuant to the Eleventh Amended Note and all predecessor notes. See Note 3 - Related Party Note Payable above.

The RHL Group is an investment holding company which provides consulting, operational and technical services to us, which we refer to as the RHL Services. As part of the RHL Services, The RHL Group provides us with unrestricted access to its internal business and relationship contact database of more than 10,000 persons and entities, which includes clients of The RHL Group and other individuals which may hold value to us. The RHL Group also provides infrastructure support to us, including allowing us unlimited access to its facilities, equipment, and data, information management and server systems. In addition to allowing us the use of its office support personnel, The RHL Group has also consented to allow us to utilize the full-time services of Mr. Lorsch as our President, Chairman and Chief Executive Officer, which requires substantial time and energy away from his required duties as The RHL Group's Chairman and Chief Executive Officer. In addition, The RHL Group has made Kira Reed, available as our spokesperson. Ms. Reed, who is Mr. Lorsch's spouse, also manages our social networking activities.

In consideration for the above, The RHL Group, Inc. has a consulting arrangement with MMR. A copy of the consulting agreement is filed as an exhibit in our Form 8-K, as filed with the SEC on May 4, 2009 and is hereby incorporated by reference.

We incurred $37,500 during the nine months ended September 30, 2016 and 2015, toward marketing consulting services from Bernard Stolar, a director. We included $260,523 and $206,272 in related party payables as of September 30, 2016 and December 31, 2015, respectively, in connection with these services and board fees.

We contract with a significant vendor for the development and maintenance of the software applications necessary to run our MyMedicalRecords PHR, MyEsafeDepositBox and MyMedicalRecords Pro products. Our outside developer supports our software development needs through a team of software engineers, programmers, quality control personnel and testers, who work with our internal product development team on all aspects of application development, design, integration and support of our products. This vendor is also a stockholder. For the nine months ended September 30, 2016 and 2015, the total expenses relating to this stockholder amounted to $90,000 and $90,000, respectively. In addition, we capitalized $0 of software development costs for the quarter ended September 30, 2016. As of September 30, 2016 and December 31, 2015, the total amounts due to the stockholder and included in related party payables amounted to $195,000 and $105,000 respectively.

 

 

 

 

 
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2016
Notes to Financial Statements  
Principles of Consolidation

Principles of Consolidation

The consolidated financial statements include the accounts of MMRGlobal, and its wholly-owned subsidiaries MMR and MMR Life Sciences Group, Inc. All intercompany transactions and balances are eliminated upon consolidation.

 

 

 

 

 

 

 

 

 

 

 

 
Basis of Presentation

Basis of Presentation

 

We have prepared the accompanying consolidated unaudited financial statements in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial statements and with instructions to Form 10-Q pursuant to the rules and regulations of Securities and Exchange Act of 1934, as amended, or the Exchange Act and Article 8-03 of Regulation S-X promulgated under the Exchange Act. Accordingly, these financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of our management, we have included all adjustments considered necessary (consisting of normal recurring adjustments) for a fair presentation. Operating results for the three and nine months ended September 30, 2016 are not indicative of the results that may be expected for the fiscal year ending December 31, 2016. You should read these unaudited condensed consolidated financial statements in conjunction with the audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2015.

 

 

 

 

 

 
Going Concern and Management's Plan

Going Concern and Management's Plan

 

As of September 30, 2016, our current liabilities exceeded our current assets by $8.8 million. Furthermore, during the nine months ended September 30, 2016, we incurred losses of $1,632,021, as further explained in Management's Discussion and Analysis of Financial Condition and Results of Operations appearing in Item 2 of Part I of this Quarterly Report on Form 10-Q.

At September 30, 2016 and December 31, 2015, we had $0 and $0, respectively, in cash and cash equivalents. Historically, we issued capital stock, sold debt and equity securities and received funds from The RHL Group, Inc. (a significant stockholder that is wholly-owned by our Chairman and Chief Executive Officer, Robert H. Lorsch) to operate our business. Although we received additional funding from The RHL Group pursuant to the Eleventh Amended and Restated Note effective June 6, 2016 (the "Line of Credit"), we will still be required to obtain additional financing in order to meet installment payment obligations and the previously existing obligations under the Line of Credit, which had a balance of $2,953,548 at September 30, 2016 and a total Unpaid Balance (as defined in the Line of Credit) of $3,203,548, which includes amounts borrowed under the Line of Credit, unpaid interest fees, any amounts guaranteed by The RHL Group, and other obligations due The RHL Group pursuant to the terms of the Eleventh Amended and Restated Note and the Security Agreement. As a result of the above, we express uncertainty about our ability to continue as a going concern. The components of the RHL Group Note payable and the related balance sheet presentation as of September 30, 2016 are as follows: $1,715,646, which is included in the Line of Credit, related party; and $1,237,902 related to other obligations due to The RHL Group which are included in related party payables.

Management's plan regarding this matter is to, amongst other things, continue to utilize our available Line of Credit with The RHL Group (see Note 3). As of September 30, 2016, under the original terms, we had approximately $1,296,452 remaining as available under The RHL Group Line of Credit, but we are now in default under the line of credit. Additionally, we plan to continue selling additional debt and equity securities, continue to settle our existing liabilities through issuance of equity securities, explore other debt financing arrangements, continue to increase our existing subscriber and affiliate customer base, sell MMRPro products, and continue efforts to license our intellectual property to obtain additional cash flow over the next twelve months. We cannot assure that funds from these sources will be available when needed or, if available, will be on terms favorable to us or to our stockholders. If we raise additional funds or settle liabilities by issuing equity securities, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution or such equity securities may provide for rights, preferences or privileges senior to those of the holders of our common stock. If we are unable to utilize our available Line of Credit with The RHL Group or obtain suitable alternative debt or equity financing, our ability to execute our business plan and continue as a going concern may be adversely affected.

These matters raise substantial doubt about our ability to continue as a going concern. These financial statements were prepared under the assumption that we will continue as a going concern and do not include any adjustments that might result from the outcome of that uncertainty.

 
Management's Use of Estimates

(a) MANAGEMENT'S USE OF ESTIMATES

 

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net revenue and expenses during each reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowances for doubtful accounts, the valuation of deferred income taxes, tax contingencies, long-lived and intangible assets, valuation of derivative liabilities and stock-based compensation. These estimates are based on historical experience and on various other factors that management believes to be reasonable under the circumstances, although actual results could differ from those estimates.

 

 
Cash and Cash Equivalents

(b) CASH AND CASH EQUIVALENTS

We consider cash equivalents to be only those investments that are highly liquid, readily convertible to cash and with maturities of 90 days or less at the purchase date. We maintain our cash in bank deposit accounts that, at times, may exceed federally insured limits. We have not experienced any losses in such accounts and believe that we are not exposed to any significant credit or deposit risk on our cash. We had cash and cash equivalents of $0 and $0 as of September 30, 2016 and December 31, 2015, respectively.

 
Trade and Other Receivables

(c) TRADE AND OTHER RECEIVABLES

Receivables represent claims against third parties that will be settled in cash. The carrying value of receivables, net of an allowance for doubtful accounts, if any, represents their estimated net realizable value. We estimate the allowance for doubtful accounts, if any, based on historical collection trends, type of customer, the age of outstanding receivables and existing economic conditions. If events or changes in circumstances indicate that specific receivable balances may be impaired, we give further consideration to the collectability of those balances and the allowance is adjusted accordingly. We write off past due receivable balances when collection efforts have been unsuccessful in collecting the amount due.

 

 
Fair Value of Financial Instruments

(d) FAIR VALUE OF FINANCIAL INSTRUMENTS

ASC 820-10, Fair Value Measurements and Disclosures, requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of June 30, 2016 and December 31, 2015, the carrying value of accounts receivable, deposits, related party payables, compensation payable, severance liabilities, and accounts payable and accrued expenses approximates fair value due to the short-term nature of such instruments. The carrying value of short-term debt approximates fair value as the related interest rates approximate rates currently available to us.

We utilize ASC 820-10 for valuing financial assets and liabilities measured on a recurring basis. ASC 820-10 defines fair value, establishes a framework for measuring fair value and generally accepted accounting principles, and expands disclosures about fair value measurements. This standard applies in situations where other accounting pronouncements either permit or require fair value measurements. ASC 820-10 does not require any new fair value measurements.

Accounting guidance also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

The standard describes three levels of inputs that may be used to measure fair value:

  Level 1: Quoted prices in active markets for identical or similar assets and liabilities.
  Level 2: Quoted prices for identical or similar assets and liabilities in markets that are not active or observable inputs other than quoted prices in active markets for identical or similar assets and liabilities.
  Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 
Impairment of Long-Lived Assets and Intangibles

(e) IMPAIRMENT OF LONG-LIVED ASSETS AND INTANGIBLES

We account for long-lived assets, which include property and equipment and identifiable intangible assets with finite useful lives (subject to amortization), in accordance with ASC 350-30. ASC 350-30 requires that we review long-lived assets for impairment whenever events or changes in circumstances indicate that we may not recover the carrying amount of an asset. We measure recoverability by comparing the carrying amount of an asset to the expected future undiscounted net cash flows generated by the asset. If we determine that the asset may not be recoverable, or if the carrying amount of an asset exceeds its estimated future undiscounted cash flows, we recognize an impairment charge to the extent of the difference between the fair value and the asset's carrying amount. Our assessment of the undiscounted future cash flows indicated that the carrying amount of the long-lived and intangible assets are recoverable, therefore, we had no impairment charges during the nine months ended September 30, 2016 and 2015.

 
Revenue Recognition

(f) REVENUE RECOGNITION

 

We generate our revenues from services, which are comprised of providing electronic access to consumer medical records and other vital documents, and from the licensing of our intellectual property and services. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and we are reasonably assured of collectability of the resulting receivable.

Our subscriber revenues consist of annual and monthly recurring retail subscriptions and usage-based fees, which are primarily paid in advance by credit card, and corporate accounts that are based on either an access-fee or actual number of users, and in each case billed in advance at the beginning of each month of service. We defer the portions of annual recurring subscription fees collected in advance and recognize them on a straight line basis over the subscription period. As part of our ongoing sales and marketing activities, we also offer sell a Personal Health Record Kit through retailers to the extent reasonably possible.

We license the rights to use portions of our intellectual property portfolio, which includes certain patent rights essential to the sale of certain PHR products. Licensees typically pay a license fee in one or more installments and ongoing royalties based on their sales of products incorporating or using the Company's licensed intellectual property. License fees are recognized over the estimated period of benefit to the licensee, typically five to fifteen years. The Company earns royalties on such licensed products sold by its licensees at the time that the licensees' sales occur. The Company recognizes royalty revenues based on royalties reported by licensees during the quarter and when other revenue recognition criteria are met.

We grant exclusive and non-exclusive licenses for the sale and marketing of our services in international territories in consideration of license fees and ongoing royalties. The royalty fee is usually a percentage of revenue earned by the licensee and there are usually certain minimum guarantees. We defer the recognition of license fee revenues received in advance from international licensees for the grant of the license and recognize them over the period covered by the agreement. We defer the recognition of minimum guaranteed royalty payments received in advance and recognize them over the period to which the royalty relates. We include all such revenues under "License Fees." In those cases where a license agreement contains multiple deliverables, we account for the agreement in accordance with ASC 605-25 - Revenue Recognition - Multiple-Element Arrangements.

We recognize revenue on sales of our MMRPro system in accordance with ASC 605-25, Revenue Recognition, Multiple-Element Arrangements.

Our multiple-deliverable arrangements consist solely of our MMRPro product. Deliverables within these arrangements include scanning equipment, various licenses to use third party software, a license to use our proprietary MMRPro application software, installation and training, dedicated telephone lines, secure online storage and warranties.

We determined all elements to be separate units of accounting as they have standalone value to the customers and/or they are sold by other vendors on a standalone basis. Delivery of the hardware and certain software elements of these arrangements occur at the inception of the agreement. We deliver installation and training at the inception of the agreement. We also provide software licenses, telephone lines and online secure storage over the three-year term of an MMRPro agreement. We include warranties in the arrangements, however the third party product manufacturer, and not us, is obligated to fulfill such warranties. The third-party warranty contracts are paid in advance and are not refundable.

We allocate the revenue derived from these arrangements among all the deliverables. We base such allocation on the relative selling price of each deliverable. With the exception of our proprietary MMRPro application software, we use third party evidence to set the selling prices used for this allocation. In all such cases, third parties sell the same or very similar products. For the MMRPro application software, we estimate the selling price based on recent discussions regarding licensure of that particular application on a standalone basis. To date, we have not licensed this software on a standalone basis.

We recognize the allocated revenue for each deliverable in accordance with SEC Staff Accounting Bulletin ("SAB") No. 104, Topic 13: Revenue Recognition. Under this guidance, we recognize revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed and determinable and collectability is reasonably assured. This results in us recognizing revenue for the hardware, certain software and the warranties upon delivery to the customer, for the installation and training upon completion of these services, and ratably over the contract period for the software licenses, telephone lines and online secure storage.

Revenue from the licensing of our biotech assets may include non-refundable license and up-front fees, non- refundable milestone payments that are triggered upon achievement of a specific event, and future royalties or lump-sum payments on sales of related products. For agreements that provide for milestone payments, we adopted ASC 605-28-25, Revenue Recognition Milestone Method.

 

 

 

 
Shared-Based Compensation

(g) SHARE-BASED COMPENSATION

 

We account for share-based compensation in accordance with ASC 718-20, Awards Classified as Equity. We apply ASC 718- 20 in accounting for stock-based awards issued to employees under the recognition of compensation expense related to the fair value of employee share-based awards, including stock options and restricted stock. Determining the fair value of options at the grant date requires judgment, including estimating the expected term that stock options will be outstanding prior to exercise, the associated volatility and the expected dividends. Judgment is required in estimating the amount of share-based awards expected to be forfeited prior to vesting. If actual forfeitures differ significantly from these estimates, share- based compensation expense could be materially impacted.

We account for options and warrants issued to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. We treat options and warrants issued to non-employees the same as those issued to employees with the exception of determination of the measurement date. The measurement date is the earlier of (1) the date at which a commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty's performance is complete. Options and warrants granted to consultants are valued at their respective measurement dates, and recognized as an expense based on the portion of the total consulting services provided during the applicable period. As further consulting services are provided in future periods, we will revalue the associated options and warrants and recognize additional expense based on their then current values.

We estimate the fair value of each stock option on the date of grant using the Black-Scholes option pricing model. We determine assumptions relative to volatility and anticipated forfeitures at the time of grant. No stock options were granted during the nine months ended September 30, 2016. We valued grants of stock options and warrants during the nine months ended September 30, 2016 using the following assumptions.

Expected life in years   2 - 5 Years
Stock price volatility   79%
Risk free interest rate   0.04 - 1.38%
Expected dividends   None
Forfeiture rate   0%

 

We base the assumptions used in the Black-Scholes models upon the following data: (1) our use of the contractual life of the underlying non-employee warrants as the expected life; the expected life of the employee options used in this calculation is the period of time the options are expected to be outstanding and has been determined based on historical exercise experience; (2) in the absence of an extensive public market for our shares, the expected stock price volatility of the underlying shares over the expected term of the option or warrant was taken at approximately the mid-point of the range for similar companies at the various grant dates; (3) we base the risk free interest rate on published U.S. Treasury Department interest rates for the expected terms of the underlying options or warrants; (4) we base expected dividends on historical dividend data and expected future dividend activity; and (5) we base the expected forfeiture rate on historical forfeiture activity and assumptions regarding future forfeitures based on the composition of current grantees.

 
Net Income/Loss Per Share

(h) NET INCOME/LOSS PER SHARE

 

We apply the guidance of ASC 260-10, Earnings Per Share for calculating the basic and diluted loss per share. We calculate basic loss per share by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding. We compute diluted loss per share similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential shares had been issued and if the additional shares were dilutive. We exclude common equivalent shares from the computation of net loss per share if their effect is anti-dilutive.

We excluded all potential anti-dilutive common shares from the computation of diluted net loss per common share for the nine months ended September 30, 2016 and 2015 because they were anti-dilutive due to our net loss position. Stock options, warrants and convertible notes excluded from the computation totaled 43,208,730 shares for the nine months ended September 30, 2016 and 33,251,116 shares for the nine months ended September 30, 2015, respectively.

 

 

 
Recent Accounting Pronouncements

(i) RECENT ACCOUNTING PRONOUNCEMENTS

 

In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. This new guidance is effective for annual and interim periods beginning after December 15, 2017, with no early adoption permitted. The standard permits the use of either the retrospective or cumulative effect transition method. At this time we have not selected a transition method. We are currently evaluating the effect that ASU 2014-09 will have on our consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

In August 2014, the FABS issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern ("ASU 2014-15"). ASU 2014-15 will explicitly require management to assess an entity's ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. These changes became effective for the Company for the 2016 annual period. The adoption of these changes did not have an impact on the consolidated financial statements.

In February 2015, the FASB issued ASU 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis. This standard modifies existing consolidation guidance for reporting organizations that are required to evaluate whether they should consolidate certain legal entities. ASU 2015-02 is effective for fiscal years and interim periods within those years beginning after December 15, 2015, and requires either a retrospective or a modified retrospective approach to adoption. Early adoption is permitted. The adoption of this standard did not have an impact on the Company's Consolidated Financial Statements.

In April 2015, the FASB issued ASU No 2015-3, Simplifying the Presentation of Debt Issuance Costs. This update changes the presentation of debt issuance costs in the balance sheet. ASU 2015-03 requires debt issuance costs related to a recognized debt obligation to be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability rather than being presented as an asset. Amortization of debt issuance costs will continue to be reported as interest expense. In August 2015, the FASB issued ASU 2015-15, "Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements". This ASU clarified guidance in ASC 2015-03 stating that the SEC staff would not object to a company presenting debt issuance costs related to a line-of-credit arrangement on the balance sheet as a deferred asset, regardless of whether there were any outstanding borrowings at period-end. This update is effective for annual and interim periods beginning after December 15, 2015, which required us to adopt these provisions starting the first quarter of 2016. This guidance did not have a material impact to our financial position or results of operations.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes existing guidance on accounting for leases in "Leases (Topic 840)" and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting. This ASU affects entities that issue share-based payment awards to their employees. The ASU is designed to simplify several aspects of accounting for share-based payment award transactions which include - the income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows and forfeiture rate calculations. ASU 2016-09 will become effective for the Company in the first quarter of fiscal 2018. Early adoption is permitted in any interim or annual period. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.

In April 2016, the FASB issued AS 2016-10, Revenue from Contracts with Customers (Topic 606), which amends certain aspects of the Board's new revenue standard, ASU 2014-09, Revenue from Contracts with Customers. The standard should be adopted concurrently with adoption of ASU 2014-09 which is effective for annual and interim periods beginning after December 15, 2017. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

 
Reclassifications

(j) RECLASSIFICATIONS

Certain numbers in the prior year have been reclassified to conform to the current year's presentation.

 

 
Income Taxes

Under ASC 740-270, Income Taxes - Interim Reporting, we are required to adjust our effective tax rate each quarter to be consistent with the estimated annual effective tax rate. We are also required to record the tax impact of certain discrete items, unusual or infrequently occurring, including changes in judgment about valuation allowances and effects of changes in tax laws or rates, in the interim period in which they occur. In addition, we exclude jurisdictions with a projected loss for the year or a year-to-date loss where we cannot recognize a tax benefit from our estimated annual effective tax rate. The impact of such an exclusion could result in a higher or lower effective tax rate during a particular quarter, based upon the mix and timing of actual earnings versus annual projections.

Pursuant to ASC 740, Income Taxes, we performed an analysis of previous tax filings and determined that there were no positions taken that it considered uncertain. Therefore, there were no unrecognized tax benefits as of September 30, 2016.

MMR Inc., in its capacity as the operating company taking over our income tax positions in addition to its own positions after January 27, 2009 (see Note 1), has estimated its annual effective tax rate to be zero. MMRGlobal has based this on an expectation that the combined entity will generate net operating losses in 2016, and it is not likely that those losses will be recovered using future taxable income. Therefore, no provision for income tax has been recorded as of and for the nine months ended September 30, 2016.

We account for income taxes in accordance with ASC 740-10, Income Taxes. We recognize deferred tax assets and liabilities to reflect the estimated future tax effects, calculated at the tax rate expected to be in effect at the time of realization. We record a valuation allowance related to a deferred tax asset when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.

 

 
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
SHARE-BASED COMPENSATION (Tables)
 9 Months Ended
Sep. 30, 2016
Share-based Compensation Tables  
Schedule of Valuation Assumptions to Determine the Fair Value of Stock Options

The inputs used for the Black-Scholes option and warrant valuation model were as follows:

Expected life in years   2 - 5 Years
Stock price volatility   79%
Risk free interest rate   0.04 - 1.38%
Expected dividends   None
Forfeiture rate   0%

 

 

 

 

 

 

 
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
COMMITMENTS AND CONTINGENCIES (Tables)
 9 Months Ended
Sep. 30, 2016
Commitments And Contingencies Tables  
Schedule of Future Minimum Rental Payments for Operating and Capital Leases

Future minimum lease payments as of September 30, 2016, under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:

Year Ending     Operating     Capital
December 31,     Leases     Leases
             
     2016 (Remainder of)    $ 24,750    $ 13,222 
     2017      99,000      -  
     2018      66,000      -  
Total minimum lease payments    $ 189,750    $ 13,222 

 

 

 

 

 

 
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
EQUITY ISSUANCES (Tables)
 9 Months Ended
Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Summary of Outstanding Option Awards

A summary of option activity for the nine months ended September 30, 2016 is presented below. Options granted by MMR Inc. prior to the date of the Merger have been retroactively restated to reflect the conversion ratio of MMR Inc. to MMR shares

              Weighted-Average      
          Weighted-   Remaining      
          Average   Contractual     Aggregate
          Exercise   Life     Intrinsic
    Options     Price   (Years)     Value
Outstanding at December 31, 2015   7,488,345    $ 0.50    3.62    $ -  
Granted   -       -            
Exercised   -       -            
Cancelled   (2,208,052)     0.65           
Outstanding at September 30, 2016 (Unaudited)   5,280,293    $ 0.45    4.15    $ -  
                     
Vested and expected to vest                    
     at September 30, 2016 (Unaudited)   5,280,293    $ 0.45    4.15    $ -  
                     
Exercisable at September 30, 2016 (Unaudited)   5,280,293    $ 0.45    4.15    $ -  

 

 

 

 

 

 
Summary of Stock Options Outstanding and Exercisable

The following table summarizes information about stock options outstanding and exercisable at September 30, 2016.

      Options Outstanding   Options Exercisable
            Weighted     Weighted       Weighted     Weighted
            Average     Average       Average     Average
  Exercise   Number     Remaining     Exercise   Number   Remaining     Exercise
  Price   of Shares     Life (Years)     Price   of Shares   Life (Years)     Price
                                 
$ 0.25 - 0.45   2,560,000      5.11   $ 0.35    2,560,000    5.11   $ 0.35 
$ 0.50 - 0.75   2,520,293      3.21   $ 0.55    2,520,293    3.21   $ 0.55 
$ > 0.75   200,000      3.71   $ 0.90    200,000    3.71   $ 0.90 
      5,280,293                5,280,293           

 

The following summarizes the total warrants outstanding and exercisable as of September 30, 2016:

    Warrants Outstanding   Warrants Exercisable
    Warrants   Weighted Avg     Weighted Avg   Warrants   Weighted Avg     Weighted Avg
Ranges   Outstanding   Remaining Life     Exercise Price   Exercisable   Remaining Life     Exercise Price
                             
$0.02 - $0.30   35,794,569   2.61   $ 0.05   33,761,236   2.59   $ 0.05
$0.30 - $0.50   255,000   0.53     0.50   255,000   0.53     0.50
Greater $0.50   522,937   0.58     1.05   522,937   0.58     1.05
                             
    36,572,506             34,539,173          

 

 

 

 
Summary of Outstanding Warrant Awards

A summary of the activity of our warrants for the nine months ended September 30, 2016 is presented below:

        Weighted Avg
  Shares     Exercise Price
Outstanding at December 31, 2015 11,428,610    $ 0.30 
Granted 40,227,714      0.02 
Exercised (11,750,000)     0.06 
Cancelled (3,333,818)     0.49 
Outstanding at September 30, 2016 (Unaudited) 36,572,506    $ 0.06 
         
Exercisable at September 30, 2016 (Unaudited) 34,539,173    $ 0.06 

 

 

 

 

 

 
Black-Scholes option and valuation model assumptions

The inputs used for the Black-Scholes option and warrant valuation model were as follows:

Expected life in years   2 - 5 Years
Stock price volatility   79%
Risk free interest rate   0.04 - 1.38%
Expected dividends   None
Forfeiture rate   0%

 

 

 

 

 

 

 
Shares Issued for Services or Reduction to Liabilities

During the nine months ended September 30, 2016, we issued 28,769,439 shares of common stock with a value of $387,855 to various third parties and charged the proceeds to the appropriate accounts for the following reasons:

    Nine Months Ended September 30, 2016
           
Purpose   Shares     Value
           
Services provided   -     $ -  
Reduction of payables   28,769,439      387,855 
Totals    28,769,439    $ 387,855 

 

 

 
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
NOTES PAYABLE (Tables)
 9 Months Ended
Sep. 30, 2016
Notes Payable Tables  
Notes Payable

Notes payable consisted of the following:

      September 30,     December 31,
      2016     2015
             
Promissory notes payable due to the former officers of MMRGlobal as part of severance
packages, due in full on August 31, 2009 with no stated interest		   $ 76,783    $ 76,783 
             
Promissory notes payable due to the former officers of MMRGlobal pursuant to the
Resignation and Post-Merger Employment Arrangement, due in full on August 31, 2009
with no stated interest		     25,444      25,444 
             
Promissory notes payable due to vendors relating to settlement of certain outstanding
accounts payable, payable in 18 equal monthly installments commencing on July 27, 2009
and ending on January 27, 2011, with no stated interest		     223,116      223,116 
             
Short-term loan due to a third-party with 6% interest     56,896      44,070 
             
Long term note payable relating to legal accounts payable, payable in full on March 30, 2018 with 10% interest per annum     328,133      - 
             
      710,372      369,413 
Less: current portion     (382,239)     (369,413)
Notes payable, less current portion   $ 328,133    $ - 
             
Short term loan due to a related-party, payable in full on January 2, 2014 with 12% interest    $ 6,743    $ 6,743 
             
Short term loan due to a related-party, payable in full on May 31, 2014 with 12% interest      -      50,000 
             
Notes payable related party, current portion     6,743      56,743 
             
Less: current portion     (6,743)     (56,743)
Notes payable related party, less current portion   $ -    $ - 

 

 

 

 
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accounting Policies (Cash and Cash Equivalents) (Narrative) (Details) - USD ($)
Sep. 30, 2016
Dec. 31, 2015
Sep. 30, 2015
Dec. 31, 2014
Accounting Policies Cash And Cash Equivalents Narrative Details        
Cash and cash equivalents $ 0 $ 0 $ 0 $ 309,393
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accounting Policies (Intangible Assets and Impairments) (Narrative) (Details) - USD ($)
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Accounting Policies Intangible Assets And Impairments Narrative Details    
Impairment charges $ 0 $ 0
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accounting Policies (Share-Based Compensation Schedule Of Assumptions Used In Black-Scholes Model) (Details)
 9 Months Ended
Sep. 30, 2016
USD ($)
Accounting Policies Share-based Compensation Schedule Of Assumptions Used In Black-scholes Model Details  
Expected life, in years, maximum 5 years
Stock price volatility, minimum 79.00%
Stock price volatility, maximum 79.00%
Risk-free interest rate, mimimum 0.04%
Risk-free interest rate, maximum 1.38%
Expected dividends $ 0
Forfeiture rate 0.00%
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accounting Policies (Net Income/Loss Per Share) (Narrative) (Details) - shares
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Accounting Policies Net Incomeloss Per Share Narrative Details    
Stock options, warrants and convertible notes excluded from the computation of net loss per share 43,208,730 33,251,116
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2
Related Party Note Payable (Narrative) (Details) - Tenth Amended and Restated Secured Promissory Note - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Date of note     Apr. 29, 2014    
Maximum line of credit under note    

On June 6, 2016, we and The RHL Group entered into an Eleventh Amended and Restated Promissory Note (the "Amended Note"), effective as of June 6, 2016. The Eleventh Note amends and restates that certain Tenth Amended Note entered into between the foregoing parties, effective May 20, 2015 (the " Existing Note") and together with its predecessor notes and the Amended Note, the ("Credit Facility"), by: (i) extending the maturity date to June 6, 2017. In connection with the Eleventh Amended Note, we issued The RHL Group warrants to purchase 2,777,714 shares of our common stock at $0.011 per share on June 6, 2016. Other than for the amounts as disclosed herein, The Eleventh Amended Note does not materially alter the terms of the previous Tenth Amended Note.

Historically, the predecessor notes have increased over time the maximum amount of credit available under the Credit Facility from $100,000 to $1,000,000 to $3,000,000 to $4,500,000. The maximum amount of the Amended Note is $4,500,000. The Amended Note continues to bear interest at the lesser of 10% or the highest rate then permitted by law, and is secured (similar to the Existing Note) by a Security Agreement, which has been in effect since July 31, 2007, as renewed and amended to date (the "Security Agreement").

The Eleventh Amended Note had a current balance of $2,953,548 at September 30, 2016. The components of the Eleventh Amended Note and the related balance sheet presentation as of September 30, 2016 are as follows: $1,715,646, which is included in the Line of Credit, related party; and $1,237,902 for other obligations due to The RHL Group, which is included in related party payables.

Total interest expense on the Line of Credit for the three months ended September 30, 2016 and 2015 amounted to $70,925 and $36,699, respectively. Total interest expense on the Line of Credit for the nine months ended September 30, 2016 and 2015 amounted to $200,237 and $102,433, respectively. The unpaid interest balances as of September 30, 2016 and December 31, 2015 were $321,737 and $60,257, respectively.

In conjunction with the Eleventh Amended Note, we were required to maintain certain financial covenants, including the requirement that we have at least $200,000 of cash in our bank accounts or such other amount as necessary to maintain operations through the subsequent thirty (30) days and timely pay any obligations due respecting payroll and all associated payroll taxes at any time during the term of the Note. As of November 21st, the Company was not in compliance with certain of the financial covenants and The RHL Group has not waived any of the covenants.

 

 

 

 

 

    
Maturity date     Jun. 06, 2017    
Warrants granted for shares     2,777,714    
Warrant price per share     $ 0.011    
Debt component classification:          
Line of credit, related party $ 1,715,646   $ 1,715,646    
Related party payables 1,237,902   1,237,902    
Total note payable balance 2,953,548   2,953,548    
Interest expense on line of credit 70,925 $ 36,699 200,237 $ 102,433  
Related party accrued interest $ 321,727   $ 321,727   $ 60,257
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2
Income Taxes (Narrative) (Details)
 9 Months Ended
Sep. 30, 2016
USD ($)
Income Taxes Narrative Details  
Unrecognized tax benefits $ 0
Income tax rate 0.00%
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments and Contingencies (Operating Leases) (Details)
Sep. 30, 2016
USD ($)
Year ending December 31:  
2016 (Remainder of) $ 24,750
2017 99,000
2018 66,000
Total minimum lease payments $ 189,750
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments and Contingencies (Capital Leases) (Details)
Sep. 30, 2016
USD ($)
Year ending December31:  
2016 (Remainder of) $ 13,222
Total minimum lease payments $ 13,222
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments and Contingencies (Leases Narrative) (Details) - USD ($)
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Rent expense $ 79,335 $ 86,854
September 2013 Lease    
Operating lease description

Effective September 1, 2013, we renewed our lease for office space in Los Angeles, California with a term through August 31, 2018. The lease currently requires a monthly payment of $8,250.

 

  
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity Issuances (Stock Option Activity Summary Of Option Activity) (Details)
 9 Months Ended
Sep. 30, 2016
USD ($)
$ / shares
shares
Equity Issuances Stock Option Activity Summary Of Option Activity Details  
Outstanding at December 31, 2015 | shares 7,488,345
Granted | shares 0
Exercised | shares 0
Cancelled | shares (2,208,052)
Outstanding at September 30, 2016 (Unaudited) | shares 5,280,293
Vested and expected to vest at September 30, 2016 (Unaudited) | shares 5,280,293
Exercisable at September 30, 2016 (Unaudited) | shares 5,280,293
Weighted-Average Exercise Prices, Outstanding at December 31, 2015 | $ / shares $ 0.50
Weighted-Average Exercise Prices, Granted | $ / shares 0
Weighted-Average Exercise Prices, Exercised | $ / shares 0
Weighted-Average Exercise Prices, Forfeited, cancelled or expired | $ / shares 0.65
Weighted-Average Exercise Prices, Outstanding at September 30, 2016 | $ / shares 0.45
Weighted-Average Exercise Prices, Vested and expected to vest | $ / shares 0.45
Weighted-Average Exercise Prices, Exercisable | $ / shares $ 0.45
Weighted-Average Remaining Contractual Life (in years), Outstanding at December 31, 2015 3 years 223 days
Weighted-Average Remaining Contractual Life (in years), Outstanding at September 30, 2016 4 years 54 days
Weighted-Average Remaining Contractual Life (in years), Vested and expected to vest 4 years 54 days
Weighted-Average Remaining Contractual Life (in years), Exercisable 4 years 54 days
Aggregate Intrinsic Value, Outstanding at December 31, 2015 | $ $ 0
Aggregate Intrinsic Value, Outstanding at September 30, 2016 | $ 0
Aggregate Intrinsic Value, Vested and expected to vest | $ 0
Aggregate Intrinsic Value, Exercisable | $ $ 0
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity Issuances (Stock Option Activity Summary Of Stock Options Outstanding and Exercisable) (Details) - $ / shares
 9 Months Ended
Sep. 30, 2016
Dec. 31, 2015
Options Outstanding, Number of Shares 5,280,293 7,488,345
Options Outstanding, Weighted-Average Exercise Price Per Share $ 0.45 $ 0.50
Options Exercisable, Number of Shares 5,280,293  
Options Exercisable, Weighted-Average Exercise Price Per Share $ 0.45  
$0.25 - $0.45    
Range of Exercise Price, Minimum 0.25  
Range of Exercise Price, Maximum $ 0.45  
Options Outstanding, Number of Shares 2,560,000  
Options Outstanding, Weighted-Average Remaining Life (in years) 5 years 39 days  
Options Outstanding, Weighted-Average Exercise Price Per Share $ 0.35  
Options Exercisable, Number of Shares 2,560,000  
Options Exercisable, Weighted-Average Remaining Life (in years) 5 years 539 days  
Options Exercisable, Weighted-Average Exercise Price Per Share $ 0.35  
$0.50 - $0.75    
Range of Exercise Price, Minimum 0.50  
Range of Exercise Price, Maximum $ 0.75  
Options Outstanding, Number of Shares 2,520,293  
Options Outstanding, Weighted-Average Remaining Life (in years) 3 years 75 days  
Options Outstanding, Weighted-Average Exercise Price Per Share $ 0.55  
Options Exercisable, Number of Shares 2,520,293  
Options Exercisable, Weighted-Average Remaining Life (in years) 3 years 75 days  
Options Exercisable, Weighted-Average Exercise Price Per Share $ 0.55  
> $0.75    
Range of Exercise Price, Minimum $ 0.75  
Options Outstanding, Number of Shares 200,000  
Options Outstanding, Weighted-Average Remaining Life (in years) 3 years 256 days  
Options Outstanding, Weighted-Average Exercise Price Per Share $ 0.90  
Options Exercisable, Number of Shares 200,000  
Options Exercisable, Weighted-Average Remaining Life (in years) 3 years 256 days  
Options Exercisable, Weighted-Average Exercise Price Per Share $ 0.90  
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity Issuances (Stock Option and Warrant Expense Narrative) (Details) - USD ($)
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Equity Issuances Stock Option And Warrant Expense Narrative Details    
Stock option expense $ 16,188 $ 16,759
Warrant expense $ 137,528 $ 11,170
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity Issuances (Summary Of Warrant Activity) (Details)
 9 Months Ended
Sep. 30, 2016
$ / shares
shares
Equity Issuances Summary Of Warrant Activity Details  
Warrants outstanding at December 31, 2015 | shares 11,428,610
Granted | shares 40,227,714
Exercised | shares (11,750,000)
Cancelled | shares (3,333,818)
Warrants outstanding at September 30, 2016 | shares 36,572,506
Warrants exercisable at September 30, 2016 | shares 34,539,173
Weighted-average exercise price, beginning balance | $ / shares $ 0.30
Weighted-average exercise price, granted | $ / shares 0.02
Weighted-average exercise price, exercised during period | $ / shares 0.06
Weighted-average exercise price, cancelled during period | $ / shares 0.49
Weighted-average exercise price, ending balance | $ / shares 0.06
Warrants exercisable, weighted average exercise price | $ / shares $ 0.06
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity Issuances (Summary Of Warrants Outstanding and Exercisable) (Details)
 9 Months Ended
Sep. 30, 2016
$ / shares
shares
Warrants outstanding at September 30, 2016 | shares 36,572,506
Warrants exercisable | shares 34,539,173
$0.02 - $0.30  
Range of Exercise Price, Minimum $ 0.02
Range of Exercise Price, Maximum $ 0.30
Warrants outstanding at September 30, 2016 | shares 35,794,569
Warrants outstanding, Weighted-average remaining life, in years 2 years 220 days
Warrants outstanding, Weighted-average exercise price $ 0.05
Warrants exercisable | shares 33,761,236
Warrants exercisable, Weighted-average remaining life, in years 2.59
Warrants exercisable, Weighted-average exercise price $ 0.05
$0.30 - $0.50  
Range of Exercise Price, Minimum 0.30
Range of Exercise Price, Maximum $ 0.50
Warrants outstanding at September 30, 2016 | shares 255,000
Warrants outstanding, Weighted-average remaining life, in years 191 days
Warrants outstanding, Weighted-average exercise price $ 0.50
Warrants exercisable | shares 255,000
Warrants exercisable, Weighted-average remaining life, in years 0.53
Warrants exercisable, Weighted-average exercise price $ 0.50
> $0.50  
Range of Exercise Price, Minimum $ 0.50
Warrants outstanding at September 30, 2016 | shares 522,937
Warrants outstanding, Weighted-average remaining life, in years 209 days
Warrants outstanding, Weighted-average exercise price $ 1.05
Warrants exercisable | shares 522,937
Warrants exercisable, Weighted-average remaining life, in years 0.31
Warrants exercisable, Weighted-average exercise price $ 1.05
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity Issuances (Inputs Used In Black-Scholesl) (Details)
 9 Months Ended
Sep. 30, 2016
USD ($)
Equity Issuances Inputs Used In Black-scholesl Details  
Expected life, in years, maximum 5 years
Stock price volatility, minimum 79.00%
Stock price volatility, maximum 79.00%
Risk-free interest rate, minimum 0.04%
Risk-free interest rate, maximum 1.38%
Expected dividends $ 0
Forfeiture rate 0.00%
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity Issuances (Shares Issued for Services or Reduction to Liabilities) (Details)
 9 Months Ended
Sep. 30, 2016
USD ($)
shares
Equity Issuances Shares Issued For Services Or Reduction To Liabilities Details  
Reduction of payables, shares | shares 28,769,439
Reduction of payables, amount | $ $ 387,855
Total payment of services provided through issuance of common stock, shares | shares 28,769,439
Total payment of accounts payable through issuance of common stock, amount | $ $ 387,855
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity Issuances (Stock Bonus Agreements) (Narrative) (Details) - USD ($)
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Stock Bonus Agreement expense $ 0 $ 0
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.5.0.2
Notes Payable (Details) - USD ($)
 9 Months Ended
Sep. 30, 2016
Dec. 31, 2015
Notes payable consisted of the following:    
Short-term debt $ 382,239 $ 369,413
Long-term Debt, Excluding Current Maturities 328,133 0
Related party short-term debt $ 6,743 56,743
Severance Package Notes    
Notes payable consisted of the following:    
Short-term Debt, Terms

Promissory notes payable due to the former officers of MMRGlobal as part of severance packages, due in full on August 31, 2009 with no stated interest

 

 

 

  
Short-term debt $ 76,783 76,783
Resignation and Post-Merger Employment Arrangement Notes    
Notes payable consisted of the following:    
Short-term Debt, Terms

Promissory notes payable due to the former officers of
MMRGlobal pursuant to the Resignation and Post-Merger Employment
Arrangement, due in full on August 31, 2009 with no stated interest

  
Short-term debt $ 25,444 25,444
Notes Payable - Vendors    
Notes payable consisted of the following:    
Short-term Debt, Terms

Promissory notes payable due to vendors relating to settlement of certain
outstanding accounts payable, payable in 18 equal monthly installments commencing
on July 27, 2009 and ending on January 27, 2011, with no stated interest

  
Short-term debt $ 223,116 223,116
Short Term Loan Two    
Notes payable consisted of the following:    
Short-term Debt, Terms

Short-term loan due to a third-party with 6% interest

 

  
Short-term debt $ 56,896 44,070
Legal Accounts Payable Note    
Notes payable consisted of the following:    
Long-term Debt, Description

Long term note payable relating to legal accounts payable, payable in full on March 30, 2018 with 10% interest per annum

 

 

  
Long-term Debt, Excluding Current Maturities $ 328,133 0
Related Party One    
Notes payable consisted of the following:    
Short-term Debt, Terms

Short term loan due to a related-party, payable in full on January 2, 2014 with 12% interest 

 

  
Short-term debt $ 6,743 6,743
Related Party Two    
Notes payable consisted of the following:    
Short-term Debt, Terms
Short term loan due to a related-party, payable in full on May 31, 2014 with 12% interest 

 

 

  
Short-term debt $ 0 $ 50,000
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.5.0.2
Convertible Promissory Notes (Narrative) (Details)
 9 Months Ended
Sep. 30, 2016
USD ($)
Sep. 30, 2015
USD ($)
Convertible Promissory Notes Narrative Details    
Debt instrument, description

From time to time, we issue Convertible Promissory Notes. As of September 30, 2016, a total of $323,749 in convertible notes remained outstanding and have matured. However, the Company and the Holders have agreed to keep the balance as a Note Payable and the note holders have elected not to convert their note balances into shares of our common stock as of September 30, 2016.

Each Note contains the following general terms and provisions:

  • The principal amount owed under each note becomes due and payable one year or less from the investment date provided that, upon ten (10) days' prior written notice to the holder, we may, in our sole discretion, extend the maturity date for an additional six month term. The Notes can be further extended upon mutual agreement.
  • These notes bear interest at a rate of 0%-6% per annum payable in cash or shares of common stock or a combination of cash and shares of common stock at our option.

 

  
Debt Instrument, Convertible, Number of Equity Instruments 1,355,932  
Interest expense $ 0 $ 55,780
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.5.0.2
Restructuring Activities (Narrative) (Details) - USD ($)
 9 Months Ended
Sep. 30, 2016
Dec. 31, 2015
Total remaining severance liability $ 620,613 $ 620,613
Favrille    
Restructuring and Related Activities, Description

In connection with the merger with Favrille, Inc. in 2009, we signed promissory notes with certain former executives totaling $76,783.

As of September 30, 2016, the total remaining severance liabilities amounted to $620,613, which is reflected as severance liability on the accompanying consolidated balance sheets. This consists of $571,362 payable to former non-executive employees.

 

  
Promissory notes with certain former executives $ 76,783  
Severance liabilty payable to former non-executive employees in 18 monthly installments starting on July 27, 2009 571,362  
Total remaining severance liability $ 620,613  
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.5.0.2
Related Party Transactions (Narrative) (Details) - USD ($)
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Related party payables $ 1,920,332   $ 1,385,901
The RHL Group, Inc.      
Nature of Common Ownership or Management Control Relationships

Our Chairman and Chief Executive Officer, Robert H. Lorsch, is also the Chief Executive Officer of The RHL Group, Inc. and has full voting power over all of the capital stock of The RHL Group, Inc. Mr. Lorsch directly and indirectly through The RHL Group, Inc., beneficially owns approximately 32.1% our total outstanding voting stock. The RHL Group, Inc. has loaned us money pursuant to the Eleventh Amended Note and all predecessor notes. See Note 3 - Related Party Note Payable above.

The RHL Group is an investment holding company which provides consulting, operational and technical services to us, which we refer to as the RHL Services. As part of the RHL Services, The RHL Group provides us with unrestricted access to its internal business and relationship contact database of more than 10,000 persons and entities, which includes clients of The RHL Group and other individuals which may hold value to us. The RHL Group also provides infrastructure support to us, including allowing us unlimited access to its facilities, equipment, and data, information management and server systems. In addition to allowing us the use of its office support personnel, The RHL Group has also consented to allow us to utilize the full-time services of Mr. Lorsch as our President, Chairman and Chief Executive Officer, which requires substantial time and energy away from his required duties as The RHL Group's Chairman and Chief Executive Officer. In addition, The RHL Group has made Kira Reed, available as our spokesperson. Ms. Reed, who is Mr. Lorsch's spouse, also manages our social networking activities.

In consideration for the above, The RHL Group, Inc. has a consulting arrangement with MMR. A copy of the consulting agreement is filed as an exhibit in our Form 8-K, as filed with the SEC on May 4, 2009 and is hereby incorporated by reference.

 

 

 

 

 

    
Bernard Stolar      
Nature of Common Ownership or Management Control Relationships

We incurred $37,500 during the nine months ended September 30, 2016 and 2015, toward marketing consulting services from Bernard Stolar, a director. We included $260,523 and $206,272 in related party payables as of September 30, 2016 and December 31, 2015, respectively, in connection with these services and board fees.

 

 

 

 

 

 

 

    
Related Party Transaction, Expenses from Transactions with Related Party $ 37,500 $ 37,500  
Related party payables $ 260,523   206,272
Significant Vendor      
Nature of Common Ownership or Management Control Relationships

We contract with a significant vendor for the development and maintenance of the software applications necessary to run our MyMedicalRecords PHR, MyEsafeDepositBox and MyMedicalRecords Pro products. Our outside developer supports our software development needs through a team of software engineers, programmers, quality control personnel and testers, who work with our internal product development team on all aspects of application development, design, integration and support of our products. This vendor is also a stockholder. For the nine months ended September 30, 2016 and 2015, the total expenses relating to this stockholder amounted to $90,000 and $90,000, respectively. In addition, we capitalized $0 of software development costs for the quarter ended September 30, 2016. As of September 30, 2016 and December 31, 2015, the total amounts due to the stockholder and included in related party payables amounted to $195,000 and $105,000 respectively.

 

 

 

 

 

 

 

 

    
Related Party Transaction, Expenses from Transactions with Related Party $ 90,000 $ 90,000  
Related party payables $ 195,000   $ 105,000
EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 59 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 60 212 1 false 19 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://mmrglobal.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://mmrglobal.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://mmrglobal.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations Sheet http://mmrglobal.com/role/StatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Cash Flows Sheet http://mmrglobal.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 5 false false R6.htm 00000006 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION - Note 1 Sheet http://mmrglobal.com/role/NatureOfOperationsAndBasisOfPresentation-Note1 NATURE OF OPERATIONS AND BASIS OF PRESENTATION - Note 1 Notes 6 false false R7.htm 00000007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Note 2 Sheet http://mmrglobal.com/role/SummaryOfSignificantAccountingPolicies-Note2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Note 2 Notes 7 false false R8.htm 00000008 - Disclosure - RELATED PARTY PAYABLES, LINE OF CREDIT AND NOTE PAYABLE - Note 3 Sheet http://mmrglobal.com/role/RelatedPartyPayablesLineOfCreditAndNotePayable-Note3 RELATED PARTY PAYABLES, LINE OF CREDIT AND NOTE PAYABLE - Note 3 Notes 8 false false R9.htm 00000009 - Disclosure - INCOME TAXES - Note 4 Sheet http://mmrglobal.com/role/IncomeTaxes-Note4 INCOME TAXES - Note 4 Notes 9 false false R10.htm 00000010 - Disclosure - COMMITMENTS AND CONTINGENCIES - Note 5 Sheet http://mmrglobal.com/role/CommitmentsAndContingencies-Note5 COMMITMENTS AND CONTINGENCIES - Note 5 Notes 10 false false R11.htm 00000011 - Disclosure - STOCKHOLDERS' DEFICIT - Note 6 Sheet http://mmrglobal.com/role/StockholdersDeficit-Note6 STOCKHOLDERS' DEFICIT - Note 6 Notes 11 false false R12.htm 00000012 - Disclosure - EQUITY ISSUANCES - Note 7 Sheet http://mmrglobal.com/role/EquityIssuances-Note7 EQUITY ISSUANCES - Note 7 Notes 12 false false R13.htm 00000013 - Disclosure - NOTES PAYABLE - Note 8 Notes http://mmrglobal.com/role/NotesPayable-Note8 NOTES PAYABLE - Note 8 Notes 13 false false R14.htm 00000014 - Disclosure - CONVERTIBLE PROMISSORY NOTES - Note 9 Notes http://mmrglobal.com/role/ConvertiblePromissoryNotes-Note9 CONVERTIBLE PROMISSORY NOTES - Note 9 Notes 14 false false R15.htm 00000015 - Disclosure - RESTRUCTURING ACTIVITIES - Note 10 Sheet http://mmrglobal.com/role/RestructuringActivities-Note10 RESTRUCTURING ACTIVITIES - Note 10 Notes 15 false false R16.htm 00000016 - Disclosure - RELATED PARTY TRANSACTIONS - Note 11 Sheet http://mmrglobal.com/role/RelatedPartyTransactions-Note11 RELATED PARTY TRANSACTIONS - Note 11 Notes 16 false false R17.htm 00000017 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://mmrglobal.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies 17 false false R18.htm 00000018 - Disclosure - SHARE-BASED COMPENSATION (Tables) Sheet http://mmrglobal.com/role/Share-basedCompensationTables SHARE-BASED COMPENSATION (Tables) Tables 18 false false R19.htm 00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://mmrglobal.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://mmrglobal.com/role/CommitmentsAndContingencies-Note5 19 false false R20.htm 00000020 - Disclosure - EQUITY ISSUANCES (Tables) Sheet http://mmrglobal.com/role/EquityIssuancesTables EQUITY ISSUANCES (Tables) Tables http://mmrglobal.com/role/EquityIssuances-Note7 20 false false R21.htm 00000021 - Disclosure - NOTES PAYABLE (Tables) Notes http://mmrglobal.com/role/NotesPayableTables NOTES PAYABLE (Tables) Tables http://mmrglobal.com/role/NotesPayable-Note8 21 false false R22.htm 00000022 - Disclosure - Accounting Policies (Cash and Cash Equivalents) (Narrative) (Details) Sheet http://mmrglobal.com/role/AccountingPoliciesCashAndCashEquivalentsNarrativeDetails Accounting Policies (Cash and Cash Equivalents) (Narrative) (Details) Details 22 false false R23.htm 00000023 - Disclosure - Accounting Policies (Intangible Assets and Impairments) (Narrative) (Details) Sheet http://mmrglobal.com/role/AccountingPoliciesIntangibleAssetsAndImpairmentsNarrativeDetails Accounting Policies (Intangible Assets and Impairments) (Narrative) (Details) Details 23 false false R24.htm 00000024 - Disclosure - Accounting Policies (Share-Based Compensation Schedule Of Assumptions Used In Black-Scholes Model) (Details) Sheet http://mmrglobal.com/role/AccountingPoliciesShare-basedCompensationScheduleOfAssumptionsUsedInBlack-scholesModelDetails Accounting Policies (Share-Based Compensation Schedule Of Assumptions Used In Black-Scholes Model) (Details) Details 24 false false R25.htm 00000025 - Disclosure - Accounting Policies (Net Income/Loss Per Share) (Narrative) (Details) Sheet http://mmrglobal.com/role/AccountingPoliciesNetIncomelossPerShareNarrativeDetails Accounting Policies (Net Income/Loss Per Share) (Narrative) (Details) Details 25 false false R26.htm 00000026 - Disclosure - Related Party Note Payable (Narrative) (Details) Sheet http://mmrglobal.com/role/RelatedPartyNotePayableNarrativeDetails Related Party Note Payable (Narrative) (Details) Details 26 false false R27.htm 00000027 - Disclosure - Income Taxes (Narrative) (Details) Sheet http://mmrglobal.com/role/IncomeTaxesNarrativeDetails Income Taxes (Narrative) (Details) Details 27 false false R28.htm 00000028 - Disclosure - Commitments and Contingencies (Operating Leases) (Details) Sheet http://mmrglobal.com/role/CommitmentsAndContingenciesOperatingLeasesDetails Commitments and Contingencies (Operating Leases) (Details) Details 28 false false R29.htm 00000029 - Disclosure - Commitments and Contingencies (Capital Leases) (Details) Sheet http://mmrglobal.com/role/CommitmentsAndContingenciesCapitalLeasesDetails Commitments and Contingencies (Capital Leases) (Details) Details 29 false false R30.htm 00000030 - Disclosure - Commitments and Contingencies (Leases Narrative) (Details) Sheet http://mmrglobal.com/role/CommitmentsAndContingenciesLeasesNarrativeDetails Commitments and Contingencies (Leases Narrative) (Details) Details 30 false false R31.htm 00000031 - Disclosure - Equity Issuances (Stock Option Activity Summary Of Option Activity) (Details) Sheet http://mmrglobal.com/role/EquityIssuancesStockOptionActivitySummaryOfOptionActivityDetails Equity Issuances (Stock Option Activity Summary Of Option Activity) (Details) Details 31 false false R32.htm 00000032 - Disclosure - Equity Issuances (Stock Option Activity Summary Of Stock Options Outstanding and Exercisable) (Details) Sheet http://mmrglobal.com/role/EquityIssuancesStockOptionActivitySummaryOfStockOptionsOutstandingAndExercisableDetails Equity Issuances (Stock Option Activity Summary Of Stock Options Outstanding and Exercisable) (Details) Details 32 false false R33.htm 00000033 - Disclosure - Equity Issuances (Stock Option and Warrant Expense Narrative) (Details) Sheet http://mmrglobal.com/role/EquityIssuancesStockOptionAndWarrantExpenseNarrativeDetails Equity Issuances (Stock Option and Warrant Expense Narrative) (Details) Details 33 false false R34.htm 00000034 - Disclosure - Equity Issuances (Summary Of Warrant Activity) (Details) Sheet http://mmrglobal.com/role/EquityIssuancesSummaryOfWarrantActivityDetails Equity Issuances (Summary Of Warrant Activity) (Details) Details 34 false false R35.htm 00000035 - Disclosure - Equity Issuances (Summary Of Warrants Outstanding and Exercisable) (Details) Sheet http://mmrglobal.com/role/EquityIssuancesSummaryOfWarrantsOutstandingAndExercisableDetails Equity Issuances (Summary Of Warrants Outstanding and Exercisable) (Details) Details 35 false false R36.htm 00000036 - Disclosure - Equity Issuances (Inputs Used In Black-Scholesl) (Details) Sheet http://mmrglobal.com/role/EquityIssuancesInputsUsedInBlack-scholeslDetails Equity Issuances (Inputs Used In Black-Scholesl) (Details) Details 36 false false R37.htm 00000037 - Disclosure - Equity Issuances (Shares Issued for Services or Reduction to Liabilities) (Details) Sheet http://mmrglobal.com/role/EquityIssuancesSharesIssuedForServicesOrReductionToLiabilitiesDetails Equity Issuances (Shares Issued for Services or Reduction to Liabilities) (Details) Details 37 false false R38.htm 00000039 - Disclosure - Equity Issuances (Stock Bonus Agreements) (Narrative) (Details) Sheet http://mmrglobal.com/role/EquityIssuancesStockBonusAgreementsNarrativeDetails Equity Issuances (Stock Bonus Agreements) (Narrative) (Details) Details 38 false false R39.htm 00000040 - Disclosure - Notes Payable (Details) Notes http://mmrglobal.com/role/NotesPayableDetails Notes Payable (Details) Details 39 false false R40.htm 00000041 - Disclosure - Convertible Promissory Notes (Narrative) (Details) Notes http://mmrglobal.com/role/ConvertiblePromissoryNotesNarrativeDetails Convertible Promissory Notes (Narrative) (Details) Details 40 false false R41.htm 00000042 - Disclosure - Restructuring Activities (Narrative) (Details) Sheet http://mmrglobal.com/role/RestructuringActivitiesNarrativeDetails Restructuring Activities (Narrative) (Details) Details 41 false false R42.htm 00000043 - Disclosure - Related Party Transactions (Narrative) (Details) Sheet http://mmrglobal.com/role/RelatedPartyTransactionsNarrativeDetails Related Party Transactions (Narrative) (Details) Details 42 false false All Reports Book All Reports mmrf-20160930.xml mmrf-20160930.xsd mmrf-20160930_cal.xml mmrf-20160930_def.xml mmrf-20160930_lab.xml mmrf-20160930_pre.xml true true ZIP 61 0001136261-16-000683-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001136261-16-000683-xbrl.zip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

  •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

    #32EUA#?'EZFIT^PL#Y]WD\_7D8G(VNIZAT=G9],OU;'+] M&=U,+R=GD_.[ J]O@>#5?Z01)GMY=/<8DW2&R9(5#M(B5&! M@TLS186$Q>>7H]GY&-V,;F>_T'_^,CJ]/+\[0)>3:^Y;SV[/QY,9]ZO7T]EY M05' \QT,>)8'"^-R(U8'337+( "+[0X%634E=G.#7_][P!%S^>:(LQ7B]&I<)P-KUW&L)(#!:2>UA<7Q M].IJ,KNBL686@9Y-^61^?EV=R3_ @/(E?O#"*R]-Z6J^:;$.P8:\+H%K94X5 MKT:,8&!JHVT3G9P7Y,^<&@MH/20FW#__=E0A=2D[N[+Z/K ML\WL_Q$&9B_CZ,%T\2ZA=3J[J]2MS>9MA&!PI=).V-:DJ^R[YC+[$PST,/WY MS75>Y?.2/0"I1,E:;V?.[A)CMD9586?*"P:)E@J+"YWKG\]O9Q,&S9O;Z15U M<]/;7U"&V1RK)S"P>HN3E*S]=$VRRWWY+9#-(S[SD+*;*+&)QR^!6&'; M0H);2%N;5D>R,3L@ -OJK-[-G]V.KN\8>-G):(%<( >@9]2N. SF/-;FQV^A5$P #9:=>$B3E?:?BH/;% M#&^FS"Z19V=0%8-FG�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